



AperTO - Archivio Istituzionale Open Access dell'Università di Torino

A guide to the use of bioassays in exploration of natural resources

This is a pre print version of the following article:				
Original Citation:				
Availability:				
This version is available http://hdl.handle.net/2318/1953751 since 2024-03-17T22:26:08Z				
Published version:				
DOI:10.1016/j.biotechadv.2024.108307				
Terms of use:				
Open Access				
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.				

(Article begins on next page)


Biotechnology Advances

A guide to the use of bioassays in exploration of natural resources --Manuscript Draft--

Manuscript Number:	JBA-D-23-00480			
Article Type:	Review Article			
Keywords:	bioassay selection; Bioactivity; Natural Products; Drug Discovery; Blue biotechnology; screening; bioactivity-guided purification; validation; preclinical trials; biodiscovery			
Corresponding Author:	Jerica Sabotič Jozef Stefan Institute SLOVENIA			
First Author:	Jerica Sabotič			
Order of Authors:	Jerica Sabotič			
	Engin Bayram			
	David Ezra			
	Susana P. Gaudêncio			
	Berat Z. Haznedaroğlu			
	Nika Janež			
	Leila Ktari			
	Anna Luganini			
	Manolis Mandalakis			
	Ivo Safarik			
	Dina Simes			
	Evita Strode			
	Anna Toruńska-Sitarz			
	Despoina Varamogianni – Mamatsi			
	Giovanna Cristina Varese			
	Marlen I Vasquez			
Abstract:	Bioassay are the main tool to decipher bioactivities from natural resources thus their selection and quality are critical for optimal bioprospecting. They are used both in the early stages of compound isolation/purification/identification, and in later stages to evaluate their safety and efficacy. In this review, we provide a comprehensive overview of the most common bioassays used in the discovery and development of new bioactive compounds with a focus on marine bioresources. We provide a comprehensive list of practical considerations for selecting appropriate bioassays and discuss in detail the bioassays typically used to explore antimicrobial, antibiofilm, cytotoxic, antiviral, antioxidant, and anti-ageing potential. The concept of quality control and bioassay validation are introduced, followed by safety considerations, which are critical to advancing bioactive compounds to a higher stage of development of pharmaceuticals, food supplements, and cosmetics, the industrial pipelines where currently known marine natural products hold most potential. We highlight the importance of gaining reliable bioassay results, as these serve as a starting point for application-based development and further testing, as well as for consideration by regulatory authorities.			
Suggested Reviewers:	John R White, PhD director, GSK john.r.white@gsk.com			

expert on bioassay development GlaxoSmithKline R&D, 1250 S Collegeville Rd, Collegeville, PA 19426, USA
Cristian Rogel-Castillo, PhD assistant professor, University of Concepción crogel@udec.cl expert in food technology and in development and validation of analytical methods
Maria João Romeu, MSc PhD student, University of Porto Laboratory for Process Engineering Environment Biotechnology and Energy mariaromeu@fe.up.pt expertise in development of antifouling strategies
Agenor Valadares Santos, PhD professor, Federal University of Para avsantos@ufpa.br expertise in biotechnology of microorganisms
Alberto Falco, PhD researcher, Miguel Hernandez University of Elche alber.falco@umh.es expert in fish mucus extracts an their functional compounds and polymer nanostructures for the encapsulation and controlled release of natural compounds
Yasuhiro Igarashi, PhD professor, University of Toyama yas@pu-toyama.ac.jp expert in natural product chemistry
Sabrina Carrella, PhD researcher, Zoological Station Anton Dohrn sabrina.carrella@szn.it expert in developing biomedical applications
Jong Seong Khim, PhD professor, Seoul National University jskocean@snu.ac.kr expert in marine biotechnology and bioassays

Jožef Stefan Institute, Ljubljana, Slovenija B3 Department of Biotechnology





Date: 7 July 2023

Dear Editor,

I am writing on behalf of 16 members of the COST action CA18238 Ocean4Biotech, who combine expertise in various areas of marine biotechnology. During our technical exchanges and discussions, we have found that understanding and conducting high quality bioassays is important for efficient use of natural resources such as the marine environment. Information on bioassays is abundant in the literature, but scattered, and reviews tend to focus on narrow fields or specific applications. Therefore, we decided to create an overview that covers all aspects of bioassays that are important in bringing a natural product from nature to the customer. We focused on marine natural products as they are an increasingly popular source, but the process is similar and applicable to all natural products. We believe that our proposed review entitled "**A guide to the use of bioassays in exploration of natural resources**" will be of interest and use to readers of Biotechnology Advances.

The aim of this review is to highlight the importance of selecting good bioassays and their properties, and to address aspects of the entire process from detection of bioactivity in natural extracts to bioactivity-guided purification and application. We raise important questions that the scientific community using bioassays should consider. We provide a comprehensive and critical overview of the bioassays most commonly used by the marine biodiscovery community, focusing on antimicrobial, cytotoxic, antiviral, antioxidant, and anti-ageing bioassays. We then introduce the concept of validation and quality control that ensures confidence in bioassay results. We then describe the importance of appropriate extraction methods and the steps involved in bioactivity-guided identification and purification. The review concludes with an application-oriented overview focusing on drug discovery, dietary supplements, and cosmetics, the industries most commonly supplied with marine-derived natural products. Safety and regulatory issues that are critical to the transition of substances to a higher stage of development are presented. In the conclusions, an outlook on trends and future developments is provided.

The review is extensive as it cites 273 references and includes 15,420 words, 9 figures, and 2 tables. In addition, a Supplementary table provides comprehensive information on commonly used bioassays with their advantages and limitations.

We believe that this topic will be of interest to a wide audience of researchers working with natural products, as bioassays are routinely used to characterise them. Such a guide would benefit novices in the field as well as those seeking to expand the potential of biodiscovery. The review focuses on marine natural products, but bioassays can be used universally for all natural products, so we believe the review will appeal to all communities that use bioassays in their research.

Yours sincerely, Dr Jerica Sabotič, corresponding author

Author declaration

[Instructions: Please check all applicable boxes and provide additional information as requested.]

1. Conflict of Interest

Potential conflict of interest exists:

We wish to draw the attention of the Editor to the following facts, which may be considered as potential conflicts of interest, and to significant financial contributions to this work:

The nature of potential conflict of interest is described below:

 \square No conflict of interest exists.

We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

2. Funding

Funding was received for this work.

All of the sources of funding for the work described in this publication are acknowledged below:

[List funding sources and their role in study design, data analysis, and result interpretation]

Funding sources had no role in study design, data analysis or result interpretation.

This publication is based upon work from COST Action CA18238 (Ocean4Biotech), supported by COST (European Cooperation in Science and Technology) program.

Research of Jerica Sabotič and Nika Janež was supported by Slovenian Research agency (J4- 2543, J4-4555, P4-0127, P4-0432).

Research of Evita Strode was supported by ERDF post-doctoral research grant 1.1.1.2/16/I/001 (application No 1.1.1.2/VIAA/3/19/465).

Susana Gaudêncio: This work is financed by national funds from FCT - Fundação para a

<u>Ciência e a Tecnologia, I.P., in the scope of the project UIDP/04378/2020 and UIDB/04378/2020 of the Research Unit on Applied Molecular Biosciences - UCIBIO and the project LA/P/0140/2020 of the Associate Laboratory Institute for Health and Bioeconomy - i4HB.</u>

Research of Anna Luganini and Giovanna Cristina Varese was financed by the University of Torino (Ricerca Locale) and the European Commission – NextGenerationEU, Project "Strengthening the MIRRI Italian Research Infrastructure for Sustainable Bioscience and Bioeconomy", code n. IR0000005.

Research of David Ezra was supported by The Chief Scientist of the Israeli Ministry of Agriculture and Rural Development (MOARD), grant number 20-02-0122, and Copia Agro Israel

Research of Dina Simes was funded by the Portuguese National Funds from FCT— Foundation for Science and Technology, through projects UIDB/04326/2020, UIDP/04326/2020 and LA/P/0101/2020 and AAC n° 41/ALG/2020 - Project n° 072583 – NUTRISAFE.

No funding was received for this work.

3. Intellectual Property

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

4. Research Ethics

We further confirm that any aspect of the work covered in this manuscript that has involved human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

IRB approval was obtained (required for studies and series of 3 or more cases)

Written consent to publish potentially identifying information, such as details or the case and photographs, was obtained from the patient(s) or their legal guardian(s).

5. Authorship

The International Committee of Medical Journal Editors (ICMJE) recommends that authorship be based on the following four criteria:

- 1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
- 2. Drafting the work or revising it critically for important intellectual content; AND
- 3. Final approval of the version to be published; AND
- 4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. For more information on authorship, please see <u>http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html#two</u>.

All listed authors meet the ICMJE criteria. We attest that all authors contributed significantly to the creation of this manuscript, each having fulfilled criteria as established by the ICMJE.

One or more listed authors do(es) not meet the ICMJE criteria.

We believe these individuals should be listed as authors because:

[Please elaborate below]

 \boxtimes We confirm that the manuscript has been read and approved by all named authors.

 \boxtimes We confirm that the order of authors listed in the manuscript has been approved by all named authors.

6. Contact with the Editorial Office

The Corresponding Author declared on the title page of the manuscript is:

[Insert name below]

This author submitted this manuscript using his/her account in EVISE.

We understand that this Corresponding Author is the sole contact for the Editorial process (including EVISE and direct communications with the office). He/she is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs.

We confirm that the email address shown below is accessible by the Corresponding Author, is the address to which Corresponding Author's EVISE account is linked, and has been configured to accept email from the editorial office of American Journal of Ophthalmology Case Reports:

[Insert email address you wish to use for communication with the journal here]

Someone other than the Corresponding Author declared above submitted this manuscript from his/her account in EVISE:

[Insert name below]

We understand that this author is the sole contact for the Editorial process (including EVISE and direct communications with the office). He/she is responsible for communicating with the other authors, including the Corresponding Author, about progress, submissions of revisions and final approval of proofs.

We the undersigned agree with all of the above.

Author's name (Fist, Last)SignatureDate

 1. __Jerica Sabotič _____
 8 July 2023 _____

A guide to the use of bioassays in exploration of natural resources

Jerica Sabotič^{a,*}, Engin Bayram^b, David Ezra^c, Susana P. Gaudêncio^{d,e}, Berat Z. Haznedaroğlu^b, Nika Janež^a, Leila Ktari^f, Anna Luganini^g, Manolis Mandalakis^h, Ivo Safarik^{i,j}, Dina Simes^{k,I}, Evita Strode^m, Anna Toruńska-Sitarzⁿ, Despoina Varamogianni – Mamatsi^h, Giovanna Cristina Varese^g, Marlen I. Vasquez^o

*Corresponding author: Jerica Sabotič, e-mail: Jerica.Sabotic@ijs.si

Highlights

Bioassay selection and quality is critical for optimal natural resource exploration.

Many variables should be considered when selecting or designing a bioassay.

Different types of bioassays are important for different phases of biodiscovery.

Validation of bioassays is important for more robust and reliable data generation.

Current marine biodiscovery mainly focuses on detection of antimicrobial activities.

A guide to the use of bioassays in exploration of natural resources

- 1 2
- Jerica Sabotič^{a,*}, Engin Bayram^b, David Ezra^c, Susana P. Gaudêncio^{d,e}, Berat Z. Haznedaroğlu^b, Nika
- 5 Janež^a, Leila Ktari^f, Anna Luganini^g, Manolis Mandalakis^h, Ivo Safarik^{i,j}, Dina Simes^{k,I}, Evita Strode^m, Anna
- 6 Toruńska-Sitarzⁿ, Despoina Varamogianni Mamatsi^h, Giovanna Cristina Varese^g, Marlen I. Vasquez^o
- 7
- 8 ^aDepartment of Biotechnology, Jožef Stefan Institute, 1000 Ljubljana, Slovenia
- 9 ^bInstitute of Environmental Sciences, Bogazici University, Bebek, Istanbul 34342, Turkey
- ^cDepartment of Plant Pathology and weed research, ARO, The Volcani Institute, P.O.Box 15159, Rishon
 LeZion, 7528809, Israel
- ^dAssociate Laboratory i4HB Institute for Health and Bioeconomy, NOVA School of Science and
 Technology, NOVA University Lisbon, 2819-516 Caparica, Portugal
- ^eUCIBIO Applied Biomolecular Sciences Unit, Department of Chemistry, Blue Biotechnology &
- 15 Biomedicine Lab, NOVA School of Science and Technology, NOVA University of Lisbon, Caparica, 16 Portugal
- ¹⁷ ^fB3Aqua Laboratory, National Institute of Marine Sciences and Technologies, Carthage University,
- 18 Tunis, Tunisia
- 19 ^gDepartment of Life Sciences and Systems Biology, University of Turin, 10123 Turin, Italy
- 20 ^hInstitute of Marine Biology, Biotechnology and Aquaculture, Hellenic Centre for Marine Research,
- 21 71500 Heraklion, Greece
- ⁱDepartment of Nanobiotechnology, Biology Centre, ISBB, CAS, Na Sadkach 7, 370 05 Ceske Budejovice,
 Czech Republic
- 24 ^jRegional Centre of Advanced Technologies and Materials, Czech Advanced Technology and Research
- 25 Institute, Palacky University, Slechtitelu 27, 783 71 Olomouc, Czech Republic
- 26 ^kCentre of Marine Sciences (CCMAR), Universidade do Algarve, 8005-139 Faro, Portugal
- 27 ¹2GenoGla Diagnostics, Centre of Marine Sciences (CCMAR), Universidade do Algarve, Faro, Portugal
- 28 ^mLatvian Institute of Aquatic Ecology, Agency of Daugavpils University, Riga LV-1007, Latvia
- ⁿDepartment of Marine Biology and Biotechnology, Faculty of Oceanography and Geography,
- 30 University of Gdańsk, 81-378 Gdynia, Poland
- ^o Department of Chemical Engineering, Cyprus University of Technology, 3036 Limassol, Cyprus
- 32
- 33
- 34 *Corresponding author: Jerica Sabotič, e-mail: Jerica.Sabotic@ijs.si
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42

43 Abstract

44 Bioassay are the main tool to decipher bioactivities from natural resources thus their selection and 45 quality are critical for optimal bioprospecting. They are used both in the early stages of compound 46 isolation/purification/identification, and in later stages to evaluate their safety and efficacy. In this 47 review, we provide a comprehensive overview of the most common bioassays used in the discovery 48 and development of new bioactive compounds with a focus on marine bioresources. We provide a comprehensive list of practical considerations for selecting appropriate bioassays and discuss in detail 49 50 the bioassays typically used to explore antimicrobial, antibiofilm, cytotoxic, antiviral, antioxidant, and 51 anti-ageing potential. The concept of quality control and bioassay validation are introduced, followed by safety considerations, which are critical to advancing bioactive compounds to a higher stage of 52 53 development. We conclude by providing an application-oriented view focused on the development of 54 pharmaceuticals, food supplements, and cosmetics, the industrial pipelines where currently known 55 marine natural products hold most potential. We highlight the importance of gaining reliable bioassay 56 results, as these serve as a starting point for application-based development and further testing, as 57 well as for consideration by regulatory authorities. 58

59 Keywords

bioassay selection; bioactivity; natural products; drug discovery; blue biotechnology; screening;
 bioactivity-guided purification; validation; preclinical trials; biodiscovery

62

63

64 Abbreviations

65 ABTS/TEAC, 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)/Trolox®-Equivalent Antioxidant 66 Capacity; ADMET, absorption, distribution, metabolism, excretion, toxicity; AFST, antifungal 67 susceptibility testing; CADD, computer-aided drug design; CC50, 50 % cytotoxicity concentration; 68 CLSI, Clinical and Laboratory Standards Institute; COST, European Cooperation in Science and 69 Technology; CFU, colony forming unit; CPE, cytopathic effect; CTA, cell transformation assays; 70 CUPRAC, CUPric Reducing Antioxidant Capacity; DPPH, 2,2-Diphenyl-1-picrylhydrazyl; EC50, 50% 71 effective concentration; EFSA, European Food Safety Authority; EMA, European Medicines Agency; 72 ET, electron transfer; EUCAST, European Committee on Antimicrobial Susceptibility Testing; FDA, 73 United States Food and Drug Administration; FFA, focus-forming assay; FMCA, fluorometric 74 microculture cytotoxicity assay; GI50, 50 % growth inhibition; GLP, good laboratory practice; HA, 75 hemagglutinin; HAT, hydrogen atom transfer; HIA, hemagglutination inhibition assay; HTS, highthroughput screening; LLPS, liquid-liquid phase separation; LOD, limit of detection; LOQ, limit of 76 77 quantitation; MALDI-TOF, matrix-assisted laser desorption ionization-time-of-flight mass 78 spectrometry; MIC, minimum inhibitory concentration; MOI, multiplication of infection; MBC, 79 minimum bactericidal concentration; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 80 bromide; a yellow tetrazole that is reduced to purple formazan in living cells; MS, mass spectrometry; 81 MSPE, magnetic solid phase extraction; NAM, new approach methodology; OECD, Organisation for 82 Economic Co-operation and Development; ORAC, oxygen radical absorbance capacity; PRA, plaque 83 reduction assay; qPCR; quantitative real-time polymerase chain reaction; RBC, red blood cells; SI,

84 selectivity index; SPE, solid phase extraction; VRA, virus yield reduction assay

85

87	Contents	
88	Abstract	2
89	Keywords	2
90	Abbreviations	2
91	Contents	3
92	1. Introduction	4
93	2. Bioassay types and their use in bioactive compound discovery	4
94	3. Practical considerations in choosing bioassays to detect target bioactivity	5
95	3.1. Specifics of marine samples	9
96	4. Prevalent bioassays in marine biodiscovery	9
97	4.1. Antimicrobial bioassays	10
98	4.1.1. Antibiofilm assays	11
99	4.1.2. Special consideration for antifungal bioassays	12
100	4.2. Cytotoxicity bioassays	13
101	4.3. Antiviral Bioassays	15
102 103	4.4. Bioassays for cosmetics and cosmeceuticals with a focus on antioxidant and anti-a effects 17	geing
104	5. Quality control and bioassay validation	19
105	5.1. The concept of validation	19
106	5.2. Validation of the analytical method	20
107	5.3. Data integrity and documentation	22
108	5.4. Good Laboratory Practice (GLP)	22
109	6. Bioactivity-guided fractionation and/or purification	22
110	7. Application-oriented development	25
111	7.1. Pharmaceutical drug discovery	
112	7.2. Cosmetics	29
113	7.3. Food and feed supplements	30
114	8. Conclusions	
115	9. Acknowledgments & funding	32
116	10. References	32
117	Figure legends	55
118		

1. Introduction 120

121 The most common approach to discovering new bioactive compounds is extensive screening of crude natural extracts using bioassay-guided protocols to determine their activity, followed by isolation and 122 123 characterization of the active compounds, which are then used in a variety of biotechnological 124 applications, including food, feed, agriculture, cosmetics, and veterinary and human medicine. The 125 discovery of new marine natural products in the last five years has been driven primarily by marine fungi, but also by sponges, tunicates (ascidians), and molluscs/cyanobacteria, which are the source of 126 127 most of the approved drugs in the marine pharmacology pipeline. In addition, marine viruses, bacteria, archaea, fungi, and phytoplankton or zooplankton, including cyanobacteria, green algae, 128 129 thraustochytrids, and dinoflagellates, have long been studied as sources of natural bioactive products. To increase the chemical space and diversity of activities detected in bioassays, modifications of culture 130 131 conditions or co-cultivation are used in the search for natural products from culturable microorganisms 132 (e.g., (Lauritano et al., 2016; Marmann et al., 2014; Oh et al., 2005; Romano et al., 2018). Other sources of marine natural products include actinomycetes, brown, and red algae, cnidarians, bryozoans, and 133 134 echinoderms (Barreca et al., 2020; Carroll et al., 2021; Jimenez et al., 2020; Rotter et al., 2021a).

135 The authors of this review are members of COST Action CA18238 Ocean4Biotech, a network 136 of more than 150 blue biotechnology scientists and practitioners from 37 countries (Rotter et al., 137 2021b, 2020). Our goal is to provide a guide for decision making in the selection and use of bioassays 138 to improve the efficiency of bioprospecting and discovery of bioactive marine compounds. A 139 comprehensive overview of bioassays currently used in the marine bioprospecting community is 140 provided, along with their strengths and weaknesses, followed by considerations for bioassay-guided 141 identification and isolation. We also consider the importance of incorporating in vitro, ex vivo, and 3D 142 human cell- or tissue-based bioassay protocols as important tools in the preclinical process to avoid 143 drug failure in clinical trials, most often due to lack of clinical efficacy and/or unacceptable toxicity. We 144 then present quality control procedures, including validation, that are required for further safety and 145 efficacy testing, which will then pave the way for eventual regulatory approval for commercialization. 146 The procedures and workflows described are general in nature and can be applied to a wide range of 147 potential applications of bioactive compounds, from industrial enzymes to pharmaceuticals for human 148 consumption. Therefore, we use the term bioactive compounds to refer to all structural variants of 149 natural molecules, from small molecules to large polymers, including, for example, proteins and 150 polysaccharides. Finally, we provide an application-oriented overview of the industrial pipelines most 151 commonly supplied with marine-derived natural products, including those focused on the 152 development of pharmaceuticals, dietary supplements, and cosmetics. By providing insight into the 153 assays used to evaluate bioactivity and best practices in bioassays, this review aims to guide the natural 154 products and blue biotechnology community in decision making for natural product discovery and 155 development.

156

2. Bioassay types and their use in bioactive compound discovery 157

158 The biological relevance of natural extracts and pure compounds, whether natural or synthetic, is 159 determined by the bioactivity assays or bioassays used (Weller, 2012). The term "bioactive" is defined 160 as "having or causing an effect on living tissue" (Strömstedt et al., 2014). Different characteristics of 161 bioassays such as throughput, complexity, speed, and cost are relevant to different stages of the 162 biodiscovery process (Fig. 1). In the pre-screening and screening phase, the goal is to detect and

potentially quantify bioactivity potential. Therefore, bioassays should be performed in a high-163 throughput format screening format (HTS) that allows rapid and cost-effective testing of large number 164 165 of samples or large libraries of extracts, extract fractions. or pure compounds. In the monitoring phase, bioassays are used to guide purification or fractionation processes to isolate and identify single pure 166 bioactive compounds (bioactivity-guided approach), so they must be designed to have a high 167 168 throughput capacity, be fast and easy to perform, and be cost-effective. Interestingly, innovative in 169 silico approaches have recently been developed that do not require extract fractionation and are 170 known as compound activity mapping (CAM) and are freely available (www.npanalyst.org) (Gaudêncio 171 et al., 2023; Kurita et al., 2015; Lee et al., 2022; O'Rourke et al., 2020). Finally, in the secondary phase, bioassays are used to identify and characterize the biological mode of action of the bioactive 172 173 compound, which typically requires a series of bioassays that must be highly specific and accurate and 174 are usually time-consuming and expensive (Claeson and Bohlin, 1997; Strömstedt et al., 2014; Suffness 175 and Pezzuto, 1991).

Bioassays can be performed *in silico, in vitro, ex vivo,* or *in vivo* at any of the levels described, and usually a combination of these methods is used to characterise a new compound or the bioactivity potential of a natural resource. When screening an extract for medicinal activity, *in silico* and *in vitro* assays are typically used to identify the bioactive compound and its mode of action, while *in silico* and *in vivo* assays (e.g., animal studies) provide information on pharmacological activity and toxicity (Mbah et al., 2012; Strömstedt et al., 2014).

- 182
- 183

184 3. Practical considerations in choosing bioassays to detect target 185 bioactivity

186The following paragraphs provide a list of questions and considerations, the answers to which187provide information on what to consider when selecting or designing a bioassay (Table 1, Fig. 2).

At what stage of the discovery process and for what purpose will the bioassay be performed? Considering the target bioactivity of interest, appropriate bioassays can be selected and used to screen crude or fractionated extracts, to guide subsequent purification, or to explain underlying mechanisms of action, as described in the previous section. First and foremost, the target bioactivity should be selected. An overview of the most commonly used bioassays can be found in Supplementary Table S1.

193 Is there an interest in a specific or general activity? In general, bioassays can be divided into 194 two distinct categories: "single-target bioassays" and "functional multi-target bioassays". Single-target 195 bioassays are generally designed to detect the effect of the tested compounds on a particular target 196 with a high degree of specificity and based on a distinct mechanism of action (Claeson and Bohlin, 197 1997). Examples include the analysis of specific enzymatic activities, such as the degradation of 198 proteins or breakdown of plastics, or the inhibition of enzymatic activities, such as the inhibition of 199 proteases and the blocking of target receptors. Another variation of single-target bioassays is 200 "chemical-genetic profiling" in yeast. A panel of yeast strains with selective mutations that highlight 201 sensitivity to specific drugs is used to screen known compounds with unknown modes of action or 202 mixtures of compounds such as natural product extracts (Harvey, 2008). The second category, 203 "functional multi-target bioassays", includes bioassays that use whole animals, organs or cells. These 204 bioassays are non-specific in their outcome and measure phenotype change or a general biological 205 effect, such as an antimicrobial or cytotoxic effect. The response to the bioactive compound tested cannot necessarily be attributed to a specific mode of action. These are often referred to as the
 "phenotype-based approach" (Claeson and Bohlin, 1997; Swinney, 2013).

208 Which are the most common bioassays for determining target activity? The target bioactivity 209 can be assessed using a variety of bioassays, but the scientific community may prefer certain assays 210 for which troubleshooting, appropriate controls, and interpretation support are available 211 (Supplementary Table S1).

Are resources available to perform bioassays (in terms of ease of execution or technical complexity)? Specialized equipment and/or trained personnel are required to perform certain bioassays. In terms of safety, it is also important to consider whether the bioassay uses hazardous chemicals or organisms that must be handled in safety chambers and comply with local regulations (e.g., consider the biosafety level (BSL) of the target organisms or the use of genetically modified organisms (GMOs)).

218 What are the associated costs for personnel, equipment, and materials? Will the bioassay be 219 used as a routine method? A bioassay may be simple (e.g., an enzymatic reaction detected by a colour 220 change) and performed by a technician, whereas some types of bioassays (e.g., bioassays using cell 221 culture) require extensive training. Similarly, bioassays may be more or less labour-intensive and 222 require specialised equipment or expensive consumables.

223 Is high throughput and full automation of the analytical process required? Bioassays often use a 224 96-well plate format. A common plate-related phenomenon is the so-called "edge effect", in which the 225 response in peripheral wells differs from the response observed in the inner wells of a microplate. 226 There are several approaches to avoid this problem, such as using only the inner wells, randomization 227 in plate design, or replication (White et al., 2019). Recently, some manufacturers offer plates with a 228 built-in moat surrounding the outer wells (or even both inner and outer wells), that is filled with water, 229 and serving as an evaporation buffer during prolonged incubation. Depending on the desired 230 throughput, robotic liquid handling systems can be used to fully automate almost any bioassay 231 workflow, but the initial cost of such systems can be prohibitive for small laboratories.

Are standardized forms of bioassay available? Although standardization of bioassays facilitates interpretation and comparison of data between laboratories and allows better monitoring of bioassay performance, standardized bioassay protocols are available for only a limited number of bioassays. Inter-laboratory reproducibility or precision under the same operating conditions becomes more and more valuable in stages of higher levels of technology readiness (TRL).

237 What is required to interpret the results of the bioassay? What are the appropriate controls to 238 distinguish true results from false positives or false negatives? Before beginning to interpret the 239 results, it is assumed that the test performance was appropriate. This can be verified by including an 240 external positive or negative control (or sometimes an internal standard) in the assays, such as 241 organisms with a known phenotype, to ensure that the bioassay performance was optimal. The 242 measurements obtained can be compared to positive and/or negative controls, as well as to blank 243 measurements, to evaluate the effects of medium/buffer/background. Although method validation at 244 the discovery level is not essential, evaluation of precision, i.e., the degree of scatter between a series 245 of replicate measurements obtained from multiple samplings of the same homogeneous sample under the same conditions – expressed as coefficient of variation (CV) - makes the data more robust and 246 247 reliable.

How are the results to be interpreted in a meaningful way? Is the extract/compound bioactive?Benchmarks and thresholds for bioactivity must be considered, as there are common thresholds below

which an extract is considered very active or moderately active, while above these thresholds it is considered of little interest for further development. Meaningful evaluation of the results in combination with chemical dereplication strategies (i.e., evaluating the presence of known compounds in the crude extracts) (Gaudêncio and Pereira, 2015) plays a very important role in prioritizing samples for further development and deciding which samples are worthwhile for further development investment.

256 What is the expected content of bioactive compounds in the extract? How complex is the crude 257 extract and what is the level of background substances that would interfere with the measurement of 258 bioactivity? Advanced dereplication methods are used for natural product profiling/fingerprinting of 259 complex extracts (Gaudêncio and Pereira, 2015). An estimate of the expected content of bioactive 260 target compounds helps in the selection of the bioassay to avoid false positives in terms of required 261 sensitivity (high sensitivity for low-content compounds), selectivity (the extent to which the bioassay 262 can differentiate and detect a target analyte without interference from concurrently present irrelevant 263 compounds), and specificity, which is a measure of high selectivity (the ability to unambiguously detect 264 the target analyte in the presence of other substances, including those with similar chemical 265 structures). It also helps in the selection of appropriate controls and thus in the interpretation of data. 266 For some compounds, spiking samples with a reference standard can be a solution for detection and 267 quantitation, but a suitable standard must be available.

268 What is the desired level of quantitative response (qualitative, semi-quantitative, quantitative 269 results)? Does the potency need to be accurately assessed? Measurements can be binary (activity 270 present or absent), or quantitative information can be obtained by comparison with appropriate 271 controls. Although only quantitative bioassays are suitable for unambiguous determination of potency, 272 the need for such accurate information may be more important at later stages of discovery, 273 purification, safety, and efficacy testing. Quantitative assays often use standard compounds (spiking, 274 calibration curves), and it is worthwhile to check the availability of appropriate standards. In the 275 context of interpretation of results, determination of the limit of detection (LOD) and limit of 276 quantification (LOQ) provides better reliability of data. In addition, selection of bioassays with lower 277 limits of detection and quantitation usually results in a higher degree of confidence in the final data.

It is useful to know what may affect the precision or repeatability of bioassays. Some metabolites show synergistic effects and bioactivity is lost after fractionation, or metabolites may act antagonistically and activity is detected only after fractionation. In addition, physical parameters of the extract (viscosity, pH, colour, etc.) can lead to false-positive and false-negative results. Potential interferences can arise from the material of the sample containers (usually polypropylene and polystyrene, treated or untreated, or glass), and these should be carefully selected based on the charge and polarity of the molecules to be tested, if known (Strömstedt et al., 2014).

285 What is the solubility and stability of the compound of interest? Is it a small molecule or a 286 complex molecule? The solvent used for extraction must not be toxic or should not be used at a 287 concentration that is toxic to the microorganisms, cells, tissues, organs, or organisms. When aqueous 288 solutions are not used for extraction, extractions are usually performed with dimethyl sulfoxide 289 (DMSO), N,N-dimethylformamide (DMF), methanol, or ethanol, which can be tolerated in microbial or 290 cell-based assays only at low concentrations (e.g., up to 1 % DMSO) and whose presence may affect 291 final results (Dyrda et al., 2019; Hipsher et al., 2021; Rekha et al., 2006). Compounds extracted with 292 organic solvents can be vacuum dried to mitigate this issue. Nevertheless, the effect of extraction 293 solvents can be evaluated by performing the bioassay with the solvent as a control. In addition, poor water solubility can lead to misleading results. Bioassay optimization strategies are recommended to
 improve bioassay performance for poorly soluble compounds (Di and Kerns, 2006).

296 As mentioned earlier, the effect of extraction medium is evaluated by performing the bioassay 297 with the extraction solution alone. If necessary, this control is performed each time the bioassay is 298 conducted. Characteristics of the extraction medium such as thermostability, volatility, and complexity 299 (sedimentation properties and migration) can also affect the design of the bioassay, while 300 characteristics of the target substance such as thermostability, susceptibility to proteolytic 301 degradation, and complexity that affect the temperature and timing of extraction can also affect the 302 desired bioactivity. For example, enzymes are typically isolated at low temperatures because they can 303 be sensitive to proteolytic degradation or thermal denaturation, which can lead to loss of bioactivity. 304 In addition, natural products should be handled at temperatures below 40 °C to avoid degradation and 305 loss of bioactivity. In general, it is preferable to work with compounds that are stable under various 306 conditions, especially with regard to further development and for practical reasons with regard to the 307 application and marketing of the final products.

308 Do seasonal and geographic differences or legal aspects of sampling affect samples used for 309 bioactivity screening and thus affect biodiscovery? For many types of natural samples, re-sampling is 310 limited due to large seasonal or geographic variations. In addition, issues of safety and sustainability 311 should be considered. Legal issues can also limit transnational access to (marine) biological resources, 312 but this obstacle can be effectively addressed under the Nagoya Protocol and by following well-313 regulated procedures (Schneider et al., 2022).

Is there a need and possibility to validate the bioassay? Validation of bioassays in the discovery phase is useful for evaluating efficacy of candidate bioactivities with high precision and accuracy. This is also important for planning safety and efficacy testing and clinical trials, establishing the basis for discussions with regulatory authorities during planning. At later stages, at the quality control level, bioassays should also reliably assess the quality across different product batches.

What are the relevant target organisms? In bioassays involving living organisms, e.g., microorganisms, cell lines, or animals, it is important to select appropriate target organisms with respect to their relevance and the particular requirements for handling these organisms. An important aspect to consider is the growth conditions, as different growth conditions may affect the outcome of the bioassay.

Do we have a clear idea of the intended application? If there is a clear idea of an application/use, the local regulatory authority should be approached early in biodiscovery, as it is beneficial to use those bioassays that are congruent with product development, as this can be very useful to expedite the process.

328

329 Table 1

330 What to consider when selecting a bioassay to search for a selected bioactivity

Purpose

Is it aimed at general or specific bioactivity?

How selective should it be?

Are quantitative or qualitative results needed?

How sensitive should it be (what is the requirement for the minimal amount of compound)?

Cost

Time requirement

Cost of material				
	Requirement of special equipment (different modes of detection)			
	Effect of the extraction procedure on bioactivity			
	Selection of source material (amount available, possibility to reacquire)			
	Availability of source material (seasonal, geographic, legal)			
	Organic solvent or water-based			
•	Temperature of extraction			
	Length of extraction			
	Homogenization steps			
	Cultivation steps			
	Stability of bioactive compound			
	nterference with materials used for extraction (e.g., plastic, solvent components)			
Feasibility				
	Errors caused by the colour or viscosity of extracts			
	Reproducibility			
	High-throughput capacity or automation possibility			
	Ease of results interpretation			
	Other			
	Availability of standards			
	Bioactivity threshold			
	Capability of dereplication			
	Regulatory requirements (e.g., use of BSL2 or GMO organisms)			

When working with marine extracts or marine microorganisms in bioassays, special considerations should be made and adapted to the presence of salt, poorly hydrophilic, often highly coloured or autofluorescent, and chemically complex materials. Moreover, when working with higher organisms as a source of bioactivity, it should be verified whether the bioactivity originates from the macroorganism or from the associated microbiota (Beutler, 2009; De La Calle, 2017; Macedo et al., 2021). Geographic or seasonal variations in the production of bioactive metabolites, which have been demonstrated for different marine organisms (El-Wahidi et al., 2011; Heavisides et al., 2018; Hellio et al., 2004; Henrikson and Pawlik, 1998), are another important issue.

342 343

331 332 333

344 4. Prevalent bioassays in marine biodiscovery

Using a literature search of the PubMed database, we analysed research efforts on marine natural product discovery between 2000 and 2022 (Fig. 3). There is a panoply of bioassays that can be used to screen natural resources for their bioactive properties. We have compiled the most common of these in Supplementary Table S1 and provided a critical overview of their advantages and disadvantages. Here, we provide an overview of antimicrobial, antifungal, antiviral, and cytotoxicity bioassays, as well as those that investigate the antioxidant and anti-ageing potential of marine extracts. These include both phenotype-based and single-target bioassays to varying degrees, e.g., antimicrobial assays are mostly phenotype-based, whereas both phenotype-based and single-target bioassays can be used to assess cytotoxicity.

354

355 4.1. Antimicrobial bioassays

356 The strongest research efforts in the field of bioactivity of natural marine sources have been dedicated 357 to the detection of antimicrobial activities using phenotypic assays (Fig. 3). The term antimicrobial activity encompasses both antibacterial and antifungal activities, but is often used in studies that work 358 359 only with bacteria, whereas other studies claiming antimicrobial activities examine both bacteria and 360 fungi. In addition, there are studies that focus on one group of organisms and investigate either 361 antibacterial or antifungal bioactivity. The increased efforts are mainly due to the worldwide decline 362 in the development of antibiotics, while the increasing emergence of microorganisms resistant to 363 antimicrobials is becoming a global health threat (Dadgostar, 2019). The problem is of particular 364 concern for the Gram-positive and Gram-negative bacterial pathogens that belong to the ESKAPE group (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter 365 366 baumannii, Pseudomonas aeruginosa, and Enterobacter spp.), and some fungal pathogens (Candida 367 auris, Candida glabrata, Aspergillus fumigatus, Cryptococcus neoformans), for which an increasing 368 number of multidrug-resistant strains have been identified worldwide (Arendrup and Patterson, 2017; 369 Liu et al., 2019; Minarini et al., 2020). The ecological diversity of the marine environment and 370 (micro)organisms in this habitat, combined with the large genetic diversity, represents a unique and 371 rich source of compounds that can be exploited by the pharmaceutical industry and potentially provide 372 solutions to the increasing number of drug-resistant infectious diseases (Hughes and Fenical, 2010; Liu 373 et al., 2019).

374 The most commonly used bioassay to investigate the antimicrobial activity of marine natural 375 products is the determination of minimum inhibitory concentration (MIC) in the form of broth 376 microdilution, macrodilution, and agar dilution, followed by the disc diffusion/Kirby-Bauer method 377 (Fig. 4, Supplementary Table S1). These bioassays determine the lowest concentration of an 378 antimicrobial agent that prevents visible or measurable growth of a microorganism. Two organizations 379 develop standardized reference methods for antimicrobial susceptibility testing: the Clinical & 380 Laboratory Standards Institute (CLSI) (https://clsi.org/) and the European Committee on Antimicrobial 381 Susceptibility Testing (https://www.eucast.org/). Although some guidelines from standardized 382 protocols should also apply to bioassays performed on marine samples, noncompliance with these 383 guidelines is relatively common. Items whose standardization has a critical impact on the repeatability 384 and reliability of results include the selection of microbial species and strains, the size and age of the 385 inoculum, the type of culture medium, and the duration of incubation. To ensure the quality of the 386 bioassay performed, a positive control of a standard antibiotic should be tested against authenticated 387 microbial strains, preferably from a type culture collection such as national type cultures collections 388 (e.g., National Collection of Type Cultures (NCTC) in the United Kingdom; German Collection of 389 Microorganisms and Cell Cultures DSMZ; American Type Culture Collection - ATCC). Reagent sterility 390 controls and negative controls (e.g., influence of solvents) should also be included in each bioassay. 391 When working with complex samples such as natural extracts, the presence of other metabolites in 392 the extract can potentially serve as a carbon source for the microorganism used, which can mask the effect. Both technical and biological replicates should be performed to increase measurementaccuracy.

395 The main advantages of dilution methods are the ability to obtain quantitative MIC values 396 (minimum concentration that inhibits microbial growth) and MBC values (minimum bactericidal 397 concentration, lowest concentration at which 99.9% of bacteria are killed). Published MIC values for 398 marine extracts vary from μ g/mL to even mg/mL and are generally below 100 μ g/mL for pure 399 compounds (Choudhary et al., 2017). There are common thresholds at which the extract is considered 400 very active (<10 µg/mL), moderately active (10-250 µg/mL), and with little or no activity (> 250 µg/mL) 401 (Fajarningsih et al., 2018; Nweze et al., 2020; Pech-Puch et al., 2020). The optimal MIC and IC₅₀ 402 (concentration at which 50 % of growth inhibition is achieved) for a pure substance should be below 1 403 μ g/mL, while concentrations above 10 μ g/mL are considered of little interest for further research 404 (Cushnie et al., 2020). In the diffusion-based method, there is no quantitative result or only a limited 405 one. However, both types of bioassays can be useful to analyse the difference in antimicrobial activity 406 of individual natural products observed in different strains of a given species (e.g., resistant and non-407 resistant mutants). In vitro assays are characterised by simplicity of design and performance. They are 408 traditionally time-consuming but can be automated. However, the results are usually not available 409 within a day and do not provide information on the mechanism of action.

410 Gram-positive bacteria are more sensitive to the effects of many known agents than Gram-411 negative ones, which increases the likelihood of hits in screening studies (Cos et al., 2006). For this 412 reason, microorganisms from different groups should be included in the screening process. For each 413 microorganism tested, the optimal growth medium and inoculum size should be determined to avoid 414 underestimation or masking of antimicrobial activity (Wiegand et al., 2008). Many published studies 415 have used Lysogeny Broth (LB) media for antibacterial testing, but their use should be avoided due to 416 the imbalanced composition of carbohydrates, low availability of divalent cations, and occasional 417 contamination with bile salts (Nikaido, 2009; Sezonov et al., 2007).

The type of extracts (the type of solvent used) should be considered when choosing one of the above methods. For example, lipophilic compounds do not diffuse well into solid culture media, whereas strongly charged molecules may undergo ion exchange processes in agar. Therefore, the agar diffusion method is more suitable for the analysis of single metabolites with known polarity and not for complex extracts.

423 To further investigate the antimicrobial activity of natural molecules, time-kill assays and flow 424 cytometry methods can be used to provide information on the nature of the inhibitory effect and the 425 cellular damage inflicted on the test microorganism (Balouiri et al., 2016). This bioassay is used in a 426 second phase of testing to determine the dynamics of microbial inhibition kinetics (Dinarvand et al., 427 2020). Most antimicrobial bioassays are performed in vitro, but secondary screening for highly potent 428 compounds may also include in vivo assays, (e.g., in murine models), to gain better insight into their 429 preclinical potential (Martín et al., 2013). In vivo bioassays are generally not performed with extracts 430 because of the difficulty of interpreting effects based on an unknown mixture of compounds. However, 431 in some examples, in vivo testing is recommended early in the development timeline because potential 432 systemic side effects may be antagonistic or synergistic (Sabotič et al., 2020).

433

434 4.1.1. Antibiofilm assays

In recent years, the control of microbial biofilms has gained significant attention as it is increasingly recognized that biofilms are responsible for microbial persistence. New strategies for 437 combating microorganisms focus on the one hand on preventing biofilm formation by inhibiting adhesion or quorum sensing and on the other hand on eliminating biofilms by dispersion. Antibiofilm 438 439 agents are therefore considered as an alternative to fight microbial resistance to antibiotics, since 440 microorganisms do not need to develop resistance to adapt, as their population is not decimated, but 441 merely prevented from persisting in the selected environment. To date, there is only one standardized 442 assay for antibiofilm activity, namely the single-tube method (ASTM E2871), which is supported by a 443 standard practice for biofilm growth in a CDC biofilm reactor (ASTM E3161) optimized for biofilms of 444 Pseudomonas aeruginosa and Staphylococcus aureus (ASTM E2871-21, 2021; ASTM E3161-21, 2022; 445 Lozano et al., 2020). Biofilm formation is usually monitored by crystal violet staining, which is used to 446 stain the biomass of the biofilm. Other commonly used methods include measuring the metabolic 447 activities of biofilm cells with tetrazolium salts, culturing biofilm cells after sonication to determine the 448 number of CFUs (colony forming units) in the biofilm, or microscopy, which can be either scanning electron microscopy or confocal laser scanning microscopy (Bridier et al., 2010; Haney et al., 2021; 449 450 Kırmusaoğlu, 2019; Klančnik et al., 2017; Peeters et al., 2008). Antibiofilm activity is often expressed 451 as minimum biofilm inhibitory concentration (MBIC) or CFU log reduction. A microplate format can be 452 adapted for high-throughput screening evaluation of antibiofilm efficacy, typically screening individual 453 compounds at concentrations of up to 100 μ M and identifying active hits as those that inhibit biofilm 454 formation by \ge 80% while simultaneously inhibiting bacterial growth by \le 40% (Kwasny and Opperman, 455 2010). Inhibiting biofilm formation without affecting bacterial growth is preferable because there is 456 less pressure on survival and consequently on the development of resistance (Sterniša et al., 2022).

457 Bacterial cell-to-cell communication, which senses the density of bacterial cells and is referred 458 to as quorum sensing, is an important component of the biofilm formation process and bacterial 459 virulence. To identify antibiofilm agents, inhibition of quorum sensing is usually tested using quorum 460 sensing reporter strains. However, this approach has some limitations, including negative effects on 461 reporter strain growth, so appropriate control experiments are essential to obtain reliable results 462 (Defoirdt, 2018; Defoirdt et al., 2013; Taga and Xavier, 2011; Zhao et al., 2020). Alternative methods 463 have been developed that provide a better approximation of real biofilm conditions but require 464 specialized equipment, such as delicate microfluidic systems (Goeres et al., 2005; Millar et al., 2001; 465 Tremblay et al., 2015), the Calgary Biofilm Device (Ceri et al., 1999) or the BioFilm Ring Test (Olivares 466 et al., 2016). Simultaneous detection of antimicrobial and antibiofilm activity against important 467 pathogenic bacteria is also possible by studying their growth kinetics with a microplate reader and 468 using a growth curve analysis (Sterniša et al., 2022). Determination of both antibiofilm (i.e., inhibition 469 of biofilm formation or promotion of biofilm dispersion) and antimicrobial (i.e., inhibition of growth 470 and/or survival) activity is important to understand whether the compounds tested affect biofilm 471 formation directly or indirectly.

- 472
- 473

4.1.2. Special consideration for antifungal bioassays

The nature of filamentous fungal growth requires the use of adapted bioassays to test the antifungal activities of metabolites and molecules. The prevalence of fungal infections (both invasive and opportunistic fungal infections) is rising due to the increase in the ageing population and immunocompromised patients (Webb et al., 2018). In addition, acquired resistance has emerged in clinically relevant fungi such as *Candida* spp. and *Aspergillus* spp. Therefore, antifungal susceptibility testing (AFST) is of increasing importance in clinical microbiology laboratories, both for selection of appropriate therapy and to provide information on resistance rates at local and global levels in epidemiological studies. The same tests are also used for screening natural products and guiding the discovery of new antifungal agents. Many factors can influence the outcome of *in vitro* AFST tests, including the definition of the endpoint, the inoculum size of the studied fungus, the incubation period, the temperature, and the culture media used for the test (Berkow et al., 2020). For this reason, AFST is not recommended for every fungal pathogen detected in a sample and is performed in clinical microbiology laboratories primarily for yeasts.

487 Broth microdilution bioassays are routinely used for fungi, and there are two standard 488 methods for broth microdilution testing of yeasts in clinical laboratories and two others for molds: 489 those established by the Clinical and Laboratory Standards Institute (CLSI) and those established by the 490 European Committee on Antimicrobial Susceptibility Testing (EUCAST) (Arendrup et al., 2008; Clinical 491 and Laboratory Standards Institute, 2017a, 2017b; Rodriguez-Tudela et al., 2008). The four standards 492 use the same criteria to define the test endpoint and use similar criteria to develop clinical breakpoints 493 and thus interpret antifungal resistance and/or susceptibility. However, they differ in several aspects 494 regarding media composition, test microorganism preparation (including inoculum size), 495 measurement methods, and positive controls. Standardized protocols based on disk diffusion are 496 available for both yeasts (Clinical and Laboratory Standards Institute, 2009) and filamentous fungi 497 (Clinical and Laboratory Standards Institute, 2010). Although the qualitative results of the disk diffusion 498 method are suitable for routine use in the clinical laboratory, the quantitative MIC data are more 499 relevant for the treatment of invasive infections. Agar-based antifungal screening or "poisoned food 500 assays", in which fungal growth on a standard agar containing antifungal agents is evaluated. 501 Commercial kits are available for antifungal screening of *Candida* and *Aspergillus* spp..

Alternative methods for determining antifungal activity using specialized equipment have also been developed. These techniques include flow cytometry, in which changes in fluorescence are interpreted as changes in cell viability and fungal damage (Chaturvedi et al., 2004). With MALDI-TOF, changes in the proteome compared to a drug-free control are interpreted as indicators of antifungal activity (Sanguinetti and Posteraro, 2016). Isothermal microcalorimetry is used to determine changes in metabolic heat flow of cultured fungi in response to an antifungal agent and indirectly assess its activity (Furustrand Tafin et al., 2013).

509 510

4.2. Cytotoxicity bioassays

511 Cytotoxic activity is the second most studied bioactivity for marine natural products in the last twenty 512 years (Fig. 9, Fig. 3, Fig. 5). Cytotoxicity is often studied in terms of possible anticancer activity. There 513 are several types of bioassays to analyse the cytotoxic properties of natural products, which include 514 phenotypic and single-target bioassays. They are based either on the selective penetration of dyes into 515 dead and living cells or on the detection of markers leaking from the cytoplasm of dead cells. 516 Cytotoxicity bioassays based on selective dye penetration can be divided according to the nature of 517 their endpoints into colorimetric assays (e.g., tetrazolium salts such as MTT, MTS, XTT, or WST, trypan 518 blue, sulforhodamine B (SRB), neutral red uptake (NRU), crystal violet), fluorometric assays (Alamar 519 Blue (AB), 5-carboxyfluorescein diacetate, acetoxymethyl ester (CFDA-AM), carboxyfluorescein 520 succinimidyl ester (CFSE), propidium iodide (PI), Hoechst-33342, protease viability using 521 glycylphenylalanyl-aminofluorumarin (GF-AFC) as substrate, and luminometric assays (ATP-based and 522 real-time viability) as reviewed elsewhere (Aslantürk, 2018; Riss et al., 2019). The most commonly used 523 bioassays based on markers leaking from dead cells measure the activity of lactate dehydrogenase 524 kinase (AK), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or (LDH), adenylate

aminopeptidase. Another option is to preload cells with a measurable marker such as calcein-AM or
 radioactive ⁵¹Cr, which is typically used for mixed cell assays in immunology (Aslantürk, 2018; Riss et
 al., 2019). Assays are usually performed either in microplate format or flow cytometrically.

528 Testing different cell types is essential, especially in the context of cancer research, as each 529 cell type may respond differently to treatment (Niepel et al., 2017). The screening of 60 human tumour 530 cell lines for anticancer drugs (NCI60) by the US National Cancer Institute (NCI) was developed in the 531 late 1980s as a tool for in vitro drug discovery and then expanded into a service screening to support cancer research. In 2018, the NCI established a Program for Natural Product Development (NPNPD) to 532 533 develop a publicly accessible HTS-amenable library of more than 1,000,000 fractions from 125,000 marine, microbial, and plant extracts gathered from around the world to advance HTS efforts and 534 535 accelerate NP drug development. By 2019, 384-well plates containing over 326,000 fractions were 536 made available for free screening against any disease target (Gaudêncio et al., 2023; Thornburg et al., 537 2018). Regarding the evaluation criteria for cytotoxic activity, it was suggested that crude extracts 538 showing 50 % growth inhibition (GI₅₀) at concentrations below 100 μ g/ml should be considered 539 cytotoxic, while those holding promise for further investigation should have a GI_{50} below 30 μ g/ml 540 (Suffness and Pezzuto, 1991). Although cytotoxicity screening aims to identify compounds with growth 541 inhibitory or toxic effects on specific tumour types (disease-oriented approach), the patterns of 542 relative drug sensitivity and resistance generated with standard anticancer drugs can also help to 543 determine the mechanisms of action of the compounds tested. The information-rich nature of the 544 screening data thus provides additional insight into cytotoxic effects (Shoemaker, 2006). The pattern 545 recognition algorithm COMPARE assigns a biological response pattern to the 60-cell line dose-response 546 data for a compound and evaluates whether the response is unique or resembles a known or 547 prototypical compound to assign a putative mechanism of action to a tested compound. As more data 548 are collected on the characterization of different cellular molecular targets of the compounds tested, 549 the compounds most likely to interact with a particular molecular target can be selected (Park et al., 550 2010; Zaharevitz et al., 2002). The accuracy of cytotoxic bioassays is strongly influenced by cell type, 551 seeding density, and medium composition. Therefore, it is important to include appropriate controls 552 such as background control (no cells), negative control (untreated cells), and positive control (all cells 553 dead) and to test different cell types (Aslantürk, 2018; Carlsen et al., 2020; Cox et al., 2021; Riss and 554 Moravec, 2004).

555 An important aspect to consider when selecting an appropriate bioassay is understanding the 556 mechanism of cell death and the resulting kinetics. In this context, apoptosis-specific (e.g., Annexin-V 557 binding or addition of a caspase inhibitor) or necrosis-specific assays (e.g., detection of the released 558 High mobility group box 1 (HMGB1) protein or addition of specific inhibitors) can be used (Raucci et 559 al., 2007; Riss and Moravec, 2004; Shounan et al., 1998). Preferably, cytotoxicity assays should be 560 performed to cover multiple endpoints and determine multiple parameters from the same cell sample 561 that can reveal the actual cause of cell death (Aslantürk, 2018; Santacroce et al., 2015). Another aspect 562 to consider is whether the effect is cytotoxic or cytostatic (Anttila et al., 2019; Mervin et al., 2016). 563 Understanding the mode of action and molecular mechanisms targeted by cytotoxic compounds is 564 important for rational decision making about their use in specific cancer types, and for assessing the risk of potential cross-reactivity with other treatments, and side effects. 565

566

567 4.3. Antiviral Bioassays

568 Viral infections are a major cause of disease in the world because of their complexity, diversity, and rapid spread, which is often accelerated by urbanization, increased migration, and globalization 569 (Drexler, 2011). The 21st century is characterized by major viral epidemics and pandemics, such as 570 571 influenza A (H1N1) pdm/09, Ebola, Zika, severe acute respiratory syndrome (SARS), Middle Eastern 572 respiratory syndrome (MERS) and SARS-CoV-2 (Ong et al., 2020). In light of these emerging viruses, as 573 well as endemic viruses and the emergence of viral resistance, attention has focused on natural 574 products as sources of new antiviral drugs, including those from the marine environment (Bhadury et 575 al., 2006; da Silva et al., 2006; Dias et al., 2018; Linnakoski et al., 2018; Tziveleka et al., 2003).

576 The very first step before an antiviral assay is to determine the potential toxicity of the 577 compounds or extracts to host cells (Fig. 6). This is essential to rule out the possibility that the antiviral 578 properties observed in vitro are not due to cytotoxicity. For cytotoxicity screening, any of the methods 579 described in the previous section can be used. Although the MTT assay has been widely used in the 580 past, the ATP-based assay has proven to be the gold standard for measuring cell viability to date. It is 581 more sensitive than conventional biochemical methods because it detects cell death by a general 582 rather than a specific biological mechanism (Herzog et al., 2007; Ponti et al., 2006). However, assays 583 based on cell metabolism are not suitable for metabolically inactive cells, for which the fluorometric 584 microculture cytotoxicity assay (FMCA) is becoming increasingly popular. The FMCA assay is based on 585 the hydrolysis of the fluorescein diacetate (FDA) probe by the cytosolic esterases of intact cells 586 (Burman et al., 2011; Lindhagen et al., 2008; Strömstedt et al., 2014), and cell survival is reported as 587 an index of survival after treatment. If the results of the cytotoxicity assays indicate no effect on cell 588 line fitness, the compounds can then be tested with primary antiviral assays (Supplementary Table S1, 589 Fig. 6)(Gomes et al., 2016).

590 In cytotoxicity evaluation, the value of the 50% cytotoxicity concentration (CC_{50}), defined as 591 the concentration of a compound that produces a 50% cytotoxic effect (Hu and Hsiung, 1989), is 592 determined and used together with the value of the 50% effective concentration (EC₅₀, i.e., the 593 concentration of a compound that produces a 50% inhibition of viral replication) to evaluate the 594 efficacy of an antiviral candidate. This relative efficacy of a compound in inhibiting viral replication with 595 respect to inducing cell death is defined as the therapeutic or selectivity index (SI). Theoretically, a high 596 SI ratio corresponds to a safer and more effective compound that is cytotoxic only at very high 597 concentrations and exhibits antiviral activity at very low concentrations (Naesens et al., 2006; Reymen 598 et al., 1995). The antiviral activity is considered effective/useful when the CC₅₀ value is 20 times higher 599 than the EC₅₀ value (Cao et al., 2015). Since the CC_{50} and EC_{50} values for a given compound depend on 600 the assays used, the SI value varies from laboratory to laboratory. Nevertheless, the SI value is a widely 601 accepted parameter of a compound that expresses its in vitro efficacy in inhibiting viral replication 602 (Naesens et al., 2006; Reymen et al., 1995).

Several different assays can be used to determine antiviral activity (Supplementary Table S1)(De Clercq et al., 1980; Sauer et al., 1984; Sidwell, 1986; WHO Scientific Group, 1987). At this point, it is necessary to determine the cell system(s) best suited for virus replication on which to test new antiviral agents. Depending on the cell type used, the replication capacity of the virus and its actual effect on cells varies considerably (i.e., some viruses may cause a cytopathic effect (CPE), while others may form plaques or induce specific functions such as hemagglutination (e.g., orthomixyxovirus and paramixovirus) or hemadsorption. 610 A cytopathic effect (CPE) test is based on the observation of morphological changes that occur 611 in host cells as a result of viral infection and replication. The CPE-based assay was the first assay 612 developed to evaluate whether a compound is antivirally effective, and it can also be scaled up for 613 high-throughput screening (Maddox et al., 2008; Severson et al., 2007). Because viral replication leads 614 to cell death, cell viability assays can be considered a substitute for CPE assessment because they are 615 more accurate, automatable, and objective compared to visual assessment by an operator. Since CPE 616 is an indirect measure of viral load, the result regarding the protective effect of drugs against a virus 617 may also vary and be lower than other tests that measure viral load directly (PRA, VRA, see below) 618 (Gorshkov et al., 2021). Although the CPE assay was one of the first antiviral assays developed, 619 commercial kits (e.g., Viral ToxGlo Assay) that measure cellular ATP as an indicator of host cell survival 620 have allowed standardization of the procedure in many laboratories, and ATP depletion can be 621 correlated with viral load.

622 A widely used quantitative biological titration method is the plaque reduction assay (PRA). This 623 method is based on counting plaques formed by lysis of infected cells in a monolayer. The plaques are 624 visible to the naked eye or under a light microscope after staining with neutral red or crystal violet. 625 The plaque assay is the preferred method of viral titration because it is economical and technically 626 simple, but it can be tedious because visible viral plagues can take from 24 hours to several weeks to 627 form (El Sayed, 2000). Conflicting results may be obtained due to various limitations (see 628 Supplementary Table S1). Therefore, in addition to PRA, the virus yield reduction assay (VRA) is 629 recommended to determine the EC_{50} value by assessing viral progeny production in a growth 630 experiment. The assay conditions must be optimized, especially the multiplication of infection (MOI, 631 i.e., the ratio of virus to cell number), because this single parameter can significantly affect the 632 evaluation of antiviral activity and (a high MOI reduces the sensitivity of the virus to an antiviral agent 633 (Collins and Bauer, 1977; Sauer et al., 1984). Therefore, it is advisable to perform VRA at both low MOI 634 (multicycle viral replication) and high MOI (single-cycle replication), to compare the resulting EC_{50} 635 values, and to evaluate the range of action of the antiviral molecule as accurately as possible (Yang et 636 al., 1989).

637 For viruses that do not cause cytopathic effects, the focus-forming assay (FFA), an indirect 638 method for virus measurement, can be used. This is a variant of the plaque assay that relies on 639 immunohistochemical techniques, as it uses chemically or fluorescently labelled antibodies specific for 640 a viral antigen to detect infected cells (Flint S.J et al., 2009). For example, quantification of infectious 641 viral particles for α - (hCoV229-E) and β - (hCoV-OC43) coronaviruses relies on an enzymatic antigen 642 detection method that uses horseradish peroxidase (HRP) to label antigen-antibody complexes 643 (Lambert et al., 2008). Alternatively, if the viruses express hemagglutinin (HA), an envelope 644 glycoprotein (e.g., influenza virus, respiratory syncytial virus), the hemagglutination inhibition assay 645 (HIA) can be used. The method is based on measuring the ability of virions to adsorb to and agglutinate 646 red blood cells (RBCs) by binding to glycans (e.g., sialic acid) on the surface of red blood cells (usually 647 from rabbits, horses, chickens or guinea pigs). In practice, the hemagglutination assay is used to 648 determine the viral concentration that agglutinates an exact (standard) number of erythrocytes, 649 making it extremely accurate, although it is only applicable to certain viruses (Joklik, 1988). 650 Standardization of the HIA assay has been described (Kaufmann et al., 2017). In particular, before 651 performing the assay, the following should be considered: (i) although HIA assays provide consistent 652 results across multiple plates, the same amount of virus particles must be used in each plate; (ii) 653 according to WHO, the standard amount of HA used in the HIA assay is 4 units per 25 μ L [HA unit is the amount of virus required to agglutinate an equal volume of standardized RBC suspension]; (iii) the RBCs used depend on the type of influenza virus in the assay; and (iv) for different types of 96-well microtiter plates (V- or U-bottom), the incubation time and the occurrence of nonagglutinated cells are different (Kaufmann et al., 2017).

After a certain type of antiviral activity is detected, it is necessary to further investigate this activity using several specialized secondary bioassays for screening and/or monitoring purposes. These *in vitro* or *in vivo* assays are time-consuming, more expensive, and more challenging than the primary screening bioassays and require the expertise of biochemists or pharmacologists. Therefore, they can only be performed by a multidisciplinary team. Such secondary assays are necessary/mandatory to select potential candidates to be tested in human clinical trials (Gomes et al., 2016; Öberg and Vrang, 1990).

665 Meanwhile, new modern assays such as flow cytometry, tunable resistive pulse sensing (TRPS), 666 and quantitative real-time PCR (qPCR) are also increasingly being developed to determine antiviral 667 activity. In particular, qPCR was widely used during the SARS-CoV-2 pandemic because it allowed 668 testing of antiviral activity of many molecules against SARS-CoV-2 in a short time. However, it is 669 important to emphasize that during viral replication, the ratio of whole virions to nucleic acid copies is 670 rarely 1:1 and that the viral assembly process can produce complete virions, empty capsids, and/or an 671 excess of free viral genomes. Therefore, positive qPCR results may also be due to the presence of 672 residual viral nucleic acid (i.e., noninfectious virus) rather than infectious virus (Tandon and Mocarski, 673 2012). For this reason, many molecules with true antiviral activity might be rejected a priori simply 674 because they are unable to reduce viral genome copy number in a solution, even if the viruses present 675 are no longer active or infectious. Therefore, it is better to use qPCR-based methods for routine 676 laboratory testing and to confirm the results obtained with the classical methods described above 677 when necessary.

678

4.4. Bioassays for cosmetics and cosmeceuticals with a focus on antioxidant andanti-ageing effects

A variety of specialized bioassays have been developed and routinely used to evaluate the 681 682 overall cosmetic activity of a marine extract (Fig. 7). The majority of these bioassays are single-target 683 bioassays, but phenotypic bioassays are also available. In the primary screening and secondary testing 684 phases for potential cosmetics and cosmeceuticals, bioassays are mostly based on in vitro assays for 685 cytotoxicity, antioxidant and anti-inflammatory activities, using either biochemical cell-free assays or 686 immortalized cell lines (e.g., THP-1 and HaCaT cells). Once selected, the extracts or compounds are 687 tested for safety, activity, and mode of action in preclinical assays using primary cells (e.g., 688 keratinocytes) and/or ex vivo skin tissue models (Brancaccio et al., 2022), with the option to perform 689 final testing in clinical trials (Fig. 9). The anti-inflammatory activity of extracts or pure compounds can 690 be assessed by TNF- α or IL-1 β production measured in LPS-stimulated THP-1 activated human 691 macrophage cells (Lauritano et al., 2016). For example, in vitro bioassays are used to investigate the 692 antioxidant capacity of extracts by mimicking the damage caused by radicals in the skin and by 693 assessing the efficacy of natural extracts in combating this damage (Thring et al., 2009). Depending on 694 the mechanism by which radicals are scavenged, antioxidant capacity assays are broadly divided into 695 two categories: electron transfer (ET) and hydrogen atom transfer (HAT) based assays (Apak et al., 696 2007). Compared to HAT-based assays, the ET reaction is relatively slow, and its actual rate depends 697 greatly on laboratory conditions, such as solvent and pH (Apak et al., 2007; Huang et al., 2005). ET 698 assays widely used in cosmetics include the DPPH (2,2-Diphenyl-1-picrylhydrazyl), ABTS/TEAC (2,2'-699 azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)/Trolox®-Equivalent Antioxidant Capacity), CUPRAC 700 (CUPric Reducing Antioxidant Capacity), and Folin-Ciocalteu methods, each of which uses a different 701 chromogenic reagent with different redox potential (Ratz-Lyko et al., 2012), as shown in 702 Supplementary Table S1. Although the actual reducing capacity of an extract or compound is not 703 directly related to its ability to scavenge radicals, these biochemical assays are useful for initial 704 screening procedures (Amorati and Valgimigli, 2015; Apak et al., 2007). Most HAT-based assays are 705 kinetic and rely on a competitive reaction scheme in which the antioxidants of a natural extract and an 706 oxidizable probe compete for peroxyl radicals, the latter being thermally generated in a solution by 707 the decomposition of azo compounds (Apak et al., 2007; Huang et al., 2005). This is the case with the 708 oxygen radical absorbance capacity (ORAC) assay, which is widely used to measure the antioxidant 709 capacity of natural products with anti-ageing and cosmetic potential (Baldisserotto et al., 2012; 710 Dávalos et al., 2004; Dudonné et al., 2011; Ky and Teissedre, 2015; Le Lann et al., 2016). However, it 711 must be emphasized that most HAT and ET assays are sensitive to either hydrophilic or hydrophobic 712 antioxidants and therefore may underestimate the total activity of an extract (Fraga et al., 2014; Ratz-713 Lyko et al., 2012). Thus, a combination of these biochemical methods may be required to obtain 714 reliable results (Ratz-Lyko et al., 2012).

Another set of in vitro assays commonly used in the screening of cosmetics and cosmeceuticals 715 716 investigates the anti-ageing effects of the extracts, which include antioxidant and anti-inflammatory 717 activities (Brancaccio et al., 2022), but may also be related to their specific ability to block enzymes 718 involved in the breakdown of skin firmness (Thring et al., 2009). These include matrix 719 metalloproteinases (e.g., collagenase), serine proteases (e.g., elastase), and endoglycosidases (e.g., 720 mucopolysaccharide hyaluronidase), which degrade the major components of the extracellular matrix 721 (ECM) of the skin: collagen, elastin, and hyaluronic acid (Li et al., 2019; Rittie and Fisher, 2002). 722 Maintaining high levels of these components is critical for skin elasticity, firmness, and hydration, and 723 thus inhibitors of these hydrolytic enzymes are being sought (Madan and Nanda, 2018). In addition, 724 there is particular interest in the regulation of melanin levels in the skin (i.e., changes in skin 725 pigmentation), the overproduction of which leads to aesthetic problems such as pigmentation spots 726 (Lall and Kishore, 2014; Saghaie et al., 2013) as well as other skin conditions such as discoloration, 727 freckles, and skin cancer (An et al., 2005). Specific assays are available to study the inhibitory properties 728 of extracts on the activity of the enzyme tyrosinase, which catalyses the first rate-limiting steps of the 729 melanin biosynthetic pathway in melanocytes (Parvez et al., 2006). Typically, L-DOPA (an intermediate 730 in melanogenesis) is used as a substrate and its enzymatic oxidation to the red-colored dopachrome is 731 monitored spectrophotometrically to assess inhibition of tyrosinase. Despite the widespread use of 732 (bio)chemical antioxidant assays, they are usually performed under non-physiological conditions 733 without taking into account the cellular uptake of compounds and their mode of action at the 734 subcellular level, which inherently limits their ability to predict the true antioxidant effect in living 735 systems.

In vitro phenotypic assays usually investigate the regenerative properties of extracts on
 specific skin cell lines (e.g., fibroblasts) by monitoring their stimulatory effects on the production of
 ECM components (Adil et al., 2010; Boonpisuttinant et al., 2014; Pastorino et al., 2017; Roh et al., 2013;
 Yodkeeree et al., 2018), as well as their photoprotective effects in terms of cell viability (Moon et al.,
 2008). The protective role of extracts against photooxidative skin damage can also be evaluated by *ex vivo* approaches. Specifically, a cosmetic formulation is applied to the skin of human volunteers and

742 after a short period of time, strips of the outermost skin layers are removed, exposed to UV radiation, 743 and lipid peroxidation is assessed by measuring the losses of unsaturated fatty acids and the amounts 744 of primary, secondary, or end products of the reaction (Alonso et al., 2009). Cell line-based bioassays 745 are also used to estimate safety parameters by assessing skin irritation by evaluating direct cytotoxicity 746 or other types of damage to the epithelial barrier of the skin by measuring the permeability of 747 fluorescein through epithelial cell monolayers (OECD test no. 460). In addition, mutagenicity and 748 carcinogenicity (OECD test no. 451) are assessed using cell cultures, e.g., the *in vitro* micronucleus test 749 (OECD test no. 487) to detect chromosomal aberrations and the bacterial reverse mutation test (OECD 750 test no. 471) to detect gene mutations. An alternative to animal models for carcinogenicity testing is 751 cell transformation assays (CTA), which are used in combination with other approaches to evaluate 752 carcinogenic potential (Creton et al., 2012; Mascolo et al., 2018; Organisation for Economic Co-753 operation and Development - OECD, 2022; Scientific Committee on Consumer Safety - SCCS, 2021).

754 The biochemical and cell-based in vitro methods described are suitable for the screening and 755 monitoring phases of the drug discovery pipeline (Fig. 9) because of their greater simplicity, speed, 756 throughput, and cost-effectiveness, although they may not adequately reflect the actual biological 757 processes in skin cells. Therefore, ex vivo bioassays using skin tissues have been developed for 758 toxicological studies, such as the reconstructed human epidermis (RhE) test methods (OECD test no. 759 439, 431), using four validated commercial human skin models, viz. i.e., EpiSkin™, EpiDerm™, 760 SkinEthic[™], and EpiCS[®], which use reconstructed human epidermis equivalents to evaluate cell viability 761 and are used to assess skin corrosion or irritation potential. Bioassays for the assessment of ocular 762 damage include organotypic assay methods using tissues from slaughterhouses, such as bovine 763 corneas (OECD test no. 437) or chicken eyes (OECD test no. 438), or in vitro assays using corneal 764 epithelial cell lines to assess irritation by measuring direct cytotoxicity on rabbit corneal cell lines 765 (OECD test no. 491) or human cornea-like epithelium (OECD test no. 492) (e.g., EpiOcular™). For assessment of genotoxicity or reproductive toxicity, new alternative approach methodologies to 766 767 animal testing are being implemented worldwide, including in vitro methods using the whole embryo 768 culture test (WEC) to evaluate developmental toxicity in rodent embryos maintained in culture during 769 the early stages of organ formation, the MicroMass Test (MM), which uses embryonic limb 770 mesenchyme or central nervous system cells from chickens, mice, or rats to evaluate effects on cell 771 differentiation into chondrocytes and neurons as an indication of potential teratogenicity, and the 772 embryonic stem cell assay (EST), which is based on permanent cell lines to predict embryotoxicity by 773 evaluating effects on cell differentiation (Organisation for Economic Co-operation and Development -774 OECD, 2022; Scientific Committee on Consumer Safety - SCCS, 2021; Seiler and Spielmann, 2011).

- 775
- 776

5. Quality control and bioassay validation

778 5.1. The concept of validation

The concept of validation can be defined as a systematic approach to collecting and analyzing a sufficient amount of data under specified conditions and based on documented evidence (validation report) and scientific judgment, to provide reasonable assurance that the process of interest will reliably and consistently reproduce results within predetermined specifications when operated within specified parameters (Haider, 2006).

The main objective of the validation process is to produce reliable and consistent data (quality data). In addition, four critical components of data quality are identified, including analytical instrument qualification, analytical method validation, system stability testing, and quality control
 sampling (United States Pharmacopeial Convention, 2018), with each of these components
 contributing to overall quality:

789 Analytical instrument qualification (AIQ) is the collection of documented evidence that an 790 instrument is fit for its intended purpose and that its use provides confidence in the validity of 791 the data produced. It includes (i) design qualification (DQ), which is performed by the 792 manufacturer prior to purchase to ensure the technical characteristics required by the user; 793 (ii) installation qualification (IQ), which is performed prior to and at the time of installation; 794 (iii) operational qualification (OQ), which is performed after installation and major repairs; and 795 (iv) performance qualification (PQ), which is performed periodically to ensure continued 796 satisfactory performance during routine operation and includes preventive maintenance, 797 recalibration, and performance testing (Bansal et al., 2004; Kaminski et al., 2010; Valigra, 2010) 798 Analytical method validation is the collection of documented evidence that demonstrates that 799 an analytical method is fit for its intended purpose and provides assurance that its use with 800 qualified analytical instruments will generate accurate data of acceptable quality (Haider, 801 2006).

- System suitability tests (SSTs) are used to verify that the system meets predefined criteria.
 They are performed in conjunction with sample analyses to ensure that the system is
 functioning properly at the time of testing.
- Quality control (QC) samples help to ensure the quality of analytical results by being included
 immediately prior to or during sample analysis.

807

808 5.2. Validation of the analytical method

809 The concept of bioassay validation is often associated with compounds that are classified as drugs by 810 regulatory authorities, because the development, production and testing of these products are strictly 811 regulated. Consequently, bioassay validation is an integral part of the quality control system. This may 812 not be the case for cosmetic preparations or dietary supplements, where product characteristics and 813 claims dictate testing or trial requirements, however, in practice many cosmetic preparations claiming 814 bioactivity are also subject to rigorous testing. For biodiscovery and research, it is not usually necessary to meet quality control requirements, but it is good to keep the concepts of validation in mind and 815 816 apply them wherever possible. This can facilitate the transition from research to industrial 817 development, as well as communication with regulatory agencies, regardless of the type of application. 818 It is important that the operator performing the validation of the analytical procedure has the 819 scientific and technical understanding, process knowledge, and/or risk assessment capability to 820 adequately perform the quality functions of analytical method validation (Chan, 2011). The parameters 821 to be evaluated for validation depend on the type of method, and the measures used to describe the 822 performance of the analytical method are typically: accuracy (trueness), precision (repeatability), limit 823 of detection (LOD), limit of quantitation (LOQ), linearity (calibration curve), range, selectivity, 824 specificity, and robustness. All of these parameters must be determined for validation of a quantitative 825 analytical method, whereas specificity and limit of detection may be sufficient for a qualitative method. 826 There are numerous guidelines (more than 30) published by regulatory organizations; some of them 827 are summarized in Table 2. These guidelines can be used as a frame of reference for the validation 828 process. Unlike instrument qualification, the type of analytical method (e.g., sample matrix, analytical 829 equipment) determines the parameters to be evaluated, so it is important to select an appropriate

830 guidance document as a frame of reference. It is important to note that the terminology used in

- 831 different guidelines varies. For example, selectivity, specificity, or diagnostic specificity are defined
- differently in different guidelines (Borman and Elder, 2017; Chan, 2011; Kadian et al., 2016).
- 833
- 834 Table 2

835 The summary of selected validation guidelines and corresponding organizations

Organization	Abbreviation	Sample Guideline(s)	Area of Interest	Remarks and References
European Medicines Agency	EMA	Guideline on bioanalytical method validation (EMEA/CHMP/EWP/192217/ 2009)	Bioanalytical assays for drug development studies (with all clinical trials)	Biological matrices such as blood, urine, tissues etc. (European Medicines Agency, 2011)
European Network of Forensic Science Institutes	ENFSI	Guidelines for the single laboratory Validation of Instrumental and Human Based Methods in Forensic Science	Forensic	Biological matrices such as blood, urine, tissues etc. (De Baere et al., 2014)
International Council for	ІСН	Validation Of Analytical Procedures: Text And Methodology Q2(R1)	Pharmaceutical QC analyses	Pharmaceutical samples such as; Active Pharmaceutical Ingredient (API), finished drug samples (ICH Expert Working Group, 2005)
Harmonisation		Bioanalytical method validation and study sample analysis (M10)	Bioanalytical assays for drug development studies	Biological matrices such as blood, urine, tissues etc., Draft document (European Medicines Agency, 2019)
United States Food and Drug Administration	USFDA	Bioanalytical Method Validation- Guidance for Industry	Bioanalytical assays for drug development studies (with all clinical trials) and for veterinary drug development as well	Biological matrices such as blood, urine, tissues etc.(USFDA, 2018)
Association of Analytical Communities	AOAC	Guidelines for Single Laboratory Validation of Chemical Methods for Dietary Supplements and Botanicals	Food & Feed Quality	Food and feed stuffs (Harnly et al., 2012)
International Union of Pure &Applied Chemistry	IUPAC	Harmonized Guidelines for Single laboratory Validation of Methods of Analysis	General terminology on analytical method characteristics	Sample matrices are not specified (Thompson et al., 2002)
European Directorate for the Quality of Medicines & HealthCare-The Directorate-General for Health and Food safety	EDQM/DG- SANTE	Analytical Quality Control and Method Validation; Procedures for Pesticide Residues Analysis in Food and Feed (SANTE/12682/2019)	Food & Feed Quality	Specified on the pesticide analysis in food and feed samples (Philström et al., 2019)
EURACHEM	n/a	The Fitness for Purpose of Analytical Methods- A Laboratory Guide to Method Validation and Related Topics	General terminology on analytical method performance characteristics	Sample matrices is not specified (Barwick et al., 2014)
European Commission Joint Research Centre Institute for Health and Consumer Protection	ECJRC-IHCP	Guidelines for performance criteria and validation procedures of analytical methods used in controls of food contact materials (EUR 24105 EN - 1st edition/2009)	Food Quality	Migration analysis (from the food contacting part of the packing materials) (Bratinova et al., 2009)

Organization	Abbreviation	Sample Guideline(s)	Area of Interest	Remarks and References
				Pharmaceutical samples such
United States	USP	General Chapter <1225> Validation	Pharmaceutical QC	as Active Pharmaceutical
Pharmacopeia		of Compendial Procedures	analyses	Ingredient (API) and finished
				drug samples (USP 40, 2017)
United States	tod States	Guidance for Methods Development and Methods Validation for the RCRA Program	Environmental analysis	Test Methods for Evaluating
				Solid Waste (SW-846)
Environmental	USEPA			Methods (EPA Office of Solid
Protection Agency				Waste, 1992)

836

Validation of analytical methods is a progressive, dynamic, and time-consuming process, so it is recommended that a validation schedule (or protocol) be established (EURL, 2022; Shabir, 2003). In addition, there are fundamental differences in validation parameters between different types of assays (e.g., chromatography-based or ligand-binding assays), and this issue is addressed differently by different regulatory agencies, either by providing separate validation guidelines (e.g., ICH, EMA) or by specifying certain aspects in a guideline (e.g., FDA) (Borman and Elder, 2017; EMA Committee for human Medicinal Products, 2011; USFDA, 2018).

844

845 5.3. Data integrity and documentation

The term data integrity refers to the degree of a data-generating system in which the acquisition and 846 847 storage of data is undivided, coherent, reliable, and accurate. This does not depend on whether the data are in paper or electronic form (Wingate, 2004). The critical issue in ensuring the quality of 848 849 analytical procedures and data integrity is the documentation of all steps. Good documentation 850 practices (GDocP) is a term used in the pharmaceutical industry to describe the guidelines, standards, 851 and regulations for creating, maintaining, and archiving documents. These apply to all parties involved 852 in a process and to all activities. GDocP-based records have the following characteristics: they are 853 complete, truthful, clear, permanent, accurate, consistent, legible, and concise (Davani, 2017).

854 855

5.4. Good Laboratory Practice (GLP)

856 It is recommended that the principles of good laboratory practice (GLP) are followed at all times when 857 performing bioassays. GLP is a quality assurance system that addresses the organizational process and 858 conditions under which nonclinical health and environmental safety studies are planned, performed, 859 monitored, recorded, archived, and reported (OECD Series on Principles of Good Laboratory Practice 860 (GLP) and Compliance Monitoring, 861 https://www.oecd.org/chemicalsafety/testing/oecdseriesonprinciplesofgoodlaboratorypracticeglpan 862 dcompliancemonitoring.htm, accessed 4 May 2022).

863 864

865 6. Bioactivity-guided fractionation and/or purification

866 With the desired bioactivity in mind, a series of fractionation and analytical steps can be applied to 867 natural resources to isolate and/or purify specific compounds that exhibit the bioactivity of interest. 868 The path from a natural extract exhibiting a specific bioactivity to a dereplicated, purified, identified, 869 and characterised compound exhibiting that bioactivity is often quite long and labour intensive.

A significant portion of the labour and operating costs in a biochemical and analytical laboratory is devoted to the preparation (extraction) of samples for subsequent analytical separation. During the extraction process, the target compound is pre-concentrated and converted into a form suitable for subsequent instrumental analysis and chromatographic or electrophoretic separations, and the complexity of the matrix is reduced. Depending on the solvents and procedures used for extraction, we expect to isolate either small molecules such as polyketides, alkaloids, and terpenoids or complex polymers such as proteins and polysaccharides, and the purification steps are then designed accordingly (Fig. 8).

878 Extraction is the first important step in the screening process, and the selection of extraction 879 method and solvent(s) is critical for successful downstream processing. For example, bioactive 880 compounds may be present in both a highly polar/aqueous extract and a moderately nonpolar/organic 881 extract. In addition, the physicochemical properties of the starting material determine the steps in the 882 extraction process. For example, microalgae have a rigid cell wall that acts as a natural barrier to 883 prevent solvent molecules from diffusing into the cells and must be broken by mechanical and/or 884 physical techniques such as high-pressure homogenization, shear mixing (high-speed 885 homogenization), ultrasound-assisted extraction (UAE), microwave-assisted extraction (MAE) prior to 886 or simultaneously with chemical extraction (Benbelkhir and Medjekal, 2022; Tian et al., 2022). It is 887 important to consider all available alternatives of the extraction procedure to optimize the extraction 888 time and avoid possible structural or conformational changes of the extracted molecules that can alter 889 their bioactivity. Such changes are more likely to occur in large molecules (e.g., polysaccharides, 890 oligosaccharides). Switching from slow extraction methods (e.g., hydrothermal extraction), which 891 require longer processing time, to faster technologies such as UAE, MAE, or UMAE can help shorten 892 the extraction process and increase the likelihood that the molecule will remain intact (Guo et al., 893 2022; Qiu et al., 2022). However, chemical reactions can also occur when microwaves and/or 894 ultrasound are used for extraction.

895 Since a natural extract contains a mixture of molecules, the concept of bioactivity-guided 896 purification is based on the sequential application of different types of fractionations that separate 897 molecules from a mixture and the concurrent application of the selected bioassay to identify fractions 898 containing the bioactive compounds until a satisfactory level of purity is achieved. In each purification 899 step, the individual fractions are tested with the bioassay to select the fractions with the highest 900 bioactivity for further purification. Since numerous fractions usually need to be tested, it is optimal to 901 use a rapid and inexpensive bioassay with low volume requirements. A quantitative bioassay is 902 sufficient to guide the purification.

903 Purification is usually performed by either liquid-liquid phase separation (LLPS) or the currently 904 predominant solid phase extraction (SPE). SPE has become a standard analytical procedure for the 905 enrichment of target analytes by partitioning and/or adsorption onto a solid stationary phase. SPE is 906 currently the most widely used method for the extraction, concentration, purification, and 907 fractionation of organic compounds from a variety of samples, as well as for solvent exchange; in 908 addition, SPE is also used efficiently for the desalting of proteins and glycan samples. SPE offers several 909 advantages over liquid-liquid extraction, including higher recoveries, avoidance of emulsion formation, 910 lower organic solvent consumption, simpler operation and automation capability, improved selectivity 911 and reproducibility, and shorter sample preparation time. The standard SPE procedure begins with the 912 application of an analysed solution to a solid phase (sorbent), usually in a cartridge, in which the target 913 analytes are eluted with a suitable solvent and collected (Andrade-Eiroa et al., 2016; Faraji et al., 2019) 914 There are numerous adsorbents for the extraction of different types of molecules. Various SPE

915 mechanisms can be applied to separate target molecules using specific sorbent materials, such as

adsorption (e.g., using silica gel, alumina, florisil, or graphitic carbon-based packing), normal separation
(e.g., cyanogen-, diol-, or amino-based silica), reversed phase separation (e.g., octadecyl-, octyl-, butyl, or phenyl-bonded silica), ion exchange (various cation or anion exchangers), size exclusion (e.g.,
macropore silica or organic gels), affinity separation (carriers with immobilized affinity ligands), and
immunoaffinity separation (carriers with immobilized specific antibodies); often two separation
mechanisms can be used simultaneously (e.g., ion exchange and reverse phase separation) (AndradeEiroa et al., 2016).

923 Efficient SPE can also be performed with magnetically responsive adsorbents. Magnetic SPE 924 (MSPE) is becoming increasingly popular due to its ease of use, high extraction efficiency, and 925 straightforward automation (Jiang et al., 2019; Pena-Pereira et al., 2021; Šafaříková and Šafařík, 1999; 926 Vasconcelos and Fernandes, 2017). MSPE uses various types of magnetically responsive adsorbents 927 based on ferrimagnetic iron oxides (magnetite, maghemite) or ferrites to which specific affinity ligands 928 are immobilized. A popular variation of MSPE is immunomagnetic separation (IMS), which uses 929 magnetic nano/microbeads with immobilized specific antibodies (monoclonal, polyclonal, or 930 engineered) to capture target analytes or cells via antigen-antibody interactions (De Meyer et al., 2014; 931 He et al., 2018; Safarik et al., 2012; Šafaříková and Šafařík, 1999). Magnetically responsive materials 932 can also be used to separate and purify various biologically active compounds on a larger scale 933 (Franzreb et al., 2006; Safarik and Safarikova, 2014, 2004). Stir-bar sorptive extraction (SBSE) is based 934 on the use of a magnetic stir bar covered with a suitable sorbent (usually polydimethylsiloxane or 935 ethylene glycol-modified silicone material) into which the analytes are extracted. The technique has 936 been successfully used for the analysis of samples of varying complexity and for the detection, 937 concentration or removal of marine toxins in crude extracts (Chen et al., 2019; González-Jartín et al., 938 2020; Pena-Pereira et al., 2021; X. Wang et al., 2017).

939 Various SPE mechanisms are used to separate compounds from the extracts, which can be 940 performed in a column chromatography format. These are used to fractionate either by size (e.g., size 941 exclusion chromatography), charge (e.g., ion exchange chromatography), hydrophobicity (e.g., 942 hydrophobic interaction chromatography), polarity (e.g., reversed-phase vs. normal phase 943 chromatography), or other specific binding interactions (e.g., affinity chromatography). These 944 chromatographic stationary phases can be used in a variety of platforms/equipments, such as fast 945 protein liquid chromatography (FPLC), generally used for proteins or nucleic acids, or high-946 performance liquid chromatography (HPLC) or ultra-performance liquid chromatography (UPLC), used 947 for both proteins and small molecules. In addition to column mode, other SPE formats can be used 948 such as extraction disks and membranes, which are usually composed of glass fibers forming a matrix 949 on which particles of pure or modified silica gel are anchored (Andrade-Eiroa et al., 2016). Supercritical 950 fluid adsorption (SFA) or supercritical fluid chromatography (SFC) are another option, especially for 951 nonpolar volatile compounds. SFA can also be used for polar compounds that are poorly soluble in 952 supercritical CO₂ by using a suitable co-solvent such as ethanol (Dinarvand et al., 2020). Various types 953 of chromatography used for isolation, purification, and characterization of natural products have been 954 reviewed (e.g., (Bucar et al., 2013; Nehete et al., 2013; Saini et al., 2021; Sarker and Nahar, 2012; Yang 955 et al., 2020). Alternatively, variants of preparative polyacrylamide gel electrophoresis (PAGE) (e.g., 956 native PAGE, isoelectric focusing, 2D PAGE) can be used to separate mixtures of compounds from 957 extracts. Miniaturized analytical techniques can also be used for sample processing. Pipette tip or in-958 syringe SPE is a miniaturized version of standard SPE in which the absorbent material is packed in 959 plastic micropipette tips or in the needle of syringes; analytes are extracted by repeated aspiration and desorption of the sample. SPME can also be used for *in vivo* analyses, such as fish tissue sampling, due
to its low invasiveness. Headspace SPME allows selective extraction of volatile and semi-volatile
compounds from samples. Thin film microextraction (TFME) increases the volume of the extraction
phase and the surface-to-volume ratio, allowing higher extraction efficiency and rapid analysis (Faraji
et al., 2019; Pena-Pereira et al., 2021).

An important step in the isolation process is dereplication (Gaudêncio and Pereira, 2015), which is usually performed using tandem mass spectrometry (MS/MS), which determines the presence of known compounds. The bioactive extracts containing unknown compounds are usually selected for further fractionation. Alternatively, known compounds can be tested for new types of bioactivities using other types of bioassays, a process known as repurposing (Dinarvand et al., 2020; Houssen and Jaspars, 2012; Nothias et al., 2018; Pereira et al., 2020; Pushpakom et al., 2019; Veerapandian et al., 2020).

972 Information about the properties of the bioactive compound can be derived from the 973 purification process, and separation into specific fractions provides information about their 974 characteristics. The number of purification steps required to purify compounds varies from case to 975 case and usually ranges from two to eight. Finally, the structures of compounds are elucidated using 976 1D and 2D nuclear magnetic resonance (NMR), high-resolution mass spectrometry (HR-MS), X-ray 977 diffraction (for crystalline compounds), and other techniques to determine the absolute configuration 978 (for non-crystalline compounds) (Gaudêncio et al., 2023). It is important to note that the use of low-979 resolution tandem mass spectrometers (e.g., triple quadrupole mass spectrometers) may be sufficient 980 for targeted analysis of known compounds, but for untargeted analysis of unknown compounds, the 981 use of a high-resolution mass spectrometer (HR-MS) in tandem mode (e.g., quadrupole time-of-flight, 982 Orbitrap) is essential for accurate measurement of both molecular and fragment ions (Berlinck et al., 983 2022; Guo et al., 2022).

- 984
- 985

986 7. Application-oriented development

987 Given the enormous richness of the marine environment in terms of global biodiversity, almost 988 unlimited resources of bioactive compounds are available for various applications (Atanasov et al., 989 2021; Newman and Cragg, 2020; Rotter et al., 2021a). Over 38 000 compounds of marine origin are 990 listed in the Dictionary of Marine Natural Products (https://dmnp.chemnetbase.com), the MarinLit 991 database (http://pubs.rsc.org/marinlit/), and the Comprehensive Marine Natural Products Database 992 CMNPD (https://www.cmnpd.org/) (Lyu et al., 2021). Currently, around 1500 new marine compounds 993 are reported annually (Carroll et al., 2021), a substantial increase from the annual average of 1200 994 compounds reported nearly a decade ago (Kiuru et al., 2014). However, marine natural product 995 discovery faces several challenges. Despite support from research funding organisations in the EU and 996 worldwide, access to the marine environment and sampling of aquatic organisms remain very 997 challenging, while several technical issues, including supply of active compounds and sustainable 998 production, can hinder the biodiscovery process (Schneider et al., 2023, 2022). Furthermore, extracts 999 derived from marine organisms are very complex, and the potentially bioactive components are 1000 usually present at low concentrations or are characterised by high structural novelty/complexity, 1001 making their identification and isolation in sufficient quantities for extensive biological testing difficult.

1002By overcoming the above-mentioned challenges, a limited number of promising bioactive1003compounds are eventually isolated in quantities large enough to enable bioactivity studies and to

1004 support the different stages of natural product development. There are no universal sets of bioassays 1005 that should be used for specific research applications, while different types of bioassays are important 1006 for different phases of biodiscovery and product development. Much practical information on 1007 selecting a bioassay has been discussed in Section 3, but it is prudent to keep in mind the potential 1008 uses and regulatory requirements associated with the various intended applications from early 1009 discovery on. To illustrate this point, we consider the development pipeline (Fig. 9) of a general natural 1010 source value chain and focus on marine products intended for specific target markets, namely the 1011 pharmaceutical industry (medicines), the cosmetics industry, and the food industry (dietary 1012 supplements and/or ingredients for food or feed).

1013 1014

7.1. Pharmaceutical drug discovery

1015 The entire process to approval of a new drug can take 12-15 years for the pharmaceutical industry and 1016 costs up to \$2.8 billion (Wouters et al., 2020). In particular, drug discovery based on natural products 1017 has proven to be an extraordinary laborious, costly, and time-consuming process. Nevertheless, this is 1018 the most effective approach to new drug development, and the number of natural-product-inspired 1019 drugs is much higher than synthetic drugs, as over 67% of modern drugs are based on natural products 1020 or their derivatives. Many pharmaceutical companies have turned to combinatorial chemistry for drug 1021 structure discovery and optimization; however, only three new chemical drugs have been approved 1022 based on this methodology (Jimenez et al., 2020; Newman and Cragg, 2020). To date, 14 approved 1023 marine drugs are in clinical use, including 11 anticancer drugs, and 38 marine natural products are in 1024 clinical trials (18 in Phase I, 14 in Phase II, and 6 in Phase III). The vast majority of the latter (i.e., 33 of 1025 38) are being tested as anticancer drugs, whereas two are being investigated for viral diseases, one for 1026 Alzheimer's disease, one for chronic pain and one for relapsed or refractory systemic amyloidosis 1027 (https://www.marinepharmacology.org/approved). The drug development process involves five major 1028 steps: (i) discovery and development; (ii) preclinical research; (iii) clinical development; (iv) review by 1029 a health authority (e.g., FDA or EMA); and (v) postmarketing surveillance, including numerous phases 1030 and stages within each of these steps. Bioassays are primarily used during the first two steps of (i) 1031 discovery, including screening and bioactivity-guided purification, and during (ii) preclinical research, 1032 which serves as the decision-making basis for the next step of clinical trials (Fig. 9). For pharmaceutical 1033 and nutraceutical products, both of which promise health benefits and are subject to the same 1034 regulatory requirements, preclinical testing is followed by (iii) the clinical development phase, which 1035 includes a sequence of clinical trial phases. Phase I clinical trials focus on testing safety, dose and side 1036 effects in a small group of healthy volunteers. Phase II then enrols a medium-sized group of patients 1037 with the target disease or condition and treats them for several months to two years, comparing them 1038 to a placebo control group or an approved standard drug to obtain efficacy and additional safety data. 1039 Phase III studies are larger and of longer duration (1-4 years) and include approximately 300-3000 1040 patients who are treated and compared to a control group. Data collected in phase III provide 1041 information on long-term and rare side effects compared to the last two phases. After the drug has 1042 been approved (iv) by the regulatory authorities, i.e., the European Medicines Agency (EMA) and the 1043 European Food Safety Authority (EFSA) in Europe and the Food and Drug Administration (FDA) in the 1044 U.S.A., (iv) post-marketing surveillance (Phase IV) is conducted to obtain additional information on the 1045 benefits and risks of using a particular drug.

1046 The screening phase relies on *in silico* and *in vitro* biochemical assays to identify bioactive 1047 extracts, fractions, or lead compounds, with high-throughput screening playing a central role. 1048 However, in recent decades, interest from the pharmaceutical industry in conducting HTS 1049 programmes, particularly for natural products, has tended to decline (Harvey et al., 2015). This is 1050 primarily due to a number of bottlenecks associated with the complexity of biological extracts that can 1051 affect the accuracy of targeted molecular screening (e.g., the effects of active compounds can be 1052 masked by other components in the crude extract), associated costly efforts to reduce matrix 1053 complexity, and the limited success of large HTS campaigns previously conducted by companies. 1054 Nonetheless, interest in HTS natural products for drug discovery remains a hot research topic in 1055 academia. Laboratory-scale studies have reported the application of HTS techniques to a repertoire of 1056 natural products to identify potential therapeutic agents for tumour metastasis (Gallardo et al., 2015), 1057 cancer and necroptosis (Li et al., 2016), cell stress and cytotoxicity (Judson et al., 2016), metabolic and 1058 age-related disorders (C. Wang et al., 2017), and, more recently, COVID -19 (Chen et al., 2021; Coelho 1059 et al., 2020; Gaudêncio et al., 2023). Other studies have investigated natural product-like small 1060 molecules for their antimalarial activity (Kato et al., 2016) and their suitability for genome engineering 1061 technologies (e.g., inhibition of CRISPR-Cas9 (Maji et al., 2019)).

1062 In addition to experimental efforts, complementary dry-lab approaches (e.g., virtual screening) 1063 have emerged under increasing pressure to reduce costs and improve the speed and simplicity of the 1064 biodiscovery process (David et al., 2015). These efforts primarily involve the use of structure-assisted 1065 drug design in conjunction with virtual HTS. With respect to natural products, this approach has been 1066 applied in a substantial number of studies to accelerate the discovery of antiviral agents against 1067 coronaviruses (Jin et al., 2020; Naik et al., 2020), while others have focused on identifying molecular 1068 entities with inhibitory activity against typical disease-related enzymes (e.g., cancer, diabetes, and 1069 neurodegenerative disorders) (Jhong et al., 2015; Khan et al., 2019; Mohammad et al., 2019).

1070 Natural products that have been evaluated for pharmacological or biological activity and have 1071 the potential to be therapeutically useful can be considered drug hits. However, in the early stages of 1072 drug development, a hit-to-lead (H2L) process is used that includes mechanism-of-action studies to 1073 identify the pharmacological targets of potent hits and a limited optimization of their chemical 1074 structure to reduce potential side effects, increase affinity and selectivity, improve efficacy, potency, 1075 metabolic stability (half-life) and oral bioavailability. A lead-optimization (LO) process is then 1076 performed to synthesize, evaluate, and modify the bioactive compounds using medicinal chemistry 1077 approaches to form new chemical entities (NCEs) that improve efficacy and reduce side effects. Lead 1078 optimization also involves experimental in vitro and in vivo testing in a variety of efficacy studies, 1079 pharmacokinetic studies, and toxicological assessments, as well as ADMET (absorption, distribution, 1080 metabolism, excretion, toxicity) assessments through the use of *in silico* models and animal testing to 1081 develop therapeutically effective drugs. For this reason, the preclinical phase is typically more time-1082 consuming, more expensive, and requires less testing capacity than the preceding screening phases, 1083 and may require more qualified personnel working according to the principles of good laboratory 1084 practice (Andrade et al., 2016; Claeson and Bohlin, 1997; Collins et al., 2020).

1085 Before the bioactive compound (lead structure) enters a new phase of development for a 1086 specific application, its toxicity to humans, animals, and the environment must be determined. The 1087 conclusions drawn from the safety and toxicity tests are highly dependent on the results of the 1088 bioassays used. Bioactivity must be quantified at this stage to determine dose (exposure) and derive 1089 potency. Different types of bioassays may be required for these steps, but often only validated versions 1090 of the quantitative bioassays already used in the discovery phase are used. The pure compounds (lead 1091 compounds) are tested in vitro on primary cell lines or ex vivo tissue models, or combinations thereof, 1092 specifically designed for the application of interest. The lack of adequate human disease models has 1093 been described as a major limitation in preclinical drug development (Khanna, 2012). Recently, 1094 however, several preclinical human disease models have been developed for several common chronic 1095 inflammatory diseases (e.g., osteoarthritis, cardiovascular disease, chronic lung disease, psoriasis, 1096 atopic dermatitis) and various cancer types, using two-dimensional (2D) cell culture methods, ex vivo 1097 and co-culture models and three-dimensional (3D) organoid structures. These disease models serve as 1098 immediate in vivo testing platforms to evaluate the efficacy and safety of drug candidates prior to 1099 entering clinical phases (Araújo et al., 2020; Ho et al., 2018; Jessica E Neil et al., 2022; Muenzebrock et 1100 al., 2022; Veldhuizen et al., 2019). Results from disease models form the basis for designing and 1101 planning potential clinical trials or conducting other safety and efficacy testing required by regulatory 1102 authorities for a particular application (e.g., pharmaceutical, nutraceutical or cosmetic). It should be 1103 emphasized that the safety evaluation of pharmaceutical, food, and cosmetic ingredients is more 1104 stringent than that of well-characterised non-food substances, such as industrial chemicals or 1105 pesticides (Śliwka et al., 2016). Moreover, cosmetics and dietary supplements are not required to be 1106 approved for sale by the FDA or EMA. Nevertheless, the cosmetics industry has recently become 1107 interested in incorporating marine bioactive compounds into cosmetic products (e.g., creams and 1108 lotions) that have medicinal or drug-like effects. In this context, the term "cosmeceuticals" has been 1109 coined to describe the combination of cosmetics and pharmaceuticals, but it does not yet have any 1110 legal meaning under current regulations.

1111 The potential toxicity of compounds is determined based on their chemical structure and 1112 mechanism of action to characterize concentration-dependent effects, long-term effects, and effects 1113 of exposure at low concentrations. Animal testing can provide valuable information on toxicity and 1114 pharmacological activity, including pharmacokinetics (ADME) and pharmacodynamics (interaction 1115 with the organism), but interspecies differences in drug toxicity and efficacy can become an important 1116 issue. Despite the recognized limitations and benefits, there are ongoing efforts to reduce the use of 1117 animals for testing. Indeed, in vivo testing in animals and humans is subject to strict ethical constraints, is costly, and therefore is generally performed only in the final stages of development (Ferdowsian and 1118 1119 Beck, 2011). Current regulatory approaches to toxicity testing and evaluation continue to rely primarily 1120 on a checklist of in vivo tests that follow standardized test guidelines or protocols. The Interagency 1121 Coordinating Committee on the Validation of Alternative Methods ICCVAM, along with other 1122 organizations, is promoting the development of non-animal alternatives to current in vivo acute 1123 systemic toxicity tests (Clippinger et al., 2018; Hamm et al., 2017; Kleinstreuer et al., 2018). There is a 1124 trend toward increased use of new technologies such as high-throughput screening (HTS), tissue chips, 1125 and computational modelling to better predict human, animal, and environmental responses to a wide 1126 range of substances relevant to new product development. The International Cooperation on 1127 Alternative Test Methods (ICATM) partnership was created to establish international cooperation in 1128 validation studies and the development of harmonized recommendations to ensure global acceptance 1129 of alternative methods and strategies

- 1130 (https://ntp.niehs.nih.gov/whatwestudy/niceatm/iccvam/international-
- 1131 partnerships/icatm/index.html).

1132 Significant efforts are being made to develop in vitro tests that cover endpoints and target 1133 organs/tissues that are most relevant to humans (Bal-Price et al., 2015). However, in some cases, 1134 animal models may still be needed to address specific developmental toxicity questions (Clippinger et 1135 al., 2018; Leist et al., 2013; Wambaugh et al., 2018). In this context, zebrafish-based bioassays offer an 1136 interesting combination of an *in vivo* model and the possibility of high-throughput screening with low 1137 compound consumption. For example, zebrafish embryos have been established as an in vivo model 1138 for the analysis of angiogenesis and vascular development and can be further developed for other 1139 specific high-throughput screening (Crawford et al., 2011). Another alternative to these assays is the use of the whole-animal *Caenorhabditis elegans* (e.g. (Durai et al., 2013; Palacios-Gorba et al., 2020).
In addition, phenotype-based bioassays are also used to retarget known compounds to unknown and
novel targets (Pushpakom et al., 2019).

1143 In recent years, computer-assisted methods have been used to predict or model the ADMET properties of lead compounds, enabling drug design and identification of potentially problematic 1144 1145 structures in the early stages of drug discovery to avoid late-stage failures (Ortega et al., 2012). 1146 Computer-aided drug design (CADD) is increasingly being used in drug discovery. Existing tools for 1147 predicting and visualising ADME/toxicity data include: i) predictors of ADME parameters, ii) predictors 1148 of metabolic fate, iii) predictors of metabolic stability, iv) predictors of cytochrome P450 substrates, 1149 and v) software for physiology-based pharmacokinetic (PBPK) modelling (Romano and Tatonetti, 2019; 1150 Wishart, 2009, 2007). These enable pharmacophore modelling (PM), molecular docking (MD), inverse 1151 docking, chemical similarity search (CS), development of quantitative structure-activity relationships 1152 (QSAR) (Pereira et al., 2015, 2014), virtual screening (VS) (Cruz et al., 2018; Dias et al., 2018; Gaudêncio 1153 and Pereira, 2020) and molecular dynamics simulations (MDS), which effectively predict the 1154 therapeutic outcome of lead structures and drug candidates and accelerate the discovery process. The 1155 importance of predictive models for clinical pharmacology is recognized by regulatory agencies, and 1156 this approach is being used for various applications. These models combine different types of data and 1157 parameters to estimate pharmacological activities and are commonly referred to as physiologically 1158 based pharmacokinetic (PBPK) models. By linking the properties of individual lead molecules to 1159 physiological properties, PBPK models also provide a rational approach to predicting drug similarity 1160 (Benjamin et al., 2010; Deepika and Kumar, 2023; Karnati et al., 2023; Mbah et al., 2012; Strömstedt 1161 et al., 2014).

By exploring structural and other data about the target (enzyme/receptor) and ligands, CADD approaches have identified compounds that can treat disease. Examples of approved drugs that have been supported by CADD include dorzolamide, saquinavir, ritonavir, indinavir, captopril, and tirofiban (Dar et al., 2019). Given the success of this approach, the development of "go/no-go" selection criteria and optimization strategies for drug candidate development should include the use of advanced CADD for drug metabolism and pharmacokinetics (DMPK) profiling in the development of safe and effective drugs.

7.2. Cosmetics

1169 1170

1171 Cosmetic products are intended to be applied to the external parts of the human body, including the 1172 teeth and oral mucous membranes, to cleanse, protect, change their appearance, improve their odour 1173 or keep them in good condition. Their use is regulated in the EU by the EU Cosmetics Directive 1174 (Directive 1223/2009) and in the US by the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the 1175 Fair Packaging and Labelling Act (FPLA). In the EU, all cosmetic products are registered with the EU 1176 Cosmetic Products Notification Portal (CPNP) and must undergo a safety assessment, have a product 1177 information file, and report serious undesirable effects. Manufacturing must be in accordance with good manufacturing practice (GMP), must not involve animal testing, and labelling is subject to strict 1178 1179 rules (Regulation EC 1233/2009). In the U.S., registration under the FDA's Voluntary Cosmetic 1180 Registration Program (VCRP) is not required but it is encouraged, the use of animals for testing is not 1181 prohibited, and truthful labelling is also regulated. It is also important to distinguish between 1182 pharmaceuticals and cosmetics, as pharmaceuticals require FDA approval and include products that 1183 claim, for example, hair restoration, pain relief, anti-ageing effects, relief of eczema, dandruff or acne, sun protection, etc. Therefore, the path of regulation may vary depending on the product's intended
use. Similarly, if a product corrects or alters physiological functions by exerting a pharmacological,
immunological or metabolic effect, it should be classified as a medicinal product in the EU (Regulation
EC 1233/2009, FDA Cosmetics Laws & Regulations https://www.fda.gov/cosmetics/cosmeticsguidance-regulation/cosmetics-laws-regulations, accessed May 6, 2023).

1189 The ingredients of cosmetic products must not be harmful or toxic and must comply with the 1190 lists of prohibited and restricted substances. Only approved colorants, preservatives, and UV filters 1191 may be included in cosmetic products. The International Nomenclature Committee (INC) manages 1192 internationally recognized systematic names for cosmetic ingredients such as plant extracts, oils and 1193 chemicals with the abbreviation INCI (International Nomenclature Cosmetic Ingredient), which are 1194 used in the European Commission's database for information on cosmetic substances and ingredients 1195 CosIng (https://ec.europa.eu/growth/tools-databases/cosing/index.cfm, accessed May 6, 2023), but 1196 inclusion in the database does not imply approval for use. INCI names are primarily used for cosmetic 1197 product labelling to avoid confusion, as an ingredient may have different chemical names (e.g., 1198 common names, CAS or IUPAC names) in different countries.

1199 Typical safety assessment procedures for cosmetic ingredients include the following elements: 1200 (i) hazard identification to identify the intrinsic toxicological properties of the substance using New 1201 Approach Methodology; (ii) exposure assessment calculated based on the declared functions and uses 1202 of a substance as a cosmetic ingredient, the amount present in each cosmetic product category, and 1203 the frequency of its use; (iii) dose-response assessment; and (iv) risk characterization, which usually 1204 focuses on systemic effects. The ban on animal testing and the requirement to use only validated 1205 replacement alternative methods in Europe ensure that the New Approach Methodology (NAM) is 1206 followed, which includes in vitro, ex vivo, in chemico, and in silico approaches, read-across, and 1207 combinations thereof, to support regulatory decision-making by providing information for hazard and 1208 risk assessment (Scientific Committee on Consumer Safety - SCCS, 2021).

Marine resources offer an interesting repertoire of bioactive ingredients with cosmetic potential. Extracts from seaweed, algae, soft corals, or other marine life are rich in proteins, amino acids, exopolysaccharides, carbohydrates, vitamins (A, B and C), fatty acids, and trace elements that contribute to hydration, firming, slimming, shine, and protection of human skin, as well as bioactive compounds with, for example, antioxidant and anti-inflammatory properties that protect the skin from ageing and photooxidation (Guillerme et al., 2017). Therefore, beauty products with marine ingredients are becoming increasingly widespread.

1216

1217 7.3. Food and feed supplements

1218 Food supplements are foods whose purpose is to supplement the normal diet and consist of 1219 concentrated sources of nutrients (e.g., vitamins, amino acids, and minerals) or other substances with 1220 nutritional or physiological effects. Their use is regulated by the establishment of substance lists that 1221 are positively evaluated by a food safety authority, such as the European Food Safety Authority (EFSA) or United States Food and Drug Administration (FDA) for safety of ingestion and bioavailability (i.e., 1222 1223 the effectiveness with which the substance is released into the body). These agencies also provide 1224 guidance on the type and extent of information that should be submitted to demonstrate 1225 bioavailability and toxicological data. Special regulations apply to foods for infants and young children 1226 and to foods for special medical purposes (Younes et al., 2021)(https://www.fda.gov/food/guidance-1227 regulation-food-and-dietary-supplements, accessed May 6, 2023).

Safety testing evaluates safety based on biological, physical, and chemical parameters. Physical tests check for the presence of foreign objects. Biological safety tests ensure the absence of pathogens and toxins, and chemical tests detect trace elements or contaminants such as food additives, flavourings, contaminants such as heavy metals, nitrates, disinfectants, pesticides, dioxins, residues of veterinary drugs including antibiotics, and components of food contact materials (EU Food safety 2022, https://ec.europa.eu/food/safety_en, accessed May 6, 2023).

1234 There is a growing interest in functional food ingredients and dietary supplements for which the 1235 marine environment is an important resource. Numerous compounds such as enzymes, proteins, 1236 peptides, polysaccharides, polyunsaturated ω -3 fatty acids (PUFA), phenols, pigments, and other 1237 secondary metabolites have already found use in the food industry (Boziaris, 2014; Šimat et al., 2020). 1238 In addition to routine identification of known toxins or contaminants using analytical chemistry 1239 methods, bioassays for detection of potentially unknown or unexpected toxic components are 1240 important for food and feed safety. Apart from animal testing, bioassays are the only way to identify 1241 novel risks in food or feed ingredients, especially when new and alternative resources are introduced. 1242 This will become especially important with the advent of the circular economy and green waste plans, 1243 which will increase the input of waste streams into the food chain (Gerssen et al., 2019).

1244 1245

1246 8. Conclusions

1247 Many new and repurposed biologically active natural products from microorganisms and 1248 macroorganisms from the marine environment have been detected and characterized using in vivo, in 1249 vitro, and in silico bioassays. The choice of bioassays used in biodiscovery is critical to the successful 1250 path from extract to marketed product. Therefore, it is important to realise that each extract contains 1251 many bioactivities and that when pursuing a bioactive compound using a series of bioassays to isolate 1252 and purify the targeted bioactive compound, the other components of the extract should not be 1253 discarded as inactive. Additional valuable bioactivities may be revealed by other bioassays. Conversely, 1254 a bioactive compound targeted for a particular application can be reassessed for other types of 1255 bioactivities as part of the repurposing process. Only when all these aspects are taken into account is 1256 it possible to optimize the potential and make the best use of the various natural resources and, in 1257 particular, the marine environment, which is now being increasingly explored.

1258 A careful inspection of the literature reveals many questions regarding the performance of 1259 bioassays used for screening and identification of bioactivity. Some of these issues relate to possible 1260 artifacts in assay results, variations in activity within different methods, differences in solubility, 1261 synergy of compounds in the tested extract, proper use of controls, storage conditions of extracts, etc. For many bioassays routinely used in research laboratories, there are no standardized assay 1262 1263 procedures, so it is often very difficult to compare results reported by different laboratories. To improve the potential for standardization of bioassays, fundamental properties such as robustness, 1264 1265 reproducibility, relevance, sensitivity, cost-effectiveness, automation, accuracy, and selectivity should 1266 be considered in the development and selection of bioassays to be used. A practical aspect is the use 1267 of validated protocols, appropriate controls, and biologically relevant concentrations in bioassays. In this way, it can be assessed at an early stage of biodiscovery whether the selected bioactivity has 1268 1269 realistic potential, for example, for pharmacological or cosmetic applications, or whether it is merely 1270 an interesting but descriptive discovery.

1271 It is important to note that computational approaches should be widely incorporated into 1272 biodiscovery screenings for two reasons: (i) these approaches are data-driven, so their inclusion in 1273 screening protocols will provide large amounts of data that can be examined for valuable patterns for 1274 further discovery; and (ii) large amounts of data are already available for analysis, so systematic 1275 analysis of data should become routine, including genome sequences, gene expression, chemical 1276 structures analytical data, genotype or proteome data, human microbiome, or electronic health 1277 records. These analyses, performed using computational tools, can save time through dereplication, 1278 prediction of new targets for already known compounds, and information on modes of action. 1279 Understanding the molecular mode of action of bioactive compounds is particularly important because 1280 this knowledge helps in the development of new ways to elicit the same effect when the original 1281 bioactive compound proves toxic or immunogenic, cannot be synthesised, and/or is not available in 1282 sufficient quantity or is lost from natural resources.

Finally, scientific research must be supported by innovation. The search for products for human and environmental health and well-being, including the development of new bioassays, must consider the principles of ethics, responsible research and innovation (RRI) (Schneider et al., 2022), good laboratory practices, and respect for natural ecosystems and habitats.

1287

1288 9. Acknowledgments & funding

- 1289 This publication is based upon work from COST Action CA18238 (Ocean4Biotech), supported by COST 1290 (European Cooperation in Science and Technology) program.
- 1291 Research of Jerica Sabotič and Nika Janež was supported by Slovenian Research agency (J4- 2543, J4-1292 4555, P4-0127, P4-0432).
- 1293 Research of Evita Strode was supported by ERDF post-doctoral research grant 1.1.1.2/16/I/001 1294 (application No 1.1.1.2/VIAA/3/19/465).
- Susana Gaudêncio: This work is financed by national funds from FCT Fundação para a Ciência e a
 Tecnologia, I.P., in the scope of the project UIDP/04378/2020 and UIDB/04378/2020 of the Research
 Unit on Applied Molecular Biosciences UCIBIO and the project LA/P/0140/2020 of the Associate
- 1298 Laboratory Institute for Health and Bioeconomy i4HB.
- 1299Research of Anna Luganini and Giovanna Cristina Varese was financed by the University of Torino1300(Ricerca Locale) and the European Commission NextGenerationEU, Project "Strengthening the MIRRI
- 1301 Italian Research Infrastructure for Sustainable Bioscience and Bioeconomy", code n. IR0000005.
- Research of David Ezra was supported by The Chief Scientist of the Israeli Ministry of Agriculture andRural Development (MOARD), grant number 20-02-0122, and Copia Agro Israel
- 1304 Research of Dina Simes was funded by the Portuguese National Funds from FCT—Foundation for
 1305 Science and Technology, through projects UIDB/04326/2020, UIDP/04326/2020 and LA/P/0101/2020
 1306 and AAC nº 41/ALG/2020 Project nº 072583 NUTRISAFE.
- 1307

1308 10. References

- Adil, M.D., Kaiser, P., Satti, N.K., Zargar, A.M., Vishwakarma, R.A., Tasduq, S.A., 2010. Effect of
 Emblica officinalis (fruit) against UVB-induced photo-aging in human skin fibroblasts. J
 Ethnopharmacol 132, 109–114. https://doi.org/10.1016/j.jep.2010.07.047
- Alonso, C., Barba, C., Rubio, L., Scott, S., Kilimnik, A., Coderch, L., Notario, J., Parra, J.L., 2009. An ex
 vivo methodology to assess the lipid peroxidation in stratum corneum. J Photochem Photobiol B
 97, 71–76. https://doi.org/10.1016/j.jphotobiol.2009.08.003

- Amorati, R., Valgimigli, L., 2015. Advantages and limitations of common testingmethods for
 antioxidants. Free Radic Res 49, 633–649. https://doi.org/10.3109/10715762.2014.996146
- An, B.-J., Kwak, J.-H., Son, J.-H., Park, J.-M., Lee, J.-Y., Park, T.S., Kim, S.-Y., Kim, Y.-S., Jo, C., Byun, M.W., 2005. Physiological Activity of Irradiated Green Tea Polyphenol on the Human Skin. Am J
 Chin Med (Gard City N Y) 33, 535–546. https://doi.org/10.1142/S0192415X05003144
- 1320 Andrade, E.L., Bento, A.F., Cavalli, J., Oliveira, S.K., Schwanke, R.C., Siqueira, J.M., Freitas, C.S.,
- 1321 Marcon, R., Calixto, J.B., 2016. Non-clinical studies in the process of new drug development -
- Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to
 clinical studies. Brazilian Journal of Medical and Biological Research 49, e5646.
- 1324 https://doi.org/10.1590/1414-431x20165646
- Andrade-Eiroa, A., Canle, M., Leroy-Cancellieri, V., Cerdà, V., 2016. Solid-phase extraction of organic
 compounds: A critical review (Part I). TrAC Trends in Analytical Chemistry 80, 641–654.
 https://doi.org/10.1016/j.trac.2015.08.015
- Anttila, J. V., Shubin, M., Cairns, J., Borse, F., Guo, Q., Mononen, T., Vázquez-García, I., Pulkkinen, O.,
 Mustonen, V., 2019. Contrasting the impact of cytotoxic and cytostatic drug therapies on
- tumour progression. PLoS Comput Biol 15, e1007493.
- 1331 https://doi.org/10.1371/journal.pcbi.1007493
- Apak, R., Güçlü, K., Demirata, B., Özyürek, M., Çelik, S., Bektaşoğlu, B., Berker, K., Özyurt, D., 2007.
 Comparative Evaluation of Various Total Antioxidant Capacity Assays Applied to Phenolic
 Compounds with the CUPRAC Assay. Molecules 12, 1496–1547.
 https://doi.org/10.3390/12071496
- Araújo, N., Viegas, C.S.B., Zubía, E., Magalhães, J., Ramos, A., Carvalho, M.M., Cruz, H., Sousa, J.P.,
 Blanco, F.J., Vermeer, C., Simes, D.C., 2020. Amentadione from the Alga Cystoseira usneoides as
 a Novel Osteoarthritis Protective Agent in an Ex Vivo Co-Culture OA Model. Mar Drugs 18, 624.
 https://doi.org/10.3390/md18120624
- Arendrup, M.C., Meletiadis, J., Mouton, J.W., Lagrou, K., Hamal, P., Guinea, J., Subcommittee on
 Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial
 Susceptibility Testing, 2008. EUCAST Technical Note on the method for the determination of
 broth dilution minimum inhibitory concentrations of antifungal agents for conidia–forming
 moulds. Clinical Microbiology and Infection 14, 982–984. https://doi.org/10.1111/j.1469 0691.2008.02086.x
- Arendrup, M.C., Patterson, T.F., 2017. Multidrug-Resistant Candida: Epidemiology, Molecular
 Mechanisms, and Treatment. J Infect Dis 216, S445–S451. https://doi.org/10.1093/infdis/jix131
- Aslantürk, Ö.S., 2018. In Vitro Cytotoxicity and Cell Viability Assays: Principles, Advantages, and
 Disadvantages, in: Larramendy, M.L., Soloneski, S. (Eds.), Genotoxicity A Predictable Risk to
 Our Actual World. InTech, London. https://doi.org/10.5772/intechopen.71923
- ASTM E2871-21, 2021. Standard Test Method for Determining Disinfectant Efficacy Against Biofilm
 Grown in the CDC Biofilm Reactor Using the Single Tube Method. Book of Standards.
- ASTM E3161-21, 2022. Standard Practice for Preparing a Pseudomonas aeruginosa or Staphylococcus
 aureus Biofilm using the CDC Biofilm Reactor. Book of Standards.

- Atanasov, A.G., Zotchev, S.B., Dirsch, V.M., Erdogan Orhan, I., Banach, M., Rollinger, J.M., Barreca, D.,
 Weckwerth, W., Bauer, R., Bayer, E.A., Majeed, M., Bishayee, A., Bochkov, V., Bonn, G.K.,
- 1357 Braidy, N., Bucar, F., Cifuentes, A., DOnofrio, G., Bodkin, M., Diederich, M., Dinkova-Kostova,
- 1358 A.T., Efferth, T., El Bairi, K., Arkells, N., Fan, T.-P., Fiebich, B.L., Freissmuth, M., Georgiev, M.I.,
- 1359 Gibbons, S., Godfrey, K.M., Gruber, C.W., Heer, J., Huber, L.A., Ibanez, E., Kijjoa, A., Kiss, A.K., Lu,
- 1360 A., Macias, F.A., S Miller, M.J., Mocan, A., Müller, R., Nicoletti, F., Perry, G., Pittalà, V., Rastrelli,
- 1361 L., Ristow, M., Luigi Russo, G., Sanches Silva, A., Schuster, D., Sheridan, H., Skalicka-Woźniak, K.,
- 1362 Skaltsounis, L., Sobarzo-Sánchez, E., Bredt, D.S., Stuppner, H., Sureda, A., Tzvetkov, N.T., Anna
- 1363 Vacca, R., Aggarwal, B.B., Battino, M., Giampieri, F., Wink, M., Wolfender, J.-L., Xiao, J., Wai Kan
- 1364 Yeung, A., Lizard, G., Popp, M.A., Heinrich, M., Berindan-Neagoe, I., Stadler, M., Daglia, M.,
- 1365 Verpoorte, R., Supuran, C.T., 2021. Natural products in drug discovery: advances and
- 1366 opportunities. Nat Rev Drug Discov 20, 200–2016. https://doi.org/10.1038/s41573-020-00114-z
- Baldisserotto, A., Malisardi, G., Scalambra, E., Andreotti, E., Romagnoli, C., Vicentini, C., Manfredini,
 S., Vertuani, S., 2012. Synthesis, Antioxidant and Antimicrobial Activity of a New Phloridzin
 Derivative for Dermo-Cosmetic Applications. Molecules 17, 13275–13289.
- 1370 https://doi.org/10.3390/molecules171113275
- Balouiri, M., Sadiki, M., Ibnsouda, S.K., 2016. Methods for in vitro evaluating antimicrobial activity: A
 review. J Pharm Anal 6, 71–79. https://doi.org/10.1016/J.JPHA.2015.11.005
- Bal-Price, A., Crofton, K.M., Leist, M., Allen, S., Arand, M., Buetler, T., Delrue, N., FitzGerald, R.E.,
 Hartung, T., Heinonen, T., Hogberg, H., Bennekou, S.H., Lichtensteiger, W., Oggier, D., Paparella,
 M., Axelstad, M., Piersma, A., Rached, E., Schilter, B., Schmuck, G., Stoppini, L., Tongiorgi, E.,
 Tiramani, M., Monnet-Tschudi, F., Wilks, M.F., Ylikomi, T., Fritsche, E., 2015. International
 STakeholder NETwork (ISTNET): creating a developmental neurotoxicity (DNT) testing road map
 for regulatory purposes. Arch Toxicol 89, 269–287. https://doi.org/10.1007/s00204-015-1464-2
- Bansal, S.K., Layloff, T., Bush, E.D., Hamilton, M., Hankinson, E.A., Landy, J.S., Lowes, S., Nasr, M.M.,
 St. Jean, P.A., Shah, V.P., 2004. Qualification of analytical instruments for use in the
 pharmaceutical industry: A scientific approach. AAPS PharmSciTech 5, 151–158.
 https://doi.org/10.1208/pt050122
- Barreca, M., Spanò, V., Montalbano, A., Cueto, M., Díaz Marrero, A.R., Deniz, I., Erdoğan, A., Lukić
 Bilela, L., Moulin, C., Taffin-de-Givenchy, E., Spriano, F., Perale, G., Mehiri, M., Rotter, A., P.
 Thomas, O., Barraja, P., Gaudêncio, S.P., Bertoni, F., 2020. Marine Anticancer Agents: An
 Overview with a Particular Focus on Their Chemical Classes. Mar Drugs 18, 619.
 https://doi.org/10.3390/md18120619
- Barwick, V., Bravo, P.P.M., Ellison, S.L.R., Engman, J., Gjengedal, E.L., Oxenboll Lund, U., Magnusson,
 B., Müller, H.-T., Patriarca, M., Pohl, B., Robouch, P., Sibbesen, L.P., Theodorsson, E., Vanstapel,
 F., Vercruysse, I., Yilmaz, A., Ömeroglu, P.Y., Örnemark, U., 2014. Eurachem Guide: The fitness
 for purpose of analytical methods a laboratory guide to method validation and related topics,
 2nd ed. Eurachem.
- Benbelkhir, F.Z., Medjekal, S., 2022. Microalgal carotenoids: A promising alternative to synthetic
 dyes. Algal Res 66, 102823. https://doi.org/10.1016/j.algal.2022.102823
- Benjamin, B., Kanta Barman, T., Chaira, T., K. Paliwal, J., 2010. Integration of Physicochemical and
 Pharmacokinetic Parameters in Lead Optimization: A Physiological Pharmacokinetic Model

- 1397 Based Approach. Curr Drug Discov Technol 7, 143–153.
- 1398 https://doi.org/10.2174/157016310793180558
- Berkow, E.L., Lockhart, S.R., Ostrosky-Zeichner, L., 2020. Antifungal Susceptibility Testing: Current
 Approaches. Clin Microbiol Rev 33. https://doi.org/10.1128/CMR.00069-19
- Berlinck, R.G.S., Crnkovic, C.M., Gubiani, J.R., Bernardi, D.I., Ióca, L.P., Quintana-Bulla, J.I., 2022. The
 isolation of water-soluble natural products challenges, strategies and perspectives. Nat Prod
 Rep 39, 596–669. https://doi.org/10.1039/D1NP00037C
- Beutler, J.A., 2009. Natural Products as a Foundation for Drug Discovery. Curr Protoc Pharmacol 46.
 https://doi.org/10.1002/0471141755.ph0911s46
- Bhadury, P., Mohammad, B.T., Wright, P.C., 2006. The current status of natural products from marine
 fungi and their potential as anti-infective agents. J Ind Microbiol Biotechnol 33, 325–337.
 https://doi.org/10.1007/s10295-005-0070-3
- Boonpisuttinant, K., Sodamook, U., Ruksiriwanich, W., Winitchai, S., 2014. In Vitro Anti melanogenesis and Collagen Biosynthesis Stimulating Activities of Star Grass (Hypoxis aurea
 Lour.) Extracts. Asian Journal of Applied Sciences 2, 2321–0893.
- Borman, P., Elder, D, 2017. Q2(R1) Validation of Analytical Procedures, Text and Methodology, in:
 Teasdale, A., Elder, David, Nims, R.W. (Eds.), ICH Quality Guidelines. John Wiley & Sons, Inc.,
 Hoboken, NJ, USA. https://doi.org/10.1002/9781118971147
- Boziaris, I.S., 2014. Food ingredients from the marine environment. Marine biotechnology meets
 food science and technology. Front Mar Sci 1. https://doi.org/10.3389/fmars.2014.00066
- Brancaccio, M., Milito, A., Viegas, C.A., Palumbo, A., Simes, D.C., Castellano, I., 2022. First evidence of
 dermo-protective activity of marine sulfur-containing histidine compounds. Free Radic Biol Med
 192, 224–234. https://doi.org/10.1016/j.freeradbiomed.2022.09.017
- Bratinova, S., Raffael, B., Simoneau, C., 2009. Guidelines for performance criteria and validation
 procedures of analytical methods used in controls of food contact materials. Ispra.
 https://doi.org/10.2788/49046
- Bridier, A., Dubois-Brissonnet, F., Boubetra, A., Thomas, V., Briandet, R., 2010. The biofilm
 architecture of sixty opportunistic pathogens deciphered using a high throughput CLSM
 method. J Microbiol Methods 82, 64–70. https://doi.org/10.1016/j.mimet.2010.04.006
- Bucar, F., Wube, A., Schmid, M., 2013. Natural product isolation-how to get from biological material
 to pure compounds. Nat Prod Rep 30, 525–545. https://doi.org/10.1039/c3np20106f

Burman, R., Strömstedt, A.A., Malmsten, M., Göransson, U., 2011. Cyclotide–membrane interactions:
 Defining factors of membrane binding, depletion and disruption. Biochimica et Biophysica Acta
 (BBA) - Biomembranes 1808, 2665–2673. https://doi.org/10.1016/j.bbamem.2011.07.004

- 1431 Cao, L., Zhu, S., Wang, Y., Lou, Z., Sun, Y., 2015. A comprehensive procedure for antiviral inhibitor
 1432 discovery using EV71 as an example. Biophys Rep 1, 81–89. https://doi.org/10.1007/s410481433 015-0006-z
- 1434 Carlsen, J., Cömert, C., Bross, P., Palmfeldt, J., 2020. Optimized High-Contrast Brightfield Microscopy
 1435 Application for Noninvasive Proliferation Assays of Human Cell Cultures. Assay Drug Dev
 1436 Technol 18, 215–225. https://doi.org/10.1089/adt.2020.981

- Carroll, A.R., Copp, B.R., Davis, R.A., Keyzers, R.A., Michèle, M., Prinsep, R., 2021. Marine natural
 products ‡. https://doi.org/10.1039/d0np00089b
- 1439 Ceri, H., Olson, M.E., Stremick, C., Read, R.R., Morck, D., Buret, A., 1999. The Calgary Biofilm Device:
 1440 New Technology for Rapid Determination of Antibiotic Susceptibilities of Bacterial Biofilms. J
 1441 Clin Microbiol 37, 1771–1776. https://doi.org/10.1128/JCM.37.6.1771-1776.1999
- 1442 Chan, C.C., 2011. Principles and Practices of Analytical Method Validation: Validation of Analytical
 1443 Methods is Time-consuming but Essential. The Quality Assurance Journal 14, 61–64.
 1444 https://doi.org/10.1002/qaj.477
- 1445 Chaturvedi, V., Ramani, R., Pfaller, M.A., 2004. Collaborative Study of the NCCLS and Flow Cytometry
 1446 Methods for Antifungal Susceptibility Testing of *Candida albicans*. J Clin Microbiol 42, 2249–
 1447 2251. https://doi.org/10.1128/JCM.42.5.2249-2251.2004
- 1448 Chen, C.Z., Shinn, P., Itkin, Z., Eastman, R.T., Bostwick, R., Rasmussen, L., Huang, R., Shen, M., Hu, X.,
 1449 Wilson, K.M., Brooks, B.M., Guo, H., Zhao, T., Klump-Thomas, C., Simeonov, A., Michael, S.G.,
 1450 Lo, D.C., Hall, M.D., Zheng, W., 2021. Drug Repurposing Screen for Compounds Inhibiting the
 1451 Cytopathic Effect of SARS-CoV-2. Front Pharmacol 11.
- 1452 https://doi.org/10.3389/fphar.2020.592737
- 1453 Chen, H., Huang, C., Zhang, W., Ding, Q., Gao, J., Zhang, L., 2019. Ultrastable nitrogen-doped carbon
 1454 nanotube encapsulated cobalt nanoparticles for magnetic solid-phase extraction of okadaic acid
 1455 from aquatic samples. J Chromatogr A 1608, 460404.
 1456 https://doi.org/10.1016/j.chroma.2019.460404
- Choudhary, A., Naughton, L.M., Montánchez, I., Dobson, A.D.W., Rai, D.K., 2017. Current Status and
 Future Prospects of Marine Natural Products (MNPs) as Antimicrobials. Mar Drugs 15, 272.
 https://doi.org/10.3390/md15090272
- 1460 Claeson, P., Bohlin, L., 1997. Some aspects of bioassay methods in natural-product research aimed at
 1461 drug lead discovery. Trends Biotechnol 15, 245–248. https://doi.org/10.1016/s01671462 7799(97)01051-2
- 1463 Clinical and Laboratory Standards Institute, 2017a. Reference method for broth dilution antifungal
 1464 susceptibility testing of filamentous fungi, 3rd ed. . Wayne, PA.
- Clinical and Laboratory Standards Institute, 2017b. Reference method for broth dilution antifungal
 susceptibility testing of yeasts, 4th ed. Approved standard M27. Wayne, PA.
- 1467 Clinical and Laboratory Standards Institute, 2010. Method for antifungal disk diffusion susceptibility
 1468 testing of nondermatophyte filamentous fungi, approved guideline. CLSI document M51-A.
 1469 Wayne, PA, USA.
- 1470 Clinical and Laboratory Standards Institute, 2009. Method for antifungal disk diffusion susceptibility
 1471 testing of yeasts; approved guideline. CLSI document M44-A2. Wayne, PA, USA.
- 1472 Clippinger, A.J., Allen, D., Behrsing, H., BéruBé, K.A., Bolger, M.B., Casey, W., DeLorme, M., Gaça, M.,
 1473 Gehen, S.C., Glover, K., Hayden, P., Hinderliter, P., Hotchkiss, J.A., Iskandar, A., Keyser, B.,
 1474 Luettich, K., Ma-Hock, L., Maione, A.G., Makena, P., Melbourne, J., Milchak, L., Ng, S.P., Paini,
 1475 A., Page, K., Patlewicz, G., Prieto, P., Raabe, H., Reinke, E.N., Roper, C., Rose, J., Sharma, M.,
- 1476 Spoo, W., Thorne, P.S., Wilson, D.M., Jarabek, A.M., 2018. Pathway-based predictive

- 1477approaches for non-animal assessment of acute inhalation toxicity. Toxicology in Vitro 52, 131–1478145. https://doi.org/10.1016/j.tiv.2018.06.009
- 1479 Coelho, C., Gallo, G., Campos, C.B., Hardy, L., Würtele, M., 2020. Biochemical screening for SARS-CoV1480 2 main protease inhibitors. PLoS One 15, e0240079.
- 1481 https://doi.org/10.1371/journal.pone.0240079
- Collins, J.E., Vanagt, T., Huys, I., Vieira, H., 2020. Marine Bioresource Development Stakeholder's
 Challenges, Implementable Actions, and Business Models. Front Mar Sci 7.
 https://doi.org/10.3389/fmars.2020.00062
- 1485 Collins, P., Bauer, D.J., 1977. RELATIVE POTENCIES OF ANTI-HERPES COMPOUNDS. Ann N Y Acad Sci
 1486 284, 49–59. https://doi.org/10.1111/j.1749-6632.1977.tb21936.x
- 1487 Cos, P., Vlietinck, A.J., Berghe, D. Vanden, Maes, L., 2006. Anti-infective potential of natural products:
 1488 How to develop a stronger in vitro 'proof-of-concept.' J Ethnopharmacol 106, 290–302.
 1489 https://doi.org/10.1016/J.JEP.2006.04.003
- 1490 Cox, M.C., Mendes, R., Silva, F., Mendes, T.F., Zelaya-Lazo, A., Halwachs, K., Purkal, J.J., Isidro, I.A.,
 1491 Félix, A., Boghaert, E.R., Brito, C., 2021. Application of LDH assay for therapeutic efficacy
 1492 evaluation of ex vivo tumor models. Sci Rep 11, 18571. https://doi.org/10.1038/s41598-0211493 97894-0
- 1494 Crawford, A.D., Liekens, S., Kamuhabwa, A.R., Maes, J., Munck, S., 2011. Zebrafish Bioassay-Guided
 1495 Natural Product Discovery: Isolation of Angiogenesis Inhibitors from East African Medicinal
 1496 Plants. PLoS One 6, e14694. https://doi.org/10.1371/journal.pone.0014694
- Creton, S., Aardema, M.J., Carmichael, P.L., Harvey, J.S., Martin, F.L., Newbold, R.F., O'Donovan, M.R.,
 Pant, K., Poth, A., Sakai, A., Sasaki, K., Scott, A.D., Schechtman, L.M., Shen, R.R., Tanaka, N.,
 Yasaei, H., 2012. Cell transformation assays for prediction of carcinogenic potential: state of the
 science and future research needs. Mutagenesis 27, 93–101.
- 1501 https://doi.org/10.1093/mutage/ger053
- Cruz, S., Gomes, S., Borralho, P., Rodrigues, C., Gaudêncio, S., Pereira, F., 2018. In Silico HCT116
 Human Colon Cancer Cell-Based Models En Route to the Discovery of Lead-Like Anticancer
 Drugs. Biomolecules 8, 56. https://doi.org/10.3390/biom8030056
- Cushnie, T.P.T., Cushnie, B., Echeverría, J., Fowsantear, W., Thammawat, S., Dodgson, J.L.A., Law, S.,
 Clow, S.M., 2020. Bioprospecting for Antibacterial Drugs: a Multidisciplinary Perspective on
 Natural Product Source Material, Bioassay Selection and Avoidable Pitfalls. Pharm Res 37, 125.
 https://doi.org/10.1007/s11095-020-02849-1
- da Silva, A.C., Kratz, J.M., Farias, F.M., Henriques, A.T., dos Santos, J., Leonel, R.M., Lerner, C.,
 Mothes, B., Barardi, C.R.M., Simões, C.M.O., 2006. In Vitro Antiviral Activity of Marine Sponges
 Collected Off Brazilian Coast. Biol Pharm Bull 29, 135–140. https://doi.org/10.1248/bpb.29.135
- 1512 Dadgostar, P., 2019. Antimicrobial Resistance: Implications and Costs. Infect Drug Resist 12, 3903–
 1513 3910. https://doi.org/10.2147/IDR.S234610
- 1514 Dar, K.B., Bhat, A.H., Amin, S., Hamid, R., Anees, S., Anjum, S., Reshi, B.A., Zargar, M.A., Masood, A.,
 1515 Ganie, S.A., 2019. Modern Computational Strategies for Designing Drugs to Curb Human
 1516 Diseases: A Prospect. Curr Top Med Chem 18, 2702–2719.
- 1517 https://doi.org/10.2174/1568026619666190119150741

- 1518 Dávalos, A., Gómez-Cordovés, C., Bartolomé, B., 2004. Extending Applicability of the Oxygen Radical
 1519 Absorbance Capacity (ORAC–Fluorescein) Assay. J Agric Food Chem 52, 48–54.
 1520 https://doi.org/10.1021/jf0305231
- 1521 Davani, B., 2017. Pharmaceutical analysis for small molecules. Wiley, Hoboken, NJ.
- David, B., Wolfender, J.-L., Dias, D.A., 2015. The pharmaceutical industry and natural products:
 historical status and new trends. Phytochemistry Reviews 14, 299–315.
 https://doi.org/10.1007/s11101-014-9367-z
- De Baere, T., Dmitruk, W., Magnusson, B., Meuwly, D., O'donnell, G., 2014. Guidelines for the single
 laboratory Validation of Instrumental and Human Based Methods in Forensic Science.
- 1527 De Clercq, E., Descamps, J., Verhelst, G., Walker, R.T., Jones, A.S., Torrence, P.F., Shugar, D., 1980.
 1528 Comparative Efficacy of Antiherpes Drugs against Different Strains of Herpes Simplex Virus.
 1529 Journal of Infectious Diseases 141, 563–574. https://doi.org/10.1093/infdis/141.5.563
- De La Calle, F., 2017. Marine microbiome as source of natural products. Microb Biotechnol 10, 1293–
 1296. https://doi.org/10.1111/1751-7915.12882
- De Meyer, T., Muyldermans, S., Depicker, A., 2014. Nanobody-based products as research and
 diagnostic tools. Trends Biotechnol 32, 263–270. https://doi.org/10.1016/j.tibtech.2014.03.001
- Deepika, D., Kumar, V., 2023. The Role of "Physiologically Based Pharmacokinetic Model (PBPK)" New
 Approach Methodology (NAM) in Pharmaceuticals and Environmental Chemical Risk
 Assessment. Int J Environ Res Public Health 20, 3473. https://doi.org/10.3390/ijerph20043473
- Defoirdt, T., 2018. Quorum-Sensing Systems as Targets for Antivirulence Therapy. Trends Microbiol
 26, 313–328. https://doi.org/10.1016/J.TIM.2017.10.005
- Defoirdt, T., Brackman, G., Coenye, T., 2013. Quorum sensing inhibitors: how strong is the evidence?
 Trends Microbiol 21, 619–624. https://doi.org/10.1016/j.tim.2013.09.006
- 1541Di, L., Kerns, E.H., 2006. Biological assay challenges from compound solubility: strategies for bioassay1542optimization. Drug Discov Today 11, 446–451. https://doi.org/10.1016/J.DRUDIS.2006.03.004
- Dias, T., Gaudêncio, S., Pereira, F., 2018. A Computer-Driven Approach to Discover Natural Product
 Leads for Methicillin-Resistant Staphylococcus aureus Infection Therapy. Mar Drugs 17, 16.
 https://doi.org/10.3390/md17010016
- Dinarvand, M., Vafaee, F., Spain, M.P., 2020. Pharmacodynamic Functions of Synthetic Derivatives for
 Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) and Mycobacterium
 tuberculosis. Front Microbiol 11, 551189. https://doi.org/10.3389/fmicb.2020.551189
- Drexler, M., 2011. What You Need to Know About Infectious Disease. National Academies Press,
 Washington, D.C. https://doi.org/10.17226/13006
- 1551 Dudonné, S., Poupard, P., Coutière, P., Woillez, M., Richard, T., Mérillon, J.-M., Vitrac, X., 2011.
- 1552 Phenolic Composition and Antioxidant Properties of Poplar Bud (Populus nigra) Extract:
- 1553Individual Antioxidant Contribution of Phenolics and Transcriptional Effect on Skin Aging. J Agric1554Food Chem 59, 4527–4536. https://doi.org/10.1021/jf104791t
 - 38

- Durai, S., Vigneshwari, L., Balamurugan, K., 2013. Caenorhabditis elegans-based in vivo screening of
 bioactives from marine sponge-associated bacteria against Vibrio alginolyticus. J Appl Microbiol
 115, 1329–1342. https://doi.org/10.1111/jam.12335
- Dyrda, G., Boniewska-Bernacka, E., Man, D., Barchiewicz, K., Słota, R., 2019. The effect of organic
 solvents on selected microorganisms and model liposome membrane. Mol Biol Rep 46, 3225–
 3232. https://doi.org/10.1007/s11033-019-04782-y
- 1561 El Sayed, K.A., 2000. Natural Products as Antiviral Agents. Studies in Natural Products Chemistry 24,
 1562 473–572. https://doi.org/10.1016/S1572-5995(00)80051-4
- El-Wahidi, M., El-Amraoui, B., Biard, J.F., Uriz, M.J., Fassouane, A., Bamhaoud, T., 2011. Variation
 saisonnière et géographique de l'activité antifongique des extraits de deux éponges marines
 récoltées sur le littoral atlantique d'El Jadida, Maroc. J Mycol Med 21, 28–32.
 https://doi.org/10.1016/J.MYCMED.2010.11.005
- EMA Committee for human Medicinal Products, 2011. European Medicines Agency Guideline on
 bioanalytical method validation. EMEA/CHMP/EWP/192217/2009 Rev. 1 Corr. 2** . London.
- 1569 EPA Office of Solid Waste, 1992. Guidance for methods development and methods validation for the1570 RCRA program.
- 1571 EURL, E.U.R.L., 2022. Analytical Quality Control and Method Validation Procedures for Pesticide
 1572 Residues Analysis in Food and Feed. SANTE 11312/2021.
- 1573 European Medicines Agency, 2019. ICH guideline M10 on bioanalytical method validation Step 2b.1574 London.
- 1575 European Medicines Agency, 2011. Committee for Medicinal Products for Human Use (CHMP)1576 Guideline on bioanalytical method validation. London.
- Fajarningsih, N.D., Munifah, I., Zilda, D.S., 2018. Evaluation of Antibacterial Assays for Screening of
 Marine Invertebrate Extracts. Squalen Bulletin of Marine and Fisheries Postharvest and
 Biotechnology 13, 1. https://doi.org/10.15578/squalen.v13i1.294
- Faraji, M., Yamini, Y., Gholami, M., 2019. Recent Advances and Trends in Applications of Solid-Phase
 Extraction Techniques in Food and Environmental Analysis. Chromatographia 82, 1207–1249.
 https://doi.org/10.1007/s10337-019-03726-9
- Ferdowsian, H.R., Beck, N., 2011. Ethical and Scientific Considerations Regarding Animal Testing and
 Research. PLoS One 6, e24059. https://doi.org/10.1371/journal.pone.0024059
- Flint, S.J., Enquist, W., Racaniello, V.R., Skalka, A.M., 2009. Virological Methods, in: Principles of
 Virology. ASM Press.
- 1587 Fraga, C.G., Oteiza, P.I., Galleano, M., 2014. In vitro measurements and interpretation of total
 1588 antioxidant capacity. Biochimica et Biophysica Acta (BBA) General Subjects 1840, 931–934.
 1589 https://doi.org/10.1016/J.BBAGEN.2013.06.030
- Franzreb, M., Siemann-Herzberg, M., Hobley, T.J., Thomas, O.R.T., 2006. Protein purification using
 magnetic adsorbent particles. Appl Microbiol Biotechnol 70, 505–516.
 https://doi.org/10.1007/s00253-006-0344-3

- Furustrand Tafin, U., Meis, J.F., Trampuz, A., 2013. Microcalorimetry Assay for Rapid Detection of
 Voriconazole Resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 57, 5704–
 5706. https://doi.org/10.1128/AAC.01379-13
- Gallardo, V.E., Varshney, G.K., Lee, M., Bupp, S., Xu, L., Shinn, P., Crawford, N.P., Inglese, J., Burgess,
 S.M., 2015. Phenotype-driven chemical screening in zebrafish for compounds that inhibit
 collective cell migration identifies multiple pathways potentially involved in metastatic invasion.
 Dis Model Mech 8, 565–576. https://doi.org/10.1242/dmm.018689
- Gaudêncio, S.P., Bayram, E., Lukić Bilela, L., Cueto, M., Díaz-Marrero, A.R., Haznedaroglu, B.Z.,
 Jimenez, C., Mandalakis, M., Pereira, F., Reyes, F., Tasdemir, D., 2023. Advanced Methods for
 Natural Products Discovery: Bioactivity Screening, Dereplication, Metabolomics Profiling,
 Genomic Sequencing, Databases and Informatic Tools, and Structure Elucidation. Mar Drugs 21,
 308. https://doi.org/10.3390/md21050308
- 1605 Gaudêncio, S.P., Pereira, F., 2020. A Computer-Aided Drug Design Approach to Predict Marine Drug 1606 Like Leads for SARS-CoV-2 Main Protease Inhibition. Mar Drugs 18, 633.
 1607 https://doi.org/10.3390/md18120633
- Gaudêncio, S.P., Pereira, F., 2015. Dereplication: racing to speed up the natural products discovery
 process. Nat Prod Rep 32, 779–810. https://doi.org/10.1039/C4NP00134F
- Gerssen, A., Bovee, T.H.F., van Ginkel, L.A., van Iersel, M.L.P.S., Hoogenboom, R.L.A.P., 2019. Food
 and feed safety: Cases and approaches to identify the responsible toxins and toxicants. Food
 Control 98, 9–18. https://doi.org/10.1016/j.foodcont.2018.10.028
- Goeres, D.M., Loetterle, L.R., Hamilton, M.A., Murga, R., Kirby, D.W., Donlan, R.M., 2005. Statistical
 assessment of a laboratory method for growing biofilms. Microbiology (N Y) 151, 757–762.
 https://doi.org/10.1099/mic.0.27709-0
- Gomes, A.R., Duarte, A.C., Rocha-Santos, T.A.P., 2016. Analytical Techniques for Discovery of
 Bioactive Compounds from Marine Fungi, in: Merillon, J., Ramawat, K. (Eds.), Fungal
 Metabolites. Reference Series in Phytochemistry. Springer International Publishing, Cham, pp.
 1–20. https://doi.org/10.1007/978-3-319-19456-1 9-1
- González-Jartín, J.M., de Castro Alves, L., Alfonso, A., Piñeiro, Y., Vilar, S.Y., Rodríguez, I., Gomez,
 M.G., Osorio, Z.V., Sainz, M.J., Vieytes, M.R., Rivas, J., Botana, L.M., 2020. Magnetic
 nanostructures for marine and freshwater toxins removal. Chemosphere 256, 127019.
 https://doi.org/10.1016/j.chemosphere.2020.127019
- Gorshkov, K., Chen, C.Z., Bostwick, R., Rasmussen, L., Tran, B.N., Cheng, Y.-S., Xu, M., Pradhan, M.,
 Henderson, M., Zhu, W., Oh, E., Susumu, K., Wolak, M., Shamim, K., Huang, W., Hu, X., Shen, M.,
 Klumpp-Thomas, C., Itkin, Z., Shinn, P., Carlos de la Torre, J., Simeonov, A., Michael, S.G., Hall,
- 1627 M.D., Lo, D.C., Zheng, W., 2021. The SARS-CoV-2 Cytopathic Effect Is Blocked by Lysosome
- 1628 Alkalizing Small Molecules. ACS Infect Dis 7, 1389–1408.
- 1629 https://doi.org/10.1021/acsinfecdis.0c00349
- Guillerme, J.-B., Couteau, C., Coiffard, L., 2017. Applications for Marine Resources in Cosmetics.
 Cosmetics 4, 1–15. https://doi.org/10.3390/cosmetics4030035

- 1632 Guo, Z., Wei, Y., Zhang, Y., Xu, Y., Zheng, L., Zhu, B., Yao, Z., 2022. Carrageenan oligosaccharides: A
 1633 comprehensive review of preparation, isolation, purification, structure, biological activities and
 1634 applications. Algal Res 61, 102593. https://doi.org/10.1016/j.algal.2021.102593
- 1635 Haider, S., 2006. Validation Standard Operating Procedures. CRC Press, London.
- Hamm, J., Sullivan, K., Clippinger, A.J., Strickland, J., Bell, S., Bhhatarai, B., Blaauboer, B., Casey, W.,
 Dorman, D., Forsby, A., Garcia-Reyero, N., Gehen, S., Graepel, R., Hotchkiss, J., Lowit, A.,
 Matheson, J., Reaves, E., Scarano, L., Sprankle, C., Tunkel, J., Wilson, D., Xia, M., Zhu, H., Allen,
- 1639 D., 2017. Alternative approaches for identifying acute systemic toxicity: Moving from research
- 1640 to regulatory testing. Toxicology in Vitro 41, 245–259. https://doi.org/10.1016/j.tiv.2017.01.004
- Haney, E.F., Trimble, M.J., Hancock, R.E.W., 2021. Microtiter plate assays to assess antibiofilm activity
 against bacteria. Nat Protoc 16, 2615–2632. https://doi.org/10.1038/s41596-021-00515-3
- Harnly, J., Applequist, W., Brown, P., Caspar, S., Harrington, P., Harbaugh-Reynaud, D., Hill, N.,
 LaBudde, R., Neal-Kababick, J., Roman, M., Roman, S., Sullivan, D., Titlow, B., Wehling, P., 2012.
 AOAC international guidelines for validation of botanical identification methods. J AOAC Int 95,
 268–272. https://doi.org/10.5740/jaoacint.11-447
- Harvey, A.L., 2008. Natural products in drug discovery. Drug Discov Today 13, 894–901.
 https://doi.org/10.1016/J.DRUDIS.2008.07.004
- Harvey, A.L., Edrada-Ebel, R., Quinn, R.J., 2015. The re-emergence of natural products for drug
 discovery in the genomics era. Nat Rev Drug Discov 14, 111–129.
 https://doi.org/10.1038/nrd4510
- He, J., Tian, J., Xu, J., Wang, K., Li, J., Gee, S.J., Hammock, B.D., Li, Q.X., Xu, T., 2018. Strong and
 oriented conjugation of nanobodies onto magnetosomes for the development of a rapid
 immunomagnetic assay for the environmental detection of tetrabromobisphenol-A. Anal
 Bioanal Chem 410, 6633–6642. https://doi.org/10.1007/s00216-018-1270-9
- Heavisides, E., Rouger, C., Reichel, A.F., Ulrich, C., Wenzel-Storjohann, A., Sebens, S., Tasdemir, D.,
 2018. Seasonal Variations in the Metabolome and Bioactivity Profile of Fucus vesiculosus
 Extracted by an Optimised, Pressurised Liquid Extraction Protocol. Mar Drugs 16, 503.
 https://doi.org/10.3390/md16120503
- Hellio, C., Marechal, J.-P., Véron, B.B., Bremer, G., Clare, A.S., Le Gal, Y., 2004. Seasonal Variation of
 Antifouling Activities of Marine Algae from the Brittany Coast (France). Marine Biotechnology 6,
 67–82. https://doi.org/10.1007/s10126-003-0020-x
- Henrikson, A.A., Pawlik, J.R., 1998. Seasonal variation in biofouling of gels containing extracts of
 marine organisms. Biofouling 12, 245–255. https://doi.org/10.1080/08927019809378357
- Herzog, E., Casey, A., Lyng, F., Chambers, G., Byrne, H., Davoren, M., 2007. A new approach to the
 toxicity testing of carbon-based nanomaterials—The clonogenic assay. Toxicol Lett 174, 49–60.
 https://doi.org/10.1016/j.toxlet.2007.08.009
- Hipsher, C., Barker, J., Lanno, R., MacKay, A., 2021. Solvent choice influences final toxicity results in
 Thamnocephalus platyurus bioassay when exposed to microcystin -LR. Toxicon 197, 33–39.
 https://doi.org/10.1016/J.TOXICON.2021.04.010

- Ho, B., Pek, N., Soh, B.-S., 2018. Disease Modeling Using 3D Organoids Derived from Human Induced
 Pluripotent Stem Cells. Int J Mol Sci 19, 936. https://doi.org/10.3390/ijms19040936
- Houssen, W.E., Jaspars, M., 2012. Isolation of Marine Natural Products, in: Sarker S, Nahar L (Eds.),
 Natural Products Isolation. Methods in Molecular Biology (Methods and Protocols). Humana
 Press, pp. 367–392. https://doi.org/10.1007/978-1-61779-624-1_14
- Hu, J.M., Hsiung, G.D., 1989. Evaluation of new antiviral agents: I. In vitro perspectives. Antiviral Res
 11, 217–232. https://doi.org/10.1016/0166-3542(89)90032-6
- Huang, D., Ou, B., Prior, R.L., 2005. The Chemistry behind Antioxidant Capacity Assays. J Agric Food
 Chem 53, 1841–1856. https://doi.org/10.1021/jf030723c
- Hughes, C.C., Fenical, W., 2010. Antibacterials from the Sea. Chem. Eur. J 16, 12512–12525.
 https://doi.org/10.1002/chem.201001279
- 1682 ICH Expert Working Group, 2005. ICH HARMONISED TRIPARTITE GUIDELINE VALIDATION OF
 1683 ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1).
- Jessica E Neil, M.S., Lenn, J.D., Brown, M.B., Williams, A.C., 2022. A new ex vivo skin model for
 mechanistic understanding of putative anti-inflammatory topical therapeutics. Int J Pharm 617,
 121610. https://doi.org/10.1016/j.ijpharm.2022.121610
- Jhong, C.-H., Riyaphan, J., Lin, S.-H., Chia, Y.-C., Weng, C.-F., 2015. Screening alpha-glucosidase and
 alpha-amylase inhibitors from natural compounds by molecular docking *in silico*. BioFactors 41,
 242–251. https://doi.org/10.1002/biof.1219
- Jiang, H.L., Li, N., Cui, L., Wang, X., Zhao, R.S., 2019. Recent application of magnetic solid phase
 extraction for food safety analysis. TrAC Trends in Analytical Chemistry 120, 115632.
 https://doi.org/10.1016/J.TRAC.2019.115632
- Jimenez, P.C., Wilke, D. V., Branco, P.C., Bauermeister, A., Rezende-Teixeira, P., Gaudêncio, S.P.,
 Costa-Lotufo, L. V., 2020. Enriching cancer pharmacology with drugs of marine origin. Br J
 Pharmacol 177, 3–27. https://doi.org/10.1111/bph.14876
- Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., Zhang, B., Li, X., Zhang, L., Peng, C., Duan, Y., Yu, J.,
 Wang, L., Yang, K., Liu, F., Jiang, R., Yang, Xinglou, You, T., Liu, Xiaoce, Yang, Xiuna, Bai, F., Liu,
 H., Liu, Xiang, Guddat, L.W., Xu, W., Xiao, G., Qin, C., Shi, Z., Jiang, H., Rao, Z., Yang, H., 2020.
 Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 582, 289–293.
 https://doi.org/10.1038/s41586-020-2223-y
- 1701 Joklik, W., 1988. Virology, 3rd ed. Appleton & Lange, Norwalk, Connecticut, San Mateo.
- Judson, R., Houck, K., Martin, M., Richard, A.M., Knudsen, T.B., Shah, I., Little, S., Wambaugh, J.,
 Woodrow Setzer, R., Kothya, P., Phuong, J., Filer, D., Smith, D., Reif, D., Rotroff, D., Kleinstreuer,
 N., Sipes, N., Xia, M., Huang, R., Crofton, K., Thomas, R.S., 2016. Editor's Highlight: Analysis of
 the Effects of Cell Stress and Cytotoxicity on *In Vitro* Assay Activity Across a Diverse Chemical
 and Assay Space. Toxicological Sciences 152, 323–339. https://doi.org/10.1093/toxsci/kfw092
- 1707 Kadian, N., Raju, K.S.R., Rashid, M., Malik, M.Y., Taneja, I., Wahajuddin, M., 2016. Comparative
 1708 assessment of bioanalytical method validation guidelines for pharmaceutical industry. J Pharm
 1709 Biomed Anal 126, 83–97. https://doi.org/10.1016/j.jpba.2016.03.052

1710 Kaminski, L., Degenhardt, M., Ermer, J., Feussner, C., Höwer-Fritzen, H., Link, P., Renger, B., Tegtmeier, M., Wätzig, H., 2010. Efficient and economic HPLC performance qualification. J 1711 1712 Pharm Biomed Anal 51, 557–64. https://doi.org/10.1016/j.jpba.2009.09.011 1713 Karnati, P., Murthy, A., Gundeti, M., Ahmed, T., 2023. Modelling Based Approaches to Support 1714 Generic Drug Regulatory Submissions-Practical Considerations and Case Studies. AAPS J 25, 63. 1715 https://doi.org/10.1208/s12248-023-00831-4 1716 Kato, N., Comer, E., Sakata-Kato, T., Sharma, Arvind, Sharma, M., Maetani, M., Bastien, J., Brancucci, 1717 N.M., Bittker, J.A., Corey, V., Clarke, D., Derbyshire, E.R., Dornan, G.L., Duffy, S., Eckley, S., Itoe, 1718 M.A., Koolen, K.M.J., Lewis, T.A., Lui, P.S., Lukens, A.K., Lund, E., March, S., Meibalan, E., Meier, 1719 B.C., McPhail, J.A., Mitasev, B., Moss, E.L., Sayes, M., Van Gessel, Y., Wawer, M.J., Yoshinaga, T., 1720 Zeeman, A.-M., Avery, V.M., Bhatia, S.N., Burke, J.E., Catteruccia, F., Clardy, J.C., Clemons, P.A., 1721 Dechering, K.J., Duvall, J.R., Foley, M.A., Gusovsky, F., Kocken, C.H.M., Marti, M., Morningstar, 1722 M.L., Munoz, B., Neafsey, D.E., Sharma, Amit, Winzeler, E.A., Wirth, D.F., Scherer, C.A., 1723 Schreiber, S.L., 2016. Diversity-oriented synthesis yields novel multistage antimalarial inhibitors. 1724 Nature 538, 344-349. https://doi.org/10.1038/nature19804 1725 Kaufmann, L., Syedbasha, M., Vogt, D., Hollenstein, Y., Hartmann, J., Linnik, J.E., Egli, A., 2017. An 1726 Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers. 1727 Journal of Visualized Experiments. https://doi.org/10.3791/55833 1728 Khan, P., Queen, A., Mohammad, T., Smita, Khan, N.S., Hafeez, Z. Bin, Hassan, Md.I., Ali, S., 2019. 1729 Identification of α -Mangostin as a Potential Inhibitor of Microtubule Affinity Regulating Kinase 1730 4. J Nat Prod 82, 2252–2261. https://doi.org/10.1021/acs.jnatprod.9b00372 1731 Khanna, I., 2012. Drug discovery in pharmaceutical industry: productivity challenges and trends. Drug 1732 Discov Today 17, 1088–1102. https://doi.org/10.1016/j.drudis.2012.05.007 1733 Kiuru, P., D'Auria, M.V., Muller, C.D., Tammela, P., Vuirela, H., Yli-Kauhaluoma, J., 2014. Exploring 1734 Marine Resources for Bioactive Compounds. Planta Med 80, 1234–1246. 1735 https://doi.org/10.1055/s-0034-1383001 1736 Kırmusaoğlu, S., 2019. The Methods for Detection of Biofilm and Screening Antibiofilm Activity of 1737 Agents, in: Kırmusaoğlu (Ed.), Antimicrobials, Antibiotic Resistance, Antibiofilm Strategies and 1738 Activity Methods. IntechOpen, London. https://doi.org/10.5772/intechopen.84411 1739 Klančnik, A., Megušar, P., Sterniša, M., Jeršek, B., Bucar, F., Smole-Možina, S., Kos, J., Sabotič, J., 1740 2017. Aqueous extracts of wild mushrooms show antimicrobial and antiadhesion activities against bacteria and fungi. Phytother Res 31, 1971–1976. https://doi.org/10.1002/ptr.5934 1741 1742 Kleinstreuer, N.C., Karmaus, A.L., Mansouri, K., Allen, D.G., Fitzpatrick, J.M., Patlewicz, G., 2018. 1743 Predictive models for acute oral systemic toxicity: A workshop to bridge the gap from research 1744 to regulation. Computational Toxicology 8, 21–24. 1745 https://doi.org/10.1016/j.comtox.2018.08.002 1746 Kurita, K.L., Glassey, E., Linington, R.G., 2015. Integration of high-content screening and untargeted 1747 metabolomics for comprehensive functional annotation of natural product libraries. 1748 Proceedings of the National Academy of Sciences 112, 11999–12004. 1749 https://doi.org/10.1073/pnas.1507743112

- 1750 Kwasny, S.M., Opperman, T.J., 2010. Static Biofilm Cultures of Gram-Positive Pathogens Grown in a
 1751 Microtiter Format Used for Anti-Biofilm Drug Discovery. Curr Protoc Pharmacol 50.
 1752 https://doi.org/10.1002/0471141755.ph13a08s50
- 1753 Ky, I., Teissedre, P.-L., 2015. Characterisation of Mediterranean Grape Pomace Seed and Skin
 1754 Extracts: Polyphenolic Content and Antioxidant Activity. Molecules 20, 2190–2207.
 1755 https://doi.org/10.3390/molecules20022190
- Lall, N., Kishore, N., 2014. Are plants used for skin care in South Africa fully explored? J
 Ethnopharmacol 153, 61–84. https://doi.org/10.1016/j.jep.2014.02.021
- Lambert, F., Jacomy, H., Marceau, G., Talbot, P.J., 2008. Titration of human coronaviruses, HcoV-229E
 and HCoV-OC43, by an indirect immunoperoxidase assay. Methods Mol Biol 454, 93–102.
 https://doi.org/10.1007/978-1-59745-181-9_8
- Lauritano, C., Andersen, J.H., Hansen, E., Albrigtsen, M., Escalera, L., Esposito, F., Helland, K.,
 Hanssen, K.Ø., Romano, G., Ianora, A., 2016. Bioactivity Screening of Microalgae for
 Antioxidant, Anti-Inflammatory, Anticancer, Anti-Diabetes, and Antibacterial Activities. Front
 Mar Sci 3, 68. https://doi.org/10.3389/fmars.2016.00068
- Le Lann, K., Surget, G., Couteau, C., Coiffard, L., Cérantola, S., Gaillard, F., Larnicol, M., Zubia, M.,
 Guérard, F., Poupart, N., Stiger-Pouvreau, V., 2016. Sunscreen, antioxidant, and bactericide
 capacities of phlorotannins from the brown macroalga Halidrys siliquosa. J Appl Phycol 28,
 3547–3559. https://doi.org/10.1007/s10811-016-0853-0
- Lee, S., van Santen, J.A., Farzaneh, N., Liu, D.Y., Pye, C.R., Baumeister, T.U.H., Wong, W.R., Linington,
 R.G., 2022. NP Analyst: An Open Online Platform for Compound Activity Mapping. ACS Cent Sci
 8, 223–234. https://doi.org/10.1021/acscentsci.1c01108
- 1772 Leist, M., Hasiwa, M., Daneshian, M., 2013. Summary and Validation of New Animal-Free Toxicity
 1773 Tests. ALTEX Proceedings 2, 27–37.
- Li, D., Li, C., Li, L., Chen, S., Wang, L., Li, Q., Wang, X., Lei, X., Shen, Z., 2016. Natural Product
 Kongensin A is a Non-Canonical HSP90 Inhibitor that Blocks RIP3-dependent Necroptosis. Cell
 Chem Biol 23, 257–266. https://doi.org/10.1016/j.chembiol.2015.08.018
- Li, M.X., Bai, X., Ma, Y.-P., Zhang, H.-X., Nama, N., Pei, S.-J., Du, Z.-Z., 2019. Cosmetic potentials of
 extracts and compounds from Zingiber cassumunar Roxb. rhizome. Ind Crops Prod 141, 111764.
 https://doi.org/10.1016/j.indcrop.2019.111764
- Lindhagen, E., Nygren, P., Larsson, R., 2008. The fluorometric microculture cytotoxicity assay. Nat
 Protoc 3, 1364–1369. https://doi.org/10.1038/nprot.2008.114
- Linnakoski, R., Reshamwala, D., Veteli, P., Cortina-Escribano, M., Vanhanen, H., Marjomäki, V., 2018.
 Antiviral Agents From Fungi: Diversity, Mechanisms and Potential Applications. Front Microbiol
 9. https://doi.org/10.3389/fmicb.2018.02325
- Liu, M., El-Hossary, E.M., Oelschlaeger, T.A., Donia, M.S., Quinn, R.J., Abdelmohsen, U.R., 2019.
 Potential of marine natural products against drug-resistant bacterial infections. Lancet Infect
 Dis. https://doi.org/10.1016/S1473-3099(18)30711-4

- Lozano, C., López, M., Rojo-Bezares, B., Sáenz, Y., 2020. Antimicrobial Susceptibility Testing in
 Pseudomonas aeruginosa Biofilms: One Step Closer to a Standardized Method. Antibiotics 9,
 880. https://doi.org/10.3390/antibiotics9120880
- Lyu, C., Chen, T., Qiang, B., Liu, N., Wang, H., Zhang, L., Liu, Z., 2021. CMNPD: a comprehensive
 marine natural products database towards facilitating drug discovery from the ocean. Nucleic
 Acids Res 49, D509–D515. https://doi.org/10.1093/nar/gkaa763
- Macedo, M.W.F.S., Cunha, N.B. da, Carneiro, J.A., Costa, R.A. da, Alencar, S.A. de, Cardoso, M.H.,
 Franco, O.L., Dias, S.C., 2021. Marine Organisms as a Rich Source of Biologically Active Peptides.
 Front Mar Sci 8, 667764. https://doi.org/10.3389/fmars.2021.667764
- Madan, K., Nanda, S., 2018. In-vitro evaluation of antioxidant, anti-elastase, anti-collagenase, anti hyaluronidase activities of safranal and determination of its sun protection factor in skin
 photoaging. Bioorg Chem 77, 159–167. https://doi.org/10.1016/j.bioorg.2017.12.030
- Maddox, C.B., Rasmussen, L., White, E.L., 2008. Adapting Cell-Based Assays to the High-Throughput
 Screening Platform: Problems Encountered and Lessons Learned. JALA: Journal of the
 Association for Laboratory Automation 13, 168–173. https://doi.org/10.1016/j.jala.2008.02.002
- Maji, B., Gangopadhyay, S.A., Lee, M., Shi, M., Wu, P., Heler, R., Mok, B., Lim, D., Siriwardena, S.U.,
 Paul, B., Dančík, V., Vetere, A., Mesleh, M.F., Marraffini, L.A., Liu, D.R., Clemons, P.A., Wagner,
 B.K., Choudhary, A., 2019. A High-Throughput Platform to Identify Small-Molecule Inhibitors of
 CRISPR-Cas9. Cell 177, 1067-1079.e19. https://doi.org/10.1016/j.cell.2019.04.009
- Marmann, A., Aly, A.H., Lin, W., Wang, B., Proksch, P., 2014. Co-Cultivation-A Powerful Emerging Tool
 for Enhancing the Chemical Diversity of Microorganisms. Mar Drugs 12, 1043–1065.
 https://doi.org/10.3390/md12021043
- 1810 Martín, J., Da Sousa, T.S., Crespo, G., Palomo, S., González, I., Tormo, J.R., De La Cruz, M., Anderson,
- 1811 M., Hill, R.T., Vicente, F., Genilloud, O., Reyes, F., 2013. Kocurin, the true structure of
- 1812 PM181104, an anti-methicillin-resistant Staphylococcus aureus (MRSA) thiazolyl peptide from
- 1813 the marine-derived bacterium Kocuria palustris. Mar Drugs 11, 387–398.
- 1814 https://doi.org/10.3390/md11020387
- Mascolo, M.G., Perdichizzi, S., Vaccari, M., Rotondo, F., Zanzi, C., Grilli, S., Paparella, M., Jacobs, M.N.,
 Colacci, A., 2018. The transformics assay: first steps for the development of an integrated
 approach to investigate the malignant cell transformation in vitro. Carcinogenesis 39, 955–967.
 https://doi.org/10.1093/carcin/bgy037
- Mbah, J.A., Ngemenya, M.N., Abawah, A.L., Babiaka, S.B., Nubed, L.N., Nyongbela, K.D., Lemuh, N.D.,
 Efange, S.M., 2012. Bioassay-guided discovery of antibacterial agents: in vitro screening of
 Peperomia vulcanica, Peperomia fernandopoioana and Scleria striatinux. Ann Clin Microbiol
 Antimicrob 11, 10. https://doi.org/10.1186/1476-0711-11-10
- Mervin, L.H., Cao, Q., Barrett, I.P., Firth, M.A., Murray, D., McWilliams, L., Haddrick, M.,
 Wigglesworth, M., Engkvist, O., Bender, A., 2016. Understanding Cytotoxicity and Cytostaticity
 in a High-Throughput Screening Collection. ACS Chem Biol 11, 3007–3023.
- 1826 https://doi.org/10.1021/acschembio.6b00538

- Millar, M.R., Linton, C.J., Sherriff, A., 2001. Use of a continuous culture system linked to a modified
 robbins device or flow cell to study attachment of bacteria to surfaces, in: Methods in
 Enzymology. pp. 43–62. https://doi.org/10.1016/S0076-6879(01)37005-2
- 1830 Minarini, L.A.D.R., Andrade, L.N. de, De Gregorio, E., Grosso, F., Naas, T., Zarrilli, R., Camargo, I.L.B.C.,
 1831 2020. Editorial: Antimicrobial Resistance as a Global Public Health Problem: How Can We
 1832 Address It? Front Public Health 8, 612844. https://doi.org/10.3389/fpubh.2020.612844
- Mohammad, T., Khan, F.I., Lobb, K.A., Islam, A., Ahmad, F., Hassan, Md.I., 2019. Identification and
 evaluation of bioactive natural products as potential inhibitors of human microtubule affinity regulating kinase 4 (MARK4). J Biomol Struct Dyn 37, 1813–1829.
- 1836 https://doi.org/10.1080/07391102.2018.1468282
- Moon, H.J., Lee, S.R., Shim, S.N., Jeong, S.H., Stonik, V.A., Rasskazov, V.A., Zvyagintseva, T., Lee, Y.H.,
 2008. Fucoidan Inhibits UVB-Induced MMP-1 Expression in Human Skin Fibroblasts. Biol Pharm
 Bull 31, 284–289. https://doi.org/10.1248/bpb.31.284
- Muenzebrock, K.A., Kersten, V., Alblas, J., Garcia, J.P., Creemers, L.B., 2022. The Added Value of the
 "Co" in Co-Culture Systems in Research on Osteoarthritis Pathology and Treatment
 Development. Front Bioeng Biotechnol 10. https://doi.org/10.3389/fbioe.2022.843056
- Naesens, L., Bonnafous, P., Agut, H., De Clercq, E., 2006. Antiviral activity of diverse classes of broadacting agents and natural compounds in HHV-6-infected lymphoblasts. Journal of Clinical
 Virology 37, S69–S75. https://doi.org/10.1016/S1386-6532(06)70015-4
- Naik, B., Gupta, N., Ojha, R., Singh, S., Prajapati, V.K., Prusty, D., 2020. High throughput virtual
 screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy
 for COVID-19 treatment. Int J Biol Macromol 160, 1–17.
- 1849 https://doi.org/10.1016/j.ijbiomac.2020.05.184
- Nehete, J.Y., Bhambar, R.S., Narkhede, M.R., Gawali, S.R., 2013. Natural proteins: Sources, isolation,
 characterization and applications. Pharmacogn Rev 7, 107–116. https://doi.org/10.4103/0973 7847.120508
- Newman, D.J., Cragg, G.M., 2020. Natural Products as Sources of New Drugs over the Nearly Four
 Decades from 01/1981 to 09/2019. J Nat Prod 83, 770–803.
 https://doi.org/10.1021/acs.jnatprod.9b01285
- Niepel, M., Hafner, M., Duan, Q., Wang, Z., Paull, E.O., Chung, M., Lu, X., Stuart, J.M., Golub, T.R.,
 Subramanian, A., Ma'ayan, A., Sorger, P.K., 2017. Common and cell-type specific responses to
 anti-cancer drugs revealed by high throughput transcript profiling. Nat Commun 8, 1186.
 https://doi.org/10.1038/s41467-017-01383-w
- 1860 Nikaido, H., 2009. The Limitations of LB Medium. Small Things Considered.
- Nothias, L.-F., Nothias-Esposito, M., da Silva, R., Wang, M., Protsyuk, I., Zhang, Z., Sarvepalli, A.,
 Leyssen, P., Touboul, D., Costa, J., Paolini, J., Alexandrov, T., Litaudon, M., Dorrestein, P.C.,
 Bioactivity-Based Molecular Networking for the Discovery of Drug Leads in Natural
- 1864 Product Bioassay-Guided Fractionation. J Nat Prod 81, 758–767.
- 1865 https://doi.org/10.1021/acs.jnatprod.7b00737
- 1866 Nweze, J.A., Mbaoji, F.N., Huang, G., Li, Y., Yang, L., Zhang, Y., Huang, S., Pan, L., Yang, D., 2020.
 1867 Antibiotics Development and the Potentials of Marine-Derived Compounds to Stem the Tide of

- 1868 Multidrug-Resistant Pathogenic Bacteria, Fungi, and Protozoa. Mar Drugs 18, 145.
 1869 https://doi.org/10.3390/md18030145
- 1870 Öberg, B., Vrang, L., 1990. Screening for new agents. European Journal of Clinical Microbiology &
 1871 Infectious Diseases 9, 466–471. https://doi.org/10.1007/BF01964285
- Oh, D.C., Jensen, P.R., Kauffman, C.A., Fenical, W., 2005. Libertellenones A–D: Induction of cytotoxic
 diterpenoid biosynthesis by marine microbial competition. Bioorg Med Chem 13, 5267–5273.
 https://doi.org/10.1016/J.BMC.2005.05.068
- Olivares, E., Badel-Berchoux, S., Provot, C., Jaulhac, B., Prévost, G., Bernardi, T., Jehl, F., 2016. The
 BioFilm Ring Test: a Rapid Method for Routine Analysis of Pseudomonas aeruginosa Biofilm
 Formation Kinetics. J Clin Microbiol 54, 657–661. https://doi.org/10.1128/JCM.02938-15
- 1878 Ong, C.W.M., Migliori, G.B., Raviglione, M., MacGregor-Skinner, G., Sotgiu, G., Alffenaar, J.-W., Tiberi, 1879 S., Adlhoch, C., Alonzi, T., Archuleta, S., Brusin, S., Cambau, E., Capobianchi, M.R., Castilletti, C., 1880 Centis, R., Cirillo, D.M., D'Ambrosio, L., Delogu, G., Esposito, S.M.R., Figueroa, J., Friedland, J.S., 1881 Ho, B.C.H., Ippolito, G., Jankovic, M., Kim, H.Y., Rosales Klintz, S., Ködmön, C., Lalle, E., Leo, Y.S., 1882 Leung, C.-C., Märtson, A.-G., Melazzini, M.G., Najafi Fard, S., Penttinen, P., Petrone, L., 1883 Petruccioli, E., Pontali, E., Saderi, L., Santin, M., Spanevello, A., van Crevel, R., van der Werf, M.J., Visca, D., Viveiros, M., Zellweger, J.-P., Zumla, A., Goletti, D., 2020. Epidemic and pandemic 1884 1885 viral infections: impact on tuberculosis and the lung. European Respiratory Journal 56, 2001727.
- 1886 https://doi.org/10.1183/13993003.01727-2020
- 1887Organisation for Economic Co-operation and Development OECD, 2022. OECD Guidelines for the1888Testing of Chemicals, Section 4 Health Effects. OECD. https://doi.org/10.1787/9789264242548-1889en
- O'Rourke, A., Beyhan, S., Choi, Y., Morales, P., Chan, A.P., Espinoza, J.L., Dupont, C.L., Meyer, K.J.,
 Spoering, A., Lewis, K., Nierman, W.C., Nelson, K.E., 2020. Mechanism-of-Action Classification of
 Antibiotics by Global Transcriptome Profiling. Antimicrob Agents Chemother 64, e01207-19.
 https://doi.org/10.1128/aac.01207-19
- Ortega, S.S., Cara, L.C.L., Salvador, M.K., 2012. In silico pharmacology for a multidisciplinary drug
 discovery process. Drug Metabol Drug Interact 27, 199–207. https://doi.org/10.1515/dmdi 2012-0021
- Palacios-Gorba, C., Pina, R., Tortajada-Girbés, M., Jiménez-Belenguer, A., Siguemoto, É., Ferrús, M.A.,
 Rodrigo, D., Pina-Pérez, M.C., 2020. Caenorhabditis elegans as an in vivo model to assess
 fucoidan bioactivity preventing Helicobacter pylori infection. Food Funct 11, 4525–4534.
 https://doi.org/10.1039/D0FO00768D
- Park, E.S., Rabinovsky, R., Carey, M., Hennessy, B.T., Agarwal, R., Liu, W., Ju, Z., Deng, W., Lu, Y., Woo,
 H.G., Kim, S.-B., Cheong, J.-H., Garraway, L.A., Weinstein, J.N., Mills, G.B., Lee, J.-S., Davies,
 M.A., 2010. Integrative Analysis of Proteomic Signatures, Mutations, and Drug Responsiveness
 in the NCI 60 Cancer Cell Line Set. Mol Cancer Ther 9, 257–267. https://doi.org/10.1158/15357163.MCT-09-0743
- Parvez, S., Kang, M., Chung, H.-S., Cho, C., Hong, M.-C., Shin, M.-K., Bae, H., 2006. Survey and
 mechanism of skin depigmenting and lightening agents. Phytotherapy Research 20, 921–934.
 https://doi.org/10.1002/ptr.1954

- Pastorino, G., Marchetti, C., Borghesi, B., Cornara, L., Ribulla, S., Burlando, B., 2017. Biological
 activities of the legume crops Melilotus officinalis and Lespedeza capitata for skin care and
 pharmaceutical applications. Ind Crops Prod 96, 158–164.
- 1912 https://doi.org/10.1016/j.indcrop.2016.11.047
- Pech-Puch, D., Pérez-Povedano, M., Gómez, P., Martínez-Guitián, M., Lasarte-Monterrubio, C., Carlos
 Vázquez-Ucha, J., Lourdes Novoa-Olmedo, M., Guillén-Hernández, S., Villegas-Hernández, H.,
 Bou, G., Rodríguez, J., Beceiro, A., Jiménez, C., 2020. Marine Organisms from the Yucatan
- 1916 Peninsula (Mexico) as a Potential Natural Source of Antibacterial Compounds. Mar. Drugs 18,
- 1917 369. https://doi.org/10.3390/md18070369
- Peeters, E., Nelis, H.J., Coenye, T., 2008. Comparison of multiple methods for quantification of
 microbial biofilms grown in microtiter plates. J Microbiol Methods 72, 157–165.
 https://doi.org/10.1016/J.MIMET.2007.11.010
- Pena-Pereira, F., Bendicho, C., Pavlović, D.M., Martín-Esteban, A., Díaz-Álvarez, M., Pan, Y., Cooper,
 J., Yang, Z., Safarik, I., Pospiskova, K., Segundo, M.A., Psillakis, E., 2021. Miniaturized analytical
 methods for determination of environmental contaminants of emerging concern A review.
 Anal Chim Acta 1158, 238108. https://doi.org/10.1016/J.ACA.2020.11.040
- Pereira, F., Almeida, J.R., Paulino, M., Grilo, I.R., Macedo, H., Cunha, I., Sobral, R.G., Vasconcelos, V.,
 Gaudêncio, S.P., 2020. Antifouling Napyradiomycins from Marine-Derived Actinomycetes
 Streptomyces aculeolatus. Mar Drugs 18, 63. https://doi.org/10.3390/md18010063
- Pereira, F., Latino, D., Gaudêncio, S., 2015. QSAR-Assisted Virtual Screening of Lead-Like Molecules
 from Marine and Microbial Natural Sources for Antitumor and Antibiotic Drug Discovery.
 Molecules 20, 4848–4873. https://doi.org/10.3390/molecules20034848
- Pereira, F., Latino, D., Gaudêncio, S., 2014. A Chemoinformatics Approach to the Discovery of Lead Like Molecules from Marine and Microbial Sources En Route to Antitumor and Antibiotic Drugs.
 Mar Drugs 12, 757–778. https://doi.org/10.3390/md12020757
- Philström, T., Fernández-Alba, A.R., Gamón, M., Amate, C.F., Poulsen, M.E., Lippold, R.,
 Anastassiades, M., De Kok, A., O'Regan, F., Pelosi, P., Valverde, A., Masselter, S., Mol, H.,
 Jezussek, M., 2019. Analytical quality control and method validation procedures for pesticide
 residues analysis in food and feed.
- Ponti, J., Ceriotti, L., Munaro, B., Farina, M., Munari, A., Whelan, M., Colpo, P., Sabbioni, E., Rossi, F.,
 2006. Comparison of Impedance-based Sensors for Cell Adhesion Monitoring and *In Vitro*Methods for Detecting Cytotoxicity Induced by Chemicals. Alternatives to Laboratory Animals
 34, 515–525. https://doi.org/10.1177/026119290603400508
- Pushpakom, S., Iorio, F., Eyers, P.A., Escott, K.J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer,
 J., McNamee, C., Norris, A., Sanseau, P., Cavalla, D., Pirmohamed, M., 2019. Drug repurposing:
 progress, challenges and recommendations. Nat Rev Drug Discov 18, 41–58.
 https://doi.org/10.1038/nrd.2018.168
- Qiu, S.-M., Aweya, J.J., Liu, X., Liu, Y., Tang, S., Zhang, W., Cheong, K.-L., 2022. Bioactive
 polysaccharides from red seaweed as potent food supplements: a systematic review of their
 extraction, purification, and biological activities. Carbohydr Polym 275, 118696.
 https://doi.org/10.1016/j.carbpol.2021.118696
 - 48

- 1950 Ratz-Lyko, A., Arct, J., Pytkowska, K., 2012. Methods for evaluation of cosmetic antioxidant capacity.
 1951 Skin Research and Technology 18, 421–430. https://doi.org/10.1111/j.1600-0846.2011.00588.x
- Raucci, A., Palumbo, R., Bianchi, M.E., 2007. HMGB1: a signal of necrosis. Autoimmunity 40, 285–9.
 https://doi.org/10.1080/08916930701356978
- 1954 Rekha, P., Chandra Mouli, B., Vijaya Kumari, S., Indumathi, C., Mithyantha MS, 2006. Studies on the
 1955 identification of suitable solvents for microbial bioassay. Curr Sci 90, 1663–1667.
- 1956 Reymen, D., Naesens, L., Balzarini, J., Holý, A., Dvořáková, H., De Clercq, E., 1995. Antiviral activity of
 1957 selected acyclic nucleoside analogues against human herpesvirus 6. Antiviral Res 28, 343–357.
 1958 https://doi.org/10.1016/0166-3542(95)00058-5
- Riss, T., Niles, A., Moravec, R., Karassina, N., Vidugiriene, J., 2019. Cytotoxicity Assays: In Vitro
 Methods to Measure Dead Cells, in: Markossian S, Grossman A, Brimacombe K, et al. (Eds.),
 Cytotoxicity Assays: In Vitro Methods to Measure Dead Cells. Eli Lilly & Company and the
 National Center for Advancing Translational Sciences, Bethesda, MD.
- 1963 Riss, T.L., Moravec, R.A., 2004. Use of Multiple Assay Endpoints to Investigate the Effects of
 1964 Incubation Time, Dose of Toxin, and Plating Density in Cell-Based Cytotoxicity Assays. Assay
 1965 Drug Dev Technol 2, 51–62. https://doi.org/10.1089/154065804322966315
- 1966 Rittie, L., Fisher, G.J., 2002. UV-light-induced signal cascades and skin aging. Ageing Res Rev 1, 705–
 1967 720. https://doi.org/10.1016/S1568-1637(02)00024-7
- Rodriguez-Tudela, J.L., Arendrup, M.C., Barchiesi, F., Bille, J., Chryssanthou, E., Cuenca-Estrella, M.,
 Dannaoui, E., Denning, D.W., Donnelly, J.P., Dromer, F., Fegeler, W., Lass-Flörl, C., Moore, C.,
 Richardson, M., Sandven, P., Velegraki, A., Verweij, P., 2008. EUCAST Definitive Document EDef
 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative
 yeasts. Clinical Microbiology and Infection 14, 398–405. https://doi.org/10.1111/j.14690691.2007.01935.x
- 1974 Roh, S.-S., Park, S.-B., Park, S.-M., Choi, B.W., Lee, M.-H., Hwang, Y.-L., Kim, C.H., Jeong, H.-A., Kim,
 1975 C.D., Lee, J.-H., 2013. A Novel Compound Rasatiol Isolated from *Raphanus sativus* Has a
 1976 Potential to Enhance Extracellular Matrix Synthesis in Dermal Fibroblasts. Ann Dermatol 25,
 1977 315. https://doi.org/10.5021/ad.2013.25.3.315
- 1978 Romano, J.D., Tatonetti, N.P., 2019. Informatics and Computational Methods in Natural Product Drug
 1979 Discovery: A Review and Perspectives. Front Genet 10, 368.
 1980 https://doi.org/10.3389/fgene.2019.00368
- Romano, S., Jackson, S.A., Patry, S., Dobson, A.D.W., 2018. Extending the "One Strain Many
 Compounds" (OSMAC) Principle to Marine Microorganisms. Mar Drugs 16, 244.
 https://doi.org/10.3390/md16070244
- Rotter, A., Bacu, A., Barbier, M., Bertoni, F., Bones, A.M., Cancela, M.L., Carlsson, J., Carvalho, M.F.,
 Cegłowska, M., Dalay, M.C., Dailianis, T., Deniz, I., Drakulovic, D., Dubnika, A., Einarsson, H.,
 Erdoğan, A., Eroldoğan, O.T., Ezra, D., Fazi, S., FitzGerald, R.J., Gargan, L.M., Gaudêncio, S.P.,
 Ivošević DeNardis, N., Joksimovic, D., Kataržytė, M., Kotta, J., Mandalakis, M., Matijošytė, I.,
 Mazur-Marzec, H., Massa-Gallucci, A., Mehiri, M., Nielsen, S.L., Novoveská, L., Overlingė, D.,
 Portman, M.E., Pyrc, K., Rebours, C., Reinsch, T., Reyes, F., Rinkevich, B., Robbens, J., Rudovica,
 V., Sabotič, J., Safarik, I., Talve, S., Tasdemir, D., Schneider, X.T., Thomas, O.P., Toruńska-Sitarz,

1991 A., Varese, G.C., Vasquez, M.I., 2020. A New Network for the Advancement of Marine

- 1992 Biotechnology in Europe and Beyond. Front Mar Sci 7.
- 1993 https://doi.org/10.3389/fmars.2020.00278
- Rotter, A., Barbier, M., Bertoni, F., Bones, A.M., Cancela, M.L., Carlsson, J., Carvalho, M.F., Cegłowska,
 M., Chirivella-Martorell, J., Conk Dalay, M., Cueto, M., Dailianis, T., Deniz, I., Díaz-Marrero, A.R.,
 Drakulovic, D., Dubnika, A., Edwards, C., Einarsson, H., Erdoğan, A., Eroldoğan, O.T., Ezra, D.,
- 1997 Fazi, S., FitzGerald, R.J., Gargan, L.M., Gaudêncio, S.P., Gligora Udovič, M., Ivošević DeNardis, N.,
- 1998 Jónsdóttir, R., Kataržytė, M., Klun, K., Kotta, J., Ktari, L., Ljubešić, Z., Lukić Bilela, L., Mandalakis,
- M., Massa-Gallucci, A., Matijošytė, I., Mazur-Marzec, H., Mehiri, M., Nielsen, S.L., Novoveská, L.,
 Overlingė, D., Perale, G., Ramasamy, P., Rebours, C., Reinsch, T., Reyes, F., Rinkevich, B.,
- 2001Robbens, J., Röttinger, E., Rudovica, V., Sabotič, J., Safarik, I., Talve, S., Tasdemir, D., Theodotou2002Schneider, X., Thomas, O.P., Toruńska-Sitarz, A., Varese, G.C., Vasquez, M.I., 2021a. The
- 2003 Essentials of Marine Biotechnology. Front Mar Sci. https://doi.org/10.3389/fmars.2021.629629
- Rotter, A., Gaudêncio, S.P., Klun, K., Macher, J.-N., Thomas, O.P., Deniz, I., Edwards, C., Grigalionyte Bembič, E., Ljubešić, Z., Robbens, J., Varese, G.C., Vasquez, M.I., 2021b. A New Tool for Faster
 Construction of Marine Biotechnology Collaborative Networks. Front Mar Sci 8.
 https://doi.org/10.3389/fmars.2021.685164
- Sabotič, J., Brzin, J., Erjavec, J., Dreo, T., Tušek Žnidarič, M., Ravnikar, M., Kos, J., 2020. L-Amino Acid
 Oxidases From Mushrooms Show Antibacterial Activity Against the Phytopathogen Ralstonia
 solanacearum. Front Microbiol 11, 977. https://doi.org/10.3389/fmicb.2020.00977
- Safarik, I., Horska, K., Pospiskova, K., Safarikova, M., 2012. Magnetic techniques for the detection and
 determination of xenobiotics and cells in water. Anal Bioanal Chem 404, 1257–1273.
 https://doi.org/10.1007/s00216-012-6056-x
- Safarik, I., Safarikova, M., 2014. One-step magnetic modification of non-magnetic solid materials.
 International Journal of Materials Research 105, 104–107. https://doi.org/10.3139/146.111009
- Safarik, I., Safarikova, M., 2004. Magnetic techniques for the isolation and purification of proteins
 and peptides. Biomagn Res Technol 2, 7. https://doi.org/10.1186/1477-044X-2-7
- Žafaříková, M., Šafařík, I., 1999. Magnetic solid-phase extraction. J Magn Magn Mater 194, 108–112.
 https://doi.org/10.1016/S0304-8853(98)00566-6
- Saghaie, L., Pourfarzam, M., Fassihi, A., Sartippour, B., 2013. Synthesis and tyrosinase inhibitory
 properties of some novel derivatives of kojic acid. Res Pharm Sci 8, 233–42.
- Saini, R.K., Prasad, P., Shang, X., Keum, Y.-S., Parinandi, L., 2021. Molecular Sciences Advances in Lipid
 Extraction Methods-A Review. Int. J. Mol. Sci 22, 13643.
 https://doi.org/10.3390/ijms222413643
- Sanguinetti, M., Posteraro, B., 2016. Mass spectrometry applications in microbiology beyond microbe
 identification: progress and potential. Expert Rev Proteomics 13, 965–977.
 https://doi.org/10.1080/14789450.2016.1231578
- 2028 Santacroce, M.P., Pastore, A.S., Tinelli, A., Colamonaco, M., Crescenzo, G., 2015. Implications for
- 2029 chronic toxicity of benzo[a]pyrene in sea bream cultured hepatocytes: Cytotoxicity,
- inflammation, and cancerogenesis. Environ Toxicol 30, 1045–1062.
- 2031 https://doi.org/10.1002/tox.21978

- Sarker, S.D., Nahar, L., 2012. Natural Products Isolation. Methods in Molecular Biology 864.
 https://doi.org/10.1007/978-1-61779-624-1_1
- Sauer, G., Amtmann, E., Melber, K., Knapp, A., Müller, K., Hummel, K., Scherm, A., 1984. DNA and
 RNA virus species are inhibited by xanthates, a class of antiviral compounds with unique
 properties. Proceedings of the National Academy of Sciences 81, 3263–3267.
 https://doi.org/10.1073/pnas.81.11.3263
- Schneider, X.T., Stroil, B.K., Tourapi, C., Rebours, C., Gaudêncio, S.P., Novoveska, L., Vasquez, M.I.,
 2022. Responsible Research and Innovation Framework, the Nagoya Protocol and Other
 European Blue Biotechnology Strategies and Regulations: Gaps Analysis and Recommendations
 for Increased Knowledge in the Marine Biotechnology Community. Mar Drugs 20, 290.
 https://doi.org/10.3390/md20050290
- Schneider, X.T., Stroil, B.K., Tourapi, C., Rebours, C., Novoveska, L., Vasquez, M.I., Gaudêncio, S.P.,
 2023. Improving awareness, understanding, and enforcement of responsibilities and regulations
 in Blue Biotechnology. Trends Biotechnol. https://doi.org/10.1016/j.tibtech.2023.05.011
- 2046Scientific Committee on Consumer Safety SCCS, 2021. SCCS Notes of Guidance for the Testing of2047Cosmetic Ingredients and their Safety Evaluation 11th revision. SCCS/1628/21.
- Seiler, A.E.M., Spielmann, H., 2011. The validated embryonic stem cell test to predict embryotoxicity
 in vitro. Nat Protoc 6, 961–978. https://doi.org/10.1038/nprot.2011.348
- Severson, W.E., Shindo, N., Sosa, M., Fletcher, I.T., White, E.L., Ananthan, S., Jonsson, C.B., 2007.
 Development and Validation of a High-Throughput Screen for Inhibitors of SARS CoV and Its
 Application in Screening of a 100,000-Compound Library. SLAS Discovery 12, 33–40.
 https://doi.org/10.1177/1087057106296688
- Sezonov, G., Joseleau-Petit, D., D'Ari, R., 2007. Escherichia coli physiology in Luria-Bertani broth. J
 Bacteriol 189, 8746–8749. https://doi.org/10.1128/JB.01368-07
- Shabir, G.A., 2003. Validation of high-performance liquid chromatography methods for
 pharmaceutical analysis. J Chromatogr A 987, 57–66. https://doi.org/10.1016/S0021 9673(02)01536-4
- Shoemaker, R.H., 2006. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6,
 813–823. https://doi.org/10.1038/nrc1951
- Shounan, Y., Feng, X., O'Connell, P.J., 1998. Apoptosis detection by annexin V binding: a novel
 method for the quantitation of cell-mediated cytotoxicity. J Immunol Methods 217, 61–70.
 https://doi.org/10.1016/s0022-1759(98)00090-8
- 2064 Sidwell, R., 1986. Determination of antiviral activity. Drugs Pharm Sci 27, 433–480.
- Šimat, V., Elabed, N., Kulawik, P., Ceylan, Z., Jamroz, E., Yazgan, H., Čagalj, M., Regenstein, J.M.,
 Özogul, F., 2020. Recent Advances in Marine-Based Nutraceuticals and Their Health Benefits.
 Mar Drugs 18, 627. https://doi.org/10.3390/md18120627
- Śliwka, L., Wiktorska, K., Suchocki, P., Milczarek, M., Mielczarek, S., Lubelska, K., Cierpiał, T., Łyżwa,
 P., Kiełbasiński, P., Jaromin, A., Flis, A., Chilmonczyk, Z., 2016. The Comparison of MTT and CVS
 Assays for the Assessment of Anticancer Agent Interactions. PLoS One 11, e0155772.
- 2071 https://doi.org/10.1371/journal.pone.0155772

- Sterniša, M., Sabotič, J., Klančnik, A., 2022. A novel approach using growth curve analysis to
 distinguish between antimicrobial and anti-biofilm activities against Salmonella. Int J Food
 Microbiol 364, 109520. https://doi.org/10.1016/j.ijfoodmicro.2021.109520
- Strömstedt, A.A., Felth, J., Bohlin, L., 2014. Bioassays in natural product research Strategies and
 methods in the search for anti-inflammatory and antimicrobial activity. Phytochemical Analysis
 2077 25, 13–28. https://doi.org/10.1002/PCA.2468
- Suffness, M., Pezzuto, J.M., 1991. Assays related to cancer drug discovery, in: Hostettmann, K., Dey,
 P.M., Harborne, J.B. (Eds.), Methods in Plant Biochemistry. Academic Press, London, pp. 71–
 153.
- Swinney, D., 2013. Phenotypic vs. Target-Based Drug Discovery for First-in-Class Medicines. Clin
 Pharmacol Ther 93, 299–301. https://doi.org/10.1038/clpt.2012.236
- Taga, M.E., Xavier, K.B., 2011. Methods for Analysis of Bacterial Autoinducer-2 Production. Curr
 Protoc Microbiol 23. https://doi.org/10.1002/9780471729259.mc01c01s23
- Tandon, R., Mocarski, E.S., 2012. Viral and host control of cytomegalovirus maturation. Trends
 Microbiol 20, 392–401. https://doi.org/10.1016/j.tim.2012.04.008
- Thompson, M., Ellison, S.L.R., Wood, R., 2002. Harmonized guidelines for single laboratory validation
 of methods of analysis (IUPAC Technical Report). Pure Appl. Chem 74, 4–5.
- Thornburg, C.C., Britt, J.R., Evans, J.R., Akee, R.K., Whitt, J.A., Trinh, S.K., Harris, M.J., Thompson, J.R.,
 Ewing, T.L., Shipley, S.M., Grothaus, P.G., Newman, D.J., Schneider, J.P., Grkovic, T., O'Keefe,
 B.R., 2018. NCI Program for Natural Product Discovery: A Publicly-Accessible Library of Natural
 Product Fractions for High-Throughput Screening. ACS Chem Biol 13, 2484–2497.
 https://doi.org/10.1021/acschembio.8b00389
- Thring, T.S., Hili, P., Naughton, D.P., 2009. Anti-collagenase, anti-elastase and anti-oxidant activities
 of extracts from 21 plants. BMC Complement Altern Med 9, 27. https://doi.org/10.1186/1472 6882-9-27
- Tian, Z., Liu, F., Li, D., Fernie, A.R., Chen, W., 2022. Strategies for structure elucidation of small
 molecules based on LC–MS/MS data from complex biological samples. Comput Struct
 Biotechnol J 20, 5085–5097. https://doi.org/10.1016/j.csbj.2022.09.004
- Tremblay, Y.D.N., Vogeleer, P., Jacques, M., Harel, J., 2015. High-Throughput Microfluidic Method To
 Study Biofilm Formation and Host-Pathogen Interactions in Pathogenic Escherichia coli. Appl
 Environ Microbiol 81, 2827–2840. https://doi.org/10.1128/AEM.04208-14
- Tziveleka, L.-A., Vagias, C., Roussis, V., 2003. Natural Products with Anti-HIV Activity from Marine
 Organisms. Curr Top Med Chem 3, 1512–1535. https://doi.org/10.2174/1568026033451790
- United States Pharmacopeial Convention, 2018. General Chapter <1058> "Analytical Instrument
 Qualification." Rockville, Maryland, USA.
- 2107 USFDA, 2018. Bioanalytical Method Validation Guidance for Industry.
- 2108 USP 40, 2017. <1225> Validation of Compendial Procedures.

- Valigra, L., 2010. Qualifying Analytical Instruments: General Chapter &It;1058> Clarifies
 Terminology, Classifies Instruments. The Quality Assurance Journal 13, 67–71.
 https://doi.org/10.1002/qaj.475
- Vasconcelos, I., Fernandes, C., 2017. Magnetic solid phase extraction for determination of drugs in
 biological matrices. TrAC Trends in Analytical Chemistry 89, 41–52.
 https://doi.org/10.1016/J.TRAC.2016.11.011
- Veerapandian, R., Paudyal, A., Chang, A., Vediyappan, G., 2020. Separation of Bioactive Small
 Molecules, Peptides from Natural Sources and Proteins from Microbes by Preparative
 Isoelectric Focusing (IEF) Method. Journal of Visualized Experiments.
- 2118 https://doi.org/10.3791/61101
- Veldhuizen, J., Migrino, R.Q., Nikkhah, M., 2019. Three-dimensional microengineered models of
 human cardiac diseases. J Biol Eng 13, 29. https://doi.org/10.1186/s13036-019-0155-6
- Wambaugh, J.F., Hughes, M.F., Ring, C.L., MacMillan, D.K., Ford, J., Fennell, T.R., Black, S.R., Snyder,
 R.W., Sipes, N.S., Wetmore, B.A., Westerhout, J., Setzer, R.W., Pearce, R.G., Simmons, J.E.,
 Thomas, R.S., 2018. Evaluating In Vitro-In Vivo Extrapolation of Toxicokinetics. Toxicological
 Sciences 163, 152–169. https://doi.org/10.1093/toxsci/kfy020
- Wang, C., Niederstrasser, H., Douglas, P.M., Lin, R., Jaramillo, J., Li, Y., Oswald, N.W., Zhou, A.,
 McMillan, E.A., Mendiratta, S., Wang, Z., Zhao, T., Lin, Z., Luo, M., Huang, G., Brekken, R.A.,
 Posner, B.A., MacMillan, J.B., Gao, J., White, M.A., 2017. Small-molecule TFEB pathway agonists
 that ameliorate metabolic syndrome in mice and extend C. elegans lifespan. Nat Commun 8,
 2270. https://doi.org/10.1038/s41467-017-02332-3
- Wang, X., Li, G., Row, K.H., 2017. Magnetic graphene oxide modified by imidazole-based ionic liquids
 for the magnetic-based solid-phase extraction of polysaccharides from brown alga. J Sep Sci 40,
 3301–3310. https://doi.org/10.1002/jssc.201700393
- Webb, B.J., Ferraro, J.P., Rea, S., Kaufusi, S., Goodman, B.E., Spalding, J., 2018. Epidemiology and
 Clinical Features of Invasive Fungal Infection in a US Health Care Network. Open Forum Infect
 Dis 5. https://doi.org/10.1093/ofid/ofy187
- Weller, M.G., 2012. A Unifying Review of Bioassay-Guided Fractionation, Effect-Directed Analysis and
 Related Techniques. Sensors 12, 9181–9209. https://doi.org/10.3390/s120709181
- White, J.R., Abodeely, M., Ahmed, S., Debauve, G., Johnson, E., Meyer, D.M., Mozier, N.M., Naumer,
 M., Pepe, A., Qahwash, I., Rocnik, E., Smith, J.G., Stokes, E.S.E., Talbot, J.J., Wong, P.Y., 2019.
 Best practices in bioassay development to support registration of biopharmaceuticals.
 Biotechniques 67, 126–137. https://doi.org/10.2144/btn-2019-0031
- 2142 WHO Scientific Group, 1987. Progress in the development and use of antiviral drugs and interferon.2143 Geneva.
- Wiegand, I., Hilpert, K., Hancock, R.E.W., 2008. Agar and broth dilution methods to determine the
 minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc 3, 163–175.
 https://doi.org/10.1038/nprot.2007.521
- Wingate, G., 2004. Computer systems validation : quality assurance, risk management, and
 regulatory compliance for pharmaceutical and healthcare companies. Interpharm/CRC, USA.

- Wishart, D.S., 2009. Computational strategies for metabolite identification in metabolomics.
 Bioanalysis 1, 1579–1596. https://doi.org/10.4155/bio.09.138
- Wishart, D.S., 2007. Improving Early Drug Discovery through ADME Modelling. Drugs in R & D 8, 349–
 362. https://doi.org/10.2165/00126839-200708060-00003
- Wouters, O.J., McKee, M., Luyten, J., 2020. Estimated Research and Development Investment
 Needed to Bring a New Medicine to Market, 2009-2018. JAMA 323, 844.
 https://doi.org/10.1001/jama.2020.1166
- Yang, Y., Khan, B.M., Zhang, X., Zhao, Y., Cheong, K.-L., Liu, Y., 2020. Advances in Separation and
 Purification of Bioactive Polysaccharides through High-speed Counter-Current Chromatography
 The prospects of bioactive polysaccharides research. J Chromatogr Sci 58, 992–1000.
 https://doi.org/10.1093/chromsci/bmaa063
- Yang, Z.H., Lucia, H.L., Tolman, R.L., Colonno, R.J., Hsiung, G.D., 1989. Effect of 2'-nor-cyclic GMP
 against guinea pig cytomegalovirus infection. Antimicrob Agents Chemother 33, 1563–1568.
 https://doi.org/10.1128/AAC.33.9.1563
- Yodkeeree, S., Thippraphan, P., Punfa, W., Srisomboon, J., Limtrakul(Dejkriengkraikul), P., 2018. Skin
 Anti-aging Assays of Proanthocyanidin Rich Red Rice Extract, Oryzanol and Other Phenolic
 Compounds. Nat Prod Commun 13, 1934578X1801300.
 https://doi.org/10.1177/1934578X1801300812
- Younes, M., Aggett, P., Aguilar, F., Crebelli, R., Dusemund, B., Filipič, M., Frutos, M.J., Galtier, P.,
 Gundert-Remy, U., Kuhnle, G.G., Lambré, C., Leblanc, J., Lillegaard, I.T., Moldeus, P., Mortensen,
- A., Oskarsson, A., Stankovic, I., Waalkens-Berendsen, I., Woutersen, R.A., Wright, M., Di
- 2170 Domenico, A., Fairweather-Tait, S., McArdle, H.J., Smeraldi, C., Gott, D., 2021. Guidance on
- safety evaluation of sources of nutrients and bioavailability of nutrient from the sources
- 2172 (Revision 1)1. EFSA Journal 19. https://doi.org/10.2903/j.efsa.2021.6552
- Zaharevitz, D.W., Holbeck, S.L., Bowerman, C., Svetlik, P.A., 2002. COMPARE: a web accessible tool
 for investigating mechanisms of cell growth inhibition. J Mol Graph Model 20, 297–303.
 https://doi.org/10.1016/S1093-3263(01)00126-7
- Zhao, X., Yu, Z., Ding, T., 2020. Quorum-Sensing Regulation of Antimicrobial Resistance in Bacteria.
 Microorganisms 8, 425. https://doi.org/10.3390/microorganisms8030425
- 2178
- 2179
- 2180

2181 Figure legends

2182

2183 **Fig. 1.** Characteristics of bioassays used at different stages of biodiscovery.

2185 **Fig. 2.** Characteristics of a good bioassay.

2186

2184

Fig. 3. Distribution of research efforts to assess bioactivity of marine natural products from 2000 to 2188 2022 based on the PubMed database. For each bioactivity, the number of publications without reviews 2189 is indicated. The last two years are highlighted, with the number of publications (without reviews) next 2190 to the columns.

2191

Fig. 4. Distribution of research methods and target microorganisms for antimicrobial bioactivity of marine natural products from 2000 to 2022 based on PubMed database. The number of publications (excluding reviews) is shown for each method or microorganism used. A, research effort by bioassay method; B, research effort by microbial species. The last two years are highlighted, with the number of publications (excluding reviews) next to the columns. MIC, minimum inhibitory concentration assay determines the lowest concentration of a substance that inhibits the visible growth of a microorganism.

2199

2200 Fig. 5. Distribution of research methods used between 2000 and 2022 to assess cytotoxic activity of 2201 marine natural products (based on PubMed database). The total number of publications (excluding 2202 reviews) is shown for each method used, with the last two years highlighted in light blue and the 2203 number next to each column. NRU, neutral red uptake cytotoxicity assay; alamar blue is a metabolic 2204 dye used to quantify proliferation; calcein assay measures cell viability by following conversion of 2205 calcein-AM to fluorescent calcein in living cells; LDH measures the activity of lactate dehydrogenase 2206 released from damaged cells; SRB, sulforhodamine B is a fluorescent dye used to quantify cellular 2207 proteins; PI, propidium iodide is a fluorescent dye that can pass freely through the cell membranes of 2208 dead cells and is excluded from viable cells; ATP, adenosine triphosphate assay measures cell viability 2209 based on the presence of ATP; Annexin-V is a protein that binds to phosphatidylserine on the plasma 2210 membrane and is used to detect apoptosis; MTT, MTS, XTT are tetrazolium salts that are reduced to 2211 formazan in living cells, where MTS and XTT yield a water-soluble formazan dye that is detected 2212 spectrophotometrically.

2213

2214 Fig. 6. Screening for antiviral activity begins with determining the potential toxicity of the compounds 2215 or extracts to cell lines that allow viral replication using bioassays such as tetrazolium salts or ATP-2216 based assays or fluorometric microculture cytotoxicity assays (FMCA). It is then necessary to determine 2217 which cell system(s) is best suited for virus replication to test for antiviral activity. The ability of the cell 2218 line to support viral replication varies and can be measured by cytopathic effect (CPE), focus-forming 2219 assay (FFA), plaque quantification (PRA, VRA), or hemagglutination inhibition (HI). Once specific 2220 antiviral activity has been established, it needs to be verified in more complex systems and using in 2221 vivo models.

2222

Fig. 7. Distribution of research methods for antioxidant and anti-ageing activities of marine naturalproducts from 2000 to 2022 based on PubMed database. The number of publications (excluding

reviews) is shown for each method. The last two years are highlighted, with the number of publications
(excluding reviews) next to the columns. CUPRAC, CUPric Reducing Antioxidant Capacity; ORAC,
oxygen radical absorbance capacity; ABTS, 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic
acid)/Trolox[®]-equivalent Antioxidant Capacity; DPPH, 2,2-diphenyl-1-picrylhydrazyl.


2230 Fig. 8. The approach for the discovery of new bioactive compounds from marine extracts, with the 2231 methodology for small (left) and large (right) biomolecules indicated separately. After extraction, 2232 bioassays are performed to determine the potential bioactivities of the extract, and several purification 2233 steps are performed to fractionate the extract for analysis and prioritise the purified compounds 2234 according to their novelty, for which the dereplication step is crucial. Several purification and analysis 2235 runs are required to narrow down the selection of bioactive compounds. Finally, a purification 2236 procedure is applied to obtain larger amounts of bioactive compounds that can be further used for 2237 compound identification and structure elucidation. The general approach for the discovery of new 2238 bioactive compounds is the same for each type of molecule, but the analysis and separation 2239 methodology differs depending on the properties.


2240

2229


Fig. 9. Overview of the different stages of drug discovery in the early discovery and preclinical phasesof natural product development. Examples are shown of various bioactivity and safety assays that can


- be used specifically at each stage.
- 2244






























Supplementary Table S1

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
Antimicrobial				
bioassays				
Disc diffusion = Agar disc diffusion method = Kirby-Bauer test = Disc- diffusion antibiotic susceptibility test	<i>In vitro</i> detection of effects on microbial growth or survival on solid media. A microbial inoculum suspension (e.g., 1-2 10 ⁸ CFU/mL for bacteria) is spread on agar plates and the test extract/compound is applied on impregnated paper discs. After 12-24 h incubation (bacteria) or 24 – 48 h incubation (fungi) in suitable growth conditions for the tested microbial strain inhibition zone diameters are read at the point where no growth is observed. Variations are available for yeasts and molds.	 Simple Standardized protocols available for bacteria and yeast (CLSI, EUCAST) Versatile (suitable for majority of bacterial pathogens) Controls for bioassay performance available in form of antibiotics and characterized typing strains with known phenotype and antibiogram No special equipment, only basic microbiological utilities required Easily used in routine Reproducible and accurate if standard protocols are followed Inexpensive Easy to interpret Adequate for primary screening 	 BSL2 and BSL3 level microorganisms require work in suitable facility Not appropriate for all bacterial pathogens Diffusion of the extract/compound can be non-homogeneous and affect accuracy Not appropriate for large molecules, amphiphilic molecules Importance of the inoculum size and preparation Importance of growth medium used Not quantitative – cannot determine MIC value Qualitative categorization into susceptible, intermediate or resistant is possible based on standardized MIC breakpoints Cannot distinguish between bactericidal and bacteriostatic effect Few interpretative criteria are available Not adapted for filamentous fungi as breakpoints for standard antibiotics are not defined 	(Alastruey- Izquierdo et al., 2015; Balouiri et al., 2016; Matuschek et al., 2014; Strömstedt et al., 2014)
Antimicrobial gradient method = Epsilometer testing (commercial version Etest®)	In vitro detection of effects on microbial growth or survival on solid media. Variant of agar diffusion method that combines the principle of dilution and diffusion methods to determine MIC. Exponential gradient of substance applied on a plastic or nitrocellulose strip (marked with concentration scale) and placed on a previously inoculated agar surface. After 12-24 h incubation (bacteria) or 24 – 48 h incubation (fungi) in suitable conditions ellipse-shaped zone of inhibition indicates the MIC that can be read off the strip.	 Simple Used for antibiotics, also antimycobacterials High sensitivity (can detect trace amount of beta-lactamase (ESBL) Quantitative (provides MIC value) Can be used to test interaction of two antimicrobials Cost-effective Useful also for yeast and filamentous fungi 	 BSL2 and BSL3 level microorganisms require work in suitable facility Not appropriate for all bacterial pathogens Subjective interpretation Diffusion of the extract/compound can be non-homogeneous and affect accuracy Not appropriate for large molecules, amphiphilic molecules Cannot distinguish between bactericidal and bacteriostatic effect Not used for MNPs (problematic preparation of gradient strip) 	(Idelevich et al., 2018)

Supplementary Table S1: Principles and characteristics of popular bioassays used in pre-screening and screening of bioactivities

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
Agar plate assay = Poisoned food method for filamentous fungi	<i>In vitro</i> evaluation of antifungal effect against filamentous fungi. The substance or extract is incorporated homogeneously into the molten agar and mycelia disc are inoculated at the center of plate. After incubation under suitable growth	 No special equipment, only basic microbiological utilities required Easy to interpret Commercial kits available that can be used as controls Simple Standardized protocols available (CLSI, EUCAST) Easy to interpret Relatively sensitive 	 BSL2 and BSL3 level microorganisms require work in suitable facility There are some commercial kits that combine identification-susceptibility testing assay for <i>Candida</i> and <i>Aspergillus</i> spp. 	(Chadwick et al., 2013)
	conditions the diameters of growth inhibition are read and compared with the unexposed control.	 Low cost Adequate for primary screening 	 Resources for work with fungi Not quantitative Possible interference with growth medium components Not appropriate for heat labile compounds Requires large amounts of compounds Time consuming 	
Broth (micro)dilution for determination of MIC (Minimum Inhibitory Concentration)	In vitro detection of microbial growth inhibition in liquid culture containing a known concentration of drug. Two-fold dilutions of antimicrobial agent or extract are mixed with the inoculum in liquid medium and after suitable growth time period of incubation (12 – 24 h) MIC value is determined by detecting the lowest concentration that inhibited visible microbial growth. Usually performed in 96- well plates (microdilution). Detection of growth is by naked eye or colorimetric assays using tetrazolium salts, resazurin, or ATP can be used to detect metabolically active cells. Different procedures are adapted for yeasts and molds including longer incubation time (24 – 72 h).	 Standard protocols are available (CLSI, EUCAST) Gold standard in clinical microbiology High-capacity bioassay Versatile Accurate and reproducible Applicable to both yeasts and molds Economic if plates are produced in the laboratory Can be used for any new discovered antimicrobials Low sample volume required Cost-effective Adequate for primary screening Appropriate for high-throughput screening 	 BSL2 and BSL3 level microorganisms require work in suitable facility Solubility of organic extract in broth medium can be challenging Not suitable for large polycationic, amphiphilic molecules Plastic interference of 96 well plates for peptide antimicrobial assessment Importance of the inoculum size and preparation Importance of growth medium used Subjective interpretation by CLSI methodology alleviated using EUCAST protocol Labor-intensive Technical training requirement high Risk of error with dilution preparation Edge effect 	(Arendrup et al., 2008; Balouiri et al., 2016; Ezra et al., 2004; Rodriguez- Tudela et al., 2008; Strömstedt et al., 2014)
MBC (Minimum bactericidal	Common estimation of bactericidal or fungicidal activity determined after broth dilution by	- Simple - Quantitative	 BSL2 and BSL3 level microorganisms require work in suitable facility 	(Balouiri et al., 2016)

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
concentration), or MFC (minimum fungicidal concentration), or MLC (minimum lethal concentration) Time-kill assay = Time- kill curve = Growth curve analysis	subculturing samples from wells with incubation time from 24 h to 72 h. It is the lowest concentration of antimicrobial agent needed to kill 99.9 % of the final inoculum after 24 h incubation in standardized conditions. <i>In vitro</i> test to measure the kinetics of dynamic interaction between the compound and the microbial strain to reveal a time-dependent or a concentration dependent antimicrobial effect. The	 Cost-effective Adequate for primary screening Existing standard guidelines CLSI and ASTM Growth curve analysis offers many variables that may indicate 	 Labor intensive Importance of growth medium used Only culturable cells are detected BSL2 and BSL3 level microorganisms require work in suitable facility Special software needed for growth curve analysis 	(Balouiri et al., 2016)
	log CFU/mL of microbial/antimicrobial solution is determined on time scale depending on the bacteria strain and the media used. Alternatively, growth is followed in a microplate reader measuring optical density at 600 nm. Typically used in secondary testing.	mode of action: growth rate, growth dynamics - Can be used to study synergy/antagonism between substances	 Labor intensive Specialized equipment needed Inoculum size, growth phase, growth medium affect outcome Possible interference with growth vessels, medium components and method of growth detection 	
Bioautography	In vitro direct detection of antibacterial compounds on TLC (Thin Layer Chromatography) plate based on incubation (12 – 24 h) and visualization of microbial growth using vital stains or metabolic stains or dehydrogenase-activity- detecting reagent to reveal zones of inhibition. A variation is possible using bioluminescent bacteria as reporters. Particularly adequate for monitoring.	 Simple Rapid Results easily visualized Inexpensive Applicable to both bacteria and fungi Can be utilized for spore-producing fungi Little amount of extract/compound required 	 BSL2 and BSL3 level microorganisms require work in suitable facility Volume of agar or broth has to be well defined otherwise resulting in poorly defined inhibition zones or irregular bacterial growth Not quantitative Difficult to standardize 	(Balouiri et al., 2016; Choma and Grzelak, 2011; Dewanjee et al., 2015; Klöppel et al., 2008; Patil et al., 2017)
Volatile antibiotics bioassays	All versions of these bioassays use the same principle to detect volatile organic compound (VOC) activity. The source of the volatile (a living organism or chemical) is placed on one side of a chamber without direct contact with the target organism, while the target is grown or located on another side or compartment of the chamber. The effect of the volatile on the growth (inhibition) or survival of the target organism is compared to a control using the same container and conditions without the volatiles.	 Easy to perform and interpret Low cost Sensitive Adequate for primary screening 	 BSL2 and BSL3 level microorganisms require work in suitable facility Not quantitative Special equipment or material required (sealed chambers) 	(Ezra, 2004; Liarzi et al., 2016; Tomsheck et al., 2010)

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
Antibiofilm				
bioassays				
Crystal violet	Gold standard for biofilm quantification in microtiter plates. Inoculum in liquid medium incubated for 24 – 72 h at selected temperature under static conditions. Washing steps and short incubation times in crystal violet, are followed by the colorimetric detection of the stained biomass.	 Adapted protocols available for different bacterial species Different surfaces can be assayed using coupons Versatile: both for G+ and G- Qualitative or quantitative, but characterized control strains need to be incorporated for interpretation Low cost Can be used to monitor biofilm growth and biofilm eradication High-throughput (96-well plates) Adequate for primary screening 	 BSL2 and BSL3 level microorganisms require work in suitable facility Non-specific binding to anionic proteins and other negatively charged molecules, like capsules, lipopolysaccharides, and DNA/nucleic acids, leading to an inability to distinguish between live and dead bacterial populations and/or exopolysaccharides Large variability between samples leading to possibly complicated interpretation Medium composition important Culture conditions important Strain to strain variability is high, need to know primary biofilm phenotype Interference of the stain with experimental setup possible 	(Haney et al., 2021; O'Toole, 2011)
CFU (Colony Forming Units)	Biofilm is sonicated to dislodge adhered biomass and serial dilutions of homogenized bacterial suspension is plated onto agar plates, incubated 24 – 48 h to count the colony forming units (CFUs).	 Simple Low cost Adequate for primary screening 	 BSL2 and BSL3 level microorganisms require work in suitable facility Need for specialized equipment Sonication parameters important (can reduce viability of recovered CFUs), Sonication parameters are different for different bacterial species aggregation can affect CFU count Labor intensive Only culturable cells are detected 	(Haney et al., 2021)
The BioFilm Ring Test	Mobility measurement of magnetic microbeads mixed with bacterial suspension in a polystyrene microplate. Without biofilm growth beads gather together in a visible central spot under magnetic action, while no spot indicates bead immobilization by biofilm formation.	 Simple Rapid No dyes or stains No washing steps Low sample volume required High-throughput (96- well plates) 	 BSL2 and BSL3 level microorganisms require work in suitable facility Need for specialized equipment Interpretation may be challenging Qualitative 	(Olivares et al., 2016)
The Calgary Biofilm device	Two-part reaction vessel containing a lid with 96 pegs that sit in channels of the reaction vessel that	 Standardized protocols available High-throughput (96-well plates) Quantitative 	 BSL2 and BSL3 level microorganisms require work in suitable facility Need for specialized equipment 	(Haney et al., 2021;

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
MBEC (Minimum	allows flow of medium across pegs to create consistent shear force. High-throughput screening of antibiofilm activity.	- Standardized method for	 Use of multiple sterile microplates for treatment and washing steps Relies on viable cell counting for experimental validation BSL2 level microorganisms require work in 	Kırmusaoğlu, 2019) (ASTM, 2022;
biofilm eradication concentration) Assay®	Plastic lid with 96 pegs on which biofilms establish under batch conditions and the lid with pegs is transferred to a new 96 well for testing, biofilm is dislodged by sonication and CFUs are determined.	Pseudomonas aeruginosa (ASTM E2799-17)	suitable facility Aggregation can affect CFU count Labor intensive Only culturable cells are detected 	Parker et al., 2014)
SIMBA – simultaneous detection of antimicrobial and antibiofilm activity	The SIMultaneous detection of antiMicrobial and anti-Biofilm Activity (SIMBA) method combines the testing of antimicrobial and antibiofilm activity against bacteria with the evaluation of the 20-hour growth curve of the <i>Salmonella</i> Infantis ŽM9 strain determined with absorbance measurements at 600 nm in a 96-well plate.	 Simple Rapid No dyes or stains Cost-effective Information on both antimicrobial and antibiofilm activity in one assay Low sample volume required High-throughput (96-well plates) Possibility of automation 	 Optimized for one Salmonella strain Not suitable for dark colored samples Need for specialized equipment (spectrophotometer with temperature control and shaking capabilities) 	(Sterniša et al., 2023, 2022)
Cytotoxicity bioassays				
MTT (also MTS, XTT, WST)	<i>In vitro</i> colorimetric assay usually performed in 96- well plates to evaluate cellular metabolic activity - glycolytic production of NADH. Based on tetrazolium salts (MTT, 3-(4,5-dimethylthiazol-2- yl)-2,5-diphenyltetrazolium bromide; XTT, 2,3-bis- (2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium- 5-carboxanilide; MTS, 3-(4,5-dimethylthiazol-2-yl)- 5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H- tetrazolium; WST, water-soluble tetrazolium salts) – difference between them is the tetrazolium salt used and the solubility and/or absorption spectrum of the formazan product. Eukaryotic cells are treated for 24 - 48 hours with different concentrations of compounds to determine the concentration of the tested	 Commercial kits with standardized protocols available Cost-effective Relatively simple Assay for whole cells Linearity between absorbance and cell count Versatile: suitable for both adherent and suspended cell cultures One-step procedure variants using water soluble tetrazolium salts include XTT, MTS, WST Possibility of automation Appropriate for high-throughput screening 	 BSL2 and BSL3 level cell lines require appropriate facility Lengthy two-step procedure Highly variable results depending on: the number of cells per well, and the high pH of the culture medium Requires optimization of cell density (untreated cells have absorbance values that fall within the linear portion of the growth curve (conditions not too close to saturation) Requires optimized incubation time Not suitable for reducing compounds Not for metabolically poor cells, i.e. thymocytes and splenocytes 	(Balbaied and Moore, 2020; Jo HY et al., 2015; Mccauley et al., 2013; Riss et al., 2019)

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
Sulforhodamine B	 compounds, which produces 50% of cytotoxicity (CC₅₀). Tetrazolium salt (e.g., MTT) is then added to the cells for 2 hours at 37°C. MTT is reduced by a cellular mitochondrial enzyme (succinate dehydrogenase) to violet formazan precipitates, which are subsequently solubilized by organic solvents before absorbance is read. Alternatively, water-soluble tetrazolium salts can be used, omitting the final solubilization step. Used for cell density determination, based on the 	- Simple	 Linearity between absorbance and cell count is lost when cells are confluent and cellular metabolism slows down The result can be variable because metabolic activity depends not only on the number of cells per well but also on several other factors Requires microplate reader (absorbance) 	(Vichai and
(SRB) assay	measurement of cellular protein content. Toxicity screening of compounds to adherent cells in a 96- well format. After an incubation period, cell monolayers are fixed with 10% (wt/vol) trichloroacetic acid and stained for 30 min, after which the excess dye is removed by washing repeatedly with 1% (vol/vol) acetic acid. The protein-bound dye is dissolved in 10 mM Tris base solution for OD determination at 510 nm using a microplate reader.	 Cost-effective Results linear over a 20-fold range of cell numbers Sensitivity comparable to those of fluorometric methods Appropriate for high-throughput screening 		Kirtikara, 2006)
ATP-based test	Gold standard luminescence test. See MTT for the procedure. Quantification of released intracellular ATP by enzymatic reaction between the enzyme luciferase and its substrate, luciferin, to produce luminescence. There is a linear relationship between the intensity of the light signal and the ATP concentration or cell number. It is one of the most sensitive endpoints for measuring cell viability.	 One-step procedure Faster than MTT and MTS Reduction of artifacts Sensitive measure of intracellular ATP rather a specific biological effect More sensitive than conventional biochemical methods Sensitive compared to other cytotoxicity tests Interferences minimal Commercial kits available Possibility of being automated 	 BSL2 and BSL3 level cell lines require suitable facility More expensive than MTT and MTS and fluorescent methods The ATP assay sensitivity is usually limited by reproducibility of pipetting Replicate samples rather than a result of the assay chemistry Need for specialized equipment (luminescence detection) 	(Aslantürk, 2018; Herzog et al., 2007; Ponti et al., 2006)
Automated fluorometric	Based on the measurement of fluorescence generated from cellular hydrolysis of fluorescein	- Highly standardized and reproducible one-step procedure	- BSL2 and BSL3 level cell lines require suitable facility	(Burman et al., 2011;
microculture	diacetate (FDA) to fluorescein by viable cells with	 Possibility of being automated 	 Need for specialized equipment 	

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
cytotoxicity assay (FMCA)	intact plasma membranes after a 48 – 72 hour culture period in microtiter plates. See MTT for procedure.		(fluorescence detection)	Lindhagen et al., 2008)
Dye exclusion method	The membrane integrity of cell is determined by its permeability to several dyes (eosin, Trypan blue, erythrosine B, Congo red assays). Trypan blue has been used the most extensively to assess the percentage of viable cells in suspension culture.	 Simple Rapid Small numbers of cells needed Can be applied in non dividing cell populations 	 BSL2 and BSL3 level cell lines require suitable facility Can be challenging to process a large number of samples simultaneously, particularly when the exact timing of progressive cytotoxic effects is taken into consideration Careful interpretation needed for living cells with metabolic activity loss (trypan blue) Its toxic side effect of some dyes on mammalian cells (trypan blue) Not suitable for adherent monolayer cell cultures Labor intensive 	(Aslantürk, 2018)
LDH (lactate dehydrogenase) cytotoxicity assay	LDH is a cytosolic enzyme present in many different cell types that is released upon damage to the plasma membrane. The assay quantitatively measures the activity of stable, cytosolic LDH released from damaged cells. It is a colorimetric assay.	 Suitable for both adherent and suspended cell cultures Commercial kits available Detects low level damage to cell membranes which cannot be detected using other methods 	 BSL2 and BSL3 level cell lines require suitable facility LDH assay is limited to serum-free or low- serum culture conditions to avoid high background readings. Interference with serum components 	(Kocherova et al., 2020)
Clonogenic cell survival assay	Determines the ability of a cell to proliferate indefinitely, retaining its reproductive ability to form a colony or a clone. These cells are considered clonogenic. Cells are seeded at low density and growth of colonies/clones is analysed after a week by staining and counting. The gold standard for measuring cellular reproductivity.	 Simple Cost-effective Gold standard 	 BSL2 and BSL3 level cell lines require suitable facility Suitable only for adherent cells Not suitable for all adherent cell lines (not all cells are able to form colonies in vitro – cell-to-cell contacts and self-produced growth factors are limited at low cell density) 	(Munshi et al., 2005)
DNA synthesis assay 3H-labeled thymidine (3HT)	The process of DNA synthesis is relatively specific for cell division and can therefore be considered a marker of cell proliferation activity. Nucleoside	- This assay is commonly regarded as reliable and accurate.	 BSL2 and BSL3 level cell lines require suitable facility Potential use of radioisotopes 	(Romar et al., 2016)

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
	analogue incorporation assays are based on the introduction of chemically or radio-labelled nucleosides that are subsequently incorporated into DNA strands synthesised during S phase. A scintillation beta counter is used to measure radioactivity in DNA recovered from cells to determine the extent of cell division that has occurred in response to a test agent. The nucleoside analogue 5-bromo-2'-deoxyuridine (BrdU) is used to avoid the use of radioisotopes and is detected with monoclonal antibodies. Alternatively, thymidine analogues are available that do not require antibody detection.	 Suitable for immunohistochemistry or immunocytochemistry, In-cell ELISA, flow cytometry It can be performed in experiments <i>in vitro</i> and <i>ex vivo</i>, but not <i>in vivo</i> Not suitable for screening, used for mechanistic studies Commercial kits available Allows quantitative assessment of proliferation levels Direct measures of proliferation Appropriate for high-throughput screening 	 It is an endpoint assay because of the DNA extraction step, and so no further studies can be performed with the treated cells. synthetic analogues such as 5-bromo-2'-deoxyuridine (BrdU) or 5-ethynyl-2'-deoxyuridine (EdU), are usually preferred (can be used not only <i>in vitro</i> or <i>ex vivo</i> but also <i>in vivo</i>) Both assays cannot identify cells that have undergone numerous divisions Need for specialized equipment 	
Antiviral bioassays				
Flow cytometry cell count assay (FACS)	Cytotoxicity-based antiviral assay based on the detection of intact and damaged cells using a flow cytometer and dyes to stain the cells (e.g., propidium iodide, carboxyfluorescein diacetate).	 Three populations discriminated (dead, viable, injured) Reproducible Rapid (2-6 h to results) 	 BSL2 and BSL3 level cell lines and/or viruses require suitable facility Need for specialized equipment: flow cytometry equipment Need for trained personnel Not easy to interpret Specific cell lines known to be susceptible to and allowing viral infection with the virus of interest. 	(Balouiri et al., 2016; Zamora and Aguilar, 2018)
Cytopathic effect assay (CPE)	Suitable for primary <i>in vitro</i> antiviral screening. In this assay, cells permissive for a virus are infected with the same virus at serial dilutions. Cells are observed daily until a cytopathic effect is detected. The virus concentration is expressed as infectious tissue culture dose (TCID ₅₀), which is the multiple of dilutions that result in CPE in 50% of wells.	standardization and automated procedures - For viruses that do or do not form viral plaques	 BSL2 and BSL3 level cell lines and/or viruses require suitable facility Only for viruses that cause morphological changes in infected cells Lengthy: the time required for the cytopathic effect to become apparent Indirect measure of viral load Works only with specific cell lines known to be susceptible and permissible to viral infection with the virus of interest. 	(El Sayed, 2000; Suchman and Blair, 2007)

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
Plaque reduction assay	Primary <i>in vitro</i> antiviral screening for the	 Appropriate for high-throughput screening Validation with a positive 	 Equipment required to work with viruses and specialized virology trained personnel BSL2 and BSL3 level cell lines and/or viruses 	(El Sayed,
(PRA)	detection of infectious viral particles A viral inoculum of approximately 50-70 viral plaques/well is adsorbed onto permissive cells in the presence of the test substance. After viral adsorption, the unbound virus is removed and the culture is covered with a semi-solid medium (agar, Avicel, methylcellulose). After an incubation period equal to the duration of the replication cycle of the virus, the cells are fixed and stained to count the viral plaques microscopically. Titers are expressed as the number of plaque-forming units (PFU) per milliliter (PFU/mI).	 control, such as a commercial compound with known antiviral activity Commonly used No special equipment is required in addition to a cell culture laboratory Results are easily visualized under a microscope or with the naked eye Cost-effective Sensitive Protocols vary from laboratory to laboratory and depend on the type of cells used Appropriate for high-throughput screening 	 require suitable facility Only for viruses that form plaques Labor intensive Sometimes lengthy Results not reproducible: depends on cell density, CPE and plaque size Counting of plaques can be subjective Specific cell lines known to be susceptible and permissible for viral infection with the virus of interest Protocol must be adapted for each host- virus combination 	2000)
Virus reduction yield assay (VRA)	Primary <i>in vitro</i> antiviral screening to detect infectious viral particles. Permissive cell cultures are infected with a specific amount of virus, and after virus adsorption (usually 2 hours at 37°C or 33°C for temperature-sensitive viruses), the unbound virus is removed, and different concentrations of the same compound are added. After an incubation period that allows virus replication, the total viral yield is titrated and determined.	 Less operator-dependent than the PRA Cost-effective Sensitive 	 BSL2 and BSL3 level cell lines and/or viruses require suitable facility Time/material-intensive Not-automatable Not reproducible: results depend on harvesting time Specific cell lines known to be susceptible and permissible to viral infection of the specific virus in focus 	(Collins and Bauer, 1977; Hu and Hsiung, 1989)
Focus Forming assay (FFA)	Primary <i>in vitro</i> antiviral screening for viruses that do not induce CPE. Procedure identical to PRA. FFA doses are expressed as concentration units per milliliter (FFU/mL).	 Faster than PRA or TCID₅₀ Reading time varies depending on the replication cycle of the virus Sensitive 	 BSL2 and BSL3 level cell lines and/or viruses require suitable facility Indirect method Expensive Specific reagents and equipment required 	(Flint et al., 2009)

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
			 Specific cell lines that are known to be susceptible and permissible to infection with the virus of interest Reading time of foci depends on the size of the area the operator is counting. A larger area will take longer, but may provide a more accurate representation of the sample. 	
Hemagglutination inhibition assay (HIA)	 Primary <i>in vitro</i> antiviral screening to detect infectious and noninfectious viral particles for viruses that do not form plaques or cause CPE. For HIA, viral samples are first mixed with dilutions of compounds that take time to bind the virus. Then red blood cells (RBCs) are added to the mixture. Antiviral activity: means that there are no free virus particles and the RBCs fall to the bottom of the well by gravity, creating a distinct red spot in a conical well. No antiviral activity: the erythrocytes clump together, resulting in a lattice-like structure. 	 Simple Does not require special equipment Fast evaluation of virus particles Standardized protocols available Validation of a modified HAI: more sensitive, easy to analyse, required only a single source of erythrocytes and allowed utilisation of virus strains which are difficult to handle by the standard HAI (e.g., H3N2, H5N1 and H1N1pdm09) 	 BSL2 and BSL3 level cell lines and/or viruses require suitable facility Less sensitive than other methods Only for hemagglutinating viruses The red blood cells used depend on the type of influenza virus in the test Required source of suitable red blood cells (horse, rabbit, chicken, guinea pig) Optimization of the type and concentration of red blood cells used is necessary to obtain reliable results. Requires skilled personnel Manual evaluation may lead to misinterpretation of results Non-specific inhibition of hemagglutination possible Low sensitivity Semiquantitative data 	(Joklik, 1988; Morokutti et al., 2013)
Quantitative polymerase chain reaction (qPCR)	PCR involves amplifying short stretches of longer genomic molecules in a thermocycler, a device that exposes the reaction to a series of different temperatures for a specified time (1 amplification cycle). With each PCR cycle, the amount of target sequence (amplicon) in the reaction theoretically doubles. In quantitative polymerase chain reaction, the amplification rate is monitored in real time during PCR using nonspecific intercalating	 Rapid (1-4h response) Sensitive High specificity Possible to validate Quantitative or semi-quantitative Protocol needs to be adapted for each virus, but the general guidelines are the same 	 Cell lines and/or viruses of BSL2 and BSL3 levels require a suitable facility More complex compared to PRA Need for specialized equipment: flow cytometry equipment Need for trained personnel Positive detection does not equate to viable (or infectious) virus, therefore not recommended for initial screening Expensive 	(Engstrom- Melnyk et al., 2015; Kralik and Ricchi, 2017)

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
	fluorescent dyes or fluorescently labeled			
	sequence-specific DNA probes.			
Antioxidant				
assays				
DPPH (2,2'-diphenyl-1- picrylhydrazyl radical) assay	Based on the reaction of the tested antioxidant with the stable synthetic radical 2,2-diphenyl-1- picrylhydrazyl (DPPH•), accompanied by a color shift of the latter. Aliquots of the extracts are mixed with a methanolic solution containing DPPH radicals, and the mixture is incubated in the dark for 30 min. Absorbance is measured with a spectrophotometer at 517 nm. Usually, quercetin is used as a reference standard, and DPPH results are expressed as quercetin equivalents (QE) in µmol per 100 mL.	 Commercial kits available Simple Cost-effective Good repeatability Quantitative Adequate for primary screening Appropriate for high-throughput screening 	 Applicable only for compounds soluble in organic solvents Radical strongly affected by light, oxygen, pH and type of solvent Steric hindrance effects for bulky antioxidants Narrow linear range Limited relevance to biological systems Need for specialized equipment (spectrophotometer, multiplate reader) 	(Apak et al., 2006; Awika et al., 2003; Molyneux P, 2004)
ABTS/TEAC (2,2'-azino-bis(3- ethylbenzothiazoline- 6-sulfonic acid)/Trolox equivalent antioxidant capacity	With the help of an oxidizing agent, the colorless ABTS salt is converted into its radical cation with characteristic blue-green color, which is then reduced back to its original colorless ABTS form by reaction with the tested antioxidant. Antioxidant activity is defined as the amount of ABTS·+ quenched after a given time (usually 5 minutes) and is expressed in Trolox (6-hydroxy-2,5,7,8- tetramethylochroman-2-carboxylic acid) equivalents as TEAC (Trolox Equivalent Antioxidant Capacity).	 Rapid Simple Sensitive Reproducible More sensitive than DPPH assay, high response to antioxidants Can be performed in a 96-well microplate. Diverse, flexible usage in multiple media (pH, solvents) Applicable to both lipophilic and hydrophilic anti-oxidants Commercial kits available Quantitative Adequate for primary screening 	 Limited relevance to biological systems Difficulties in the formation of the colored radical and limited stability Steric hindrance effects for bulky antioxidants Specialized equipment required (spectrophotometer, multiplate reader) 	(Apak et al., 2007; Awika et al., 2003; Erel, 2004; Lee et al., 2015; Re et al., 1999)
Cupric ion (Cu ²⁺) reducing assay (CUPRAC)	In vitro assay for measurement of the absorbance of the colored Cu(I)-neocuproine (Nc) chelate formed as a result of the redox reaction between the chromogenic oxidizing CUPRAC reagent (i.e., Cu(II)-Nc) and the chain-breaking antioxidant under study. Trolox is used as the standard.	 Applicable to both lipophilic and hydrophilic antioxidants Selective detection of antioxidants Simulates antioxidant action under nearly physiological conditions 	 Unable to react with compounds having isolated hydrocarbon double bonds or alternating double and single bonds (e.g., ferulic acid, β-carotene) An incubation at elevated temperature may be required for slow-reacting compounds (e.g., naringin and naringenin) 	(Apak et al., 2007, 2006; Gulcin, 2020; Özyürek et al., 2011)

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
		 Ffavorable redox potential High stability of reagents No steric hindrance effects Commercial kits available Quantitative Adequate for primary screening Appropriate for high-throughput screening 	 Need for specialized equipment (spectrophotometer, multiplate reader) 	
Folin-Ciocalteu	The Folin-Ciocalteu phenolic reagent is used to obtain a rough estimate of the total amount of phenolic compounds present in an extract. Specifically, the phenolic compounds undergo a complex redox reaction with the phosphotungstic and phosphomolybdic acids present in the reaction mixture, yielding a blue color proportional to the amount of phenols. The assay can be performed in a 96-well microplate. The absorbance is read at 760 nm and quantification is based on a calibration curve generated using gallic acid standards (GA).	 Adequate for primary screening Simple Reproducible Excellent correlation between measured "antioxidant capacity" and "total phenolic content" Quantitative Commercial kits available Adequate for primary screening 	 Non-specific to phenolics (it reacts with many non-phenolic compounds) not applicable to lipophilic components Need for specialized equipment (spectrophotometer, multiplate reader) 	(Apak et al., 2007; Bravo et al., 2016; Singleton et al., 1999)
Oxygen radical absorbance capacity (ORAC)	This method is based on the ability of antioxidants to protect fluorescein, a highly fluorescent protein, from oxidative damage caused by peroxyl radicals. The experimental procedure of ORAC involves the addition of the extract under study and a free radical, usually AAPH (2,2'-azobis(2- amidinopropane) dihydrochloride), which forms a moiety together with fluorescein, followed by heating in a phosphate buffer. Thermal decomposition produces free radicals that react with antioxidant compounds, resulting in loss of fluorescence due to decrease in radical concentration. The test can be performed in a 96- well microplate.	 Easily automated and largely standardized adaptable for numerous sample matrices High biological relevance Quantitative Commercial kits available Appropriate for high-throughput screening 	 It is based on fluorescence detection and it requires more expensive instrumentation Need for specialized equipment (fluorescence detection, multiplate reader) 	(Awika et al., 2003; Bravo et al., 2016; Ou et al., 2001)
Anti-aging enzyme- based assays				
Anti-elastase	This <i>in vitro</i> assay is performed in Tris-HCl buffer and at room temperature using porcine pancreatic	- Rapid - Simple	 High cost and limited lifetime of enzymes used 	(Pastorino et al., 2017;

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
	elastase (PPE; E.C.3.4.21.36) and N-succinyl-Ala- Ala-Ala- <i>p</i> -nitroanilide (Suc-Ala3- <i>p</i> NA) as substrate. Inhibition of PPE by natural extracts is determined spectrophotometrically by monitoring the release of p-nitroaniline from Suc-Ala3-pNA at 410 nm. Can be performed in a 96-well microplate. Epigallocathechin-3-gallate (EGCG) is commonly used as a positive control.	 Provide effective approaches to evaluate inhibitory effects of unknown samples against skin- aging enzymes Quantitative Commercial kits available Appropriate for high-throughput screening 	 Considerable consumption of tested compounds/samples Do not closely mimic cellular processes and <i>in vivo</i> conditions Need for specialized equipment (absorbance detection with spectrophotometer or microplate reader) 	Thring et al., 2009)
Anti-collagenase	The ability of the extracts to inhibit collagenase activity is evaluated by a spectrophotometric method based on hydrolysis of the synthetic substrate N-[3-(2-furyl)acryloyl]-Leu-Gly-Pro-Ala (FALGPA) using collagenase from <i>Clostridium</i> <i>histolyticum</i> (ChC – EC.3.4.23.3). Can be performed in a 96-well microplate. EGCG is usually used as positive control.	 Rapid Simple Provide effective approaches to evaluate inhibitory effects of unknown samples against skin- aging enzymes Quantitative Commercial kits available Appropriate for high-throughput screening 	 High cost and limited lifetime of enzymes used Considerable consumption of tested compounds/samples Do not closely mimic cellular processes and <i>in vivo</i> conditions Need for specialized equipment (absorbance detection with spectrophotometer or microplate reader) 	(Thring et al., 2009; Van Wart and Steinbrink, 1981)
Anti-hyaluronidase	In vitro assay that determines activity indirectly by measuring the amount of undegraded hyaluronic acid (HA) substrate remaining after the enzyme is allowed to react with the HA for 30 min at 37°C.	 Rapid Simple Provide effective approaches to evaluate inhibitory effects of unknown samples against skin- aging enzymes Standardized protocol Commercial kits available Quantitative 	 High cost and limited lifetime of enzymes used Considerable consumption of tested compounds/samples Do not closely mimic cellular processes and <i>in vivo</i> conditions Need for specialized equipment (turbidimeter) 	(Bailey and Levine, 1993; Kim et al., 1995)
Anti-tyrosinase	The ability of the extracts to inhibit the catalytic action of tyrosinase in the oxidation of L- DOPA, a precursor of melanin biosynthesis, is usually determined by an enzymatic procedure using the substrate L- DOPA and fungal tyrosinase followed by incubation in a phosphate buffer. The absorbance of the final solutions is measured at 492 nm using a microplate reader. Kojic acid (500 mM) is usually used as a reference inhibitor.	 Rapid Simple Provide effective approaches to evaluate inhibitory effects of unknown samples against skin- aging enzymes Quantitative Commercial kits available Appropriate for high-throughput screening 	 High cost and limited lifetime of enzymes used Considerable consumption of tested compounds/samples Do not closely mimic cellular processes and in vivo conditions Need for specialized equipment (absorbance detection with spectrophotometer or microplate reader) 	(Momtaz et al., 2008)

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
Anti-aging Fibroblast- based assays				
Cytotoxicity/cytoprote ction	Cultured human fibroblast cell lines are pretreated with the samples and subjected to UV irradiation. Cell viability is measured by the colorimetric 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The amount of formazan is measured by recording the absorbance changes at 570 nm with a spectrophotometer.	 Rapid Precise Avoids manipulation of radioactive isotopes Constitutes a vital cellular setting and a real-life model for simulating oxidative damages and assessing the protective role of natural extracts/compounds 	 Handling and preservation of human fibroblast cell lines can be cumbersome Results should be interpreted with caution as the biological effect is evaluated against a specific type of cells (the interaction of the tested substance with other cell types are not taken into account) Need for specialized equipment (cell culture, absorbance detection) 	(Mosmann, 1983; Ramata- Stunda A et al., 2013; Ratz-Lyko et al., 2012; Riss et al., 2019, 2004)
Regenerative potential	This assay involves exposure of seeded human fibroblast cells to extracts followed by washing with chemical reagents and measurement of procollagen type I or hyaluronic acid content in cell-free supernatants by enzyme-linked immunosorbent assay (ELISA).	 Constitutes a vital cellular setting and a real-life model for simulating oxidative damages and assessing the protective role of natural extracts/compounds 	 Expensive Results should be interpreted with caution as the biological effect is evaluated against a specific type of cells (the interaction of the tested substance with other cell types are not taken into account) Need for specialized equipment 	(Koudan et al., 2022)
Pesticidal bioassays				
Feeding bioassay = poisoned food assay	Compound is incorporated into food (mixing in an artificial diet or producing a genetically modified plant) or spread/sprayed over food. Different parameters can be followed after exposure depending on the pest – e.g., survival, weight gain, size gain, offspring count, food consumption or a specific trait	 Simple Easy interpretation Qualitative or quantitative – depending on the set up 	 Live animals (e.g., arthropods, gastropods) are used so a rearing facility is required Dependent on test insect availability – laboratory cultures or seasonal collection Time-consuming Development of artificial diet or GM food can be challenging 	(Burgess et al., 2020; Phan et al., 2020; Portilla, 2020; Razinger et al., 2014; Sanané et al., 2021; Šmid et al., 2015)
Volatile organic compounds (VOCs) Anti-insect activity test	The bioactivity of metabolites can be based on different mechanisms, two of which that are most often studied are to repel or to kill the insect.	 Simple Easy interpretation Qualitative or quantitative – depending on the set up 	 Live animals (e.g., arthropods, gastropods) are used so a rearing facility is required Dependent on test insect availability – laboratory cultures or seasonal collection Time-consuming Need for specialized equipment 	(Daisy et al., 2002; Sternberg et al., 2014)
Other				

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
Enzymatic activity or inhibition of enzymatic activity	To determine enzymatic activity, the sample is incubated with the substrate in an appropriate buffer and at an appropriate temperature, and the reaction is followed by measuring absorbance or fluorescence change (depending on the substrate used). For inhibition of enzymatic activity, the sample is added to an enzyme in a suitable buffer, and after pre-incubation period of 10 to 60 min the substrate is added and the reaction is followed with a spectrophotometer or fluorimeter kinetically or at a selected endpoint (incubation time).	 For some enzymes SOPs (Standard Operating Procedures) available Simple Versatile Quantitative or qualitative Mechanism of action can be determined Commercial kits available for selected enzymes High-throughput 	 High cost and limited lifetime of enzymes used Can be time-consuming Optimization of conditions (buffer, pH, temperature, cofactors, incubation time) needed for each enzyme Prone to false positive and false negative results Enzyme inhibitors in the extracts may affect activity Specific for each enzyme-substrate pair 	(Brooks et al., 2012; Mohan et al., 2018; Pohanka, 2019; Sabotič et al., 2009; Sepčić et al., 2019)
In-gel detection of enzymatic activity	Sample is resolved in polycrylamide gel under nondenaturing conditions and gel is then incubated in a series of solutions until colored or fluorescent bands appear.	 Additional info on size of enzyme Can be simple one-step but also multiple step staining Qualitative, can be semiquantitative 	 Not all enzymes withstand the conditions of in-gel separation Optimization of each enzymatic reaction required with many variables Can take variable time for signal development (e.g. from minutes to days) 	(Covian et al., 2012; Rivoal et al., 2002; Sabotič et al., 2007; Sepčić et al., 2019; Sims, 1965; Žun et al., 2017)

References

- Alastruey-Izquierdo, A., Melhem, M.S.C., Bonfietti, L.X., Rodriguez-Tudela, J.L., 2015. SUSCEPTIBILITY TEST FOR FUNGI: CLINICAL AND LABORATORIAL CORRELATIONS IN MEDICAL MYCOLOGY. Rev Inst Med Trop Sao Paulo 57, 57–64. https://doi.org/10.1590/S0036-46652015000700011
- Apak, R., Güçlü, K., Demirata, B., Özyürek, M., Çelik, S., Bektaşoğlu, B., Berker, K., Özyurt, D., 2007. Comparative Evaluation of Various Total Antioxidant Capacity Assays Applied to Phenolic Compounds with the CUPRAC Assay. Molecules 12, 1496–1547. https://doi.org/10.3390/12071496
- Apak, R., Güçlü, K., Özyürek, M., Esin Karademir, S., Erçağ, E., 2006. The cupric ion reducing antioxidant capacity and polyphenolic content of some herbal teas. Int J Food Sci Nutr 57, 292–304. https://doi.org/10.1080/09637480600798132

- Arendrup, M.C., Meletiadis, J., Mouton, J.W., Lagrou, K., Hamal, P., Guinea, J., Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing, 2008. EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia–forming moulds. Clinical Microbiology and Infection 14, 982–984. https://doi.org/10.1111/j.1469-0691.2008.02086.x
- Aslantürk, Ö.S., 2018. In Vitro Cytotoxicity and Cell Viability Assays: Principles, Advantages, and Disadvantages, in: Larramendy, M.L., Soloneski, S. (Eds.), Genotoxicity A Predictable Risk to Our Actual World. InTech, London. https://doi.org/10.5772/intechopen.71923
- ASTM, 2022. Standard Test Method for Testing Disinfectant Efficacy against *Pseudomonas aeruginosa* Biofilm using the MBEC Assay. ASTM E2799-17. https://doi.org/10.1520/E2799-17
- Awika, J.M., Rooney, L.W., Wu, X., Prior, R.L., Cisneros-Zevallos, L., 2003. Screening Methods To Measure Antioxidant Activity of Sorghum (*Sorghum bicolor*) and Sorghum Products. J Agric Food Chem 51, 6657–6662. https://doi.org/10.1021/jf034790i
- Bailey, L.C., Levine, N.A., 1993. Optimization of the USP assay for hyaluronidase. J Pharm Biomed Anal 11, 285–292. https://doi.org/10.1016/0731-7085(93)80019-W
- Balbaied, T., Moore, E., 2020. Resazurin-Based Assay for Quantifying Living Cells during Alkaline Phosphatase (ALP) Release. Applied Sciences 10, 3840. https://doi.org/10.3390/app10113840
- Balouiri, M., Sadiki, M., Ibnsouda, S.K., 2016. Methods for in vitro evaluating antimicrobial activity: A review. J Pharm Anal 6, 71–79. https://doi.org/10.1016/J.JPHA.2015.11.005
- Bravo, K., Alzate, F., Osorio, E., 2016. Fruits of selected wild and cultivated Andean plants as sources of potential compounds with antioxidant and anti-aging activity. Ind Crops Prod 85, 341–352. https://doi.org/10.1016/j.indcrop.2015.12.074
- Brooks, H.B., Geeganage, S., Kahl, S.D., Montrose, C., Sittampalam, S., Smith, M.C., Weidner, J.R., 2012. Basics of Enzymatic Assays for HTS, in: Markossian S, Grossman A, Brimacombe K, et al. (Eds.), Assay Guidance Manual [Internet]. Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda (MD).
- Burgess, E.R., King, B.H., Geden, C.J., 2020. Oral and Topical Insecticide Response Bioassays and Associated Statistical Analyses Used Commonly in Veterinary and Medical Entomology. Journal of Insect Science 20. https://doi.org/10.1093/jisesa/ieaa041
- Burman, R., Strömstedt, A.A., Malmsten, M., Göransson, U., 2011. Cyclotide–membrane interactions: Defining factors of membrane binding, depletion and disruption. Biochimica et Biophysica Acta (BBA) - Biomembranes 1808, 2665–2673. https://doi.org/10.1016/j.bbamem.2011.07.004
- Chadwick, S.G., Schuyler, J.A., Vermitsky, J.-P., Adelson, M.E., Mordechai, E., Gygax, S.E., 2013. X-Plate Technology: a new method for detecting fluconazole resistance in Candida species. J Med Microbiol 62, 720–726. https://doi.org/10.1099/jmm.0.054445-0

Choma, I.M., Grzelak, E.M., 2011. Bioautography detection in thin-layer chromatography. J Chromatogr A 1218, 2684–2691. https://doi.org/10.1016/j.chroma.2010.12.069

Collins, P., Bauer, D.J., 1977. RELATIVE POTENCIES OF ANTI-HERPES COMPOUNDS. Ann N Y Acad Sci 284, 49–59. https://doi.org/10.1111/j.1749-6632.1977.tb21936.x

- Covian, R., Chess, D., Balaban, R.S., 2012. Continuous monitoring of enzymatic activity within native electrophoresis gels: Application to mitochondrial oxidative phosphorylation complexes. Anal Biochem 431, 30–39. https://doi.org/10.1016/j.ab.2012.08.023
- Daisy, B.H., Strobel, G.A., Castillo, U., Ezra, D., Sears, J., Weaver, D.K., Runyon, J.B., 2002. Naphthalene, an insect repellent, is produced by Muscodor vitigenus, a novel endophytic fungus. Microbiology (N Y) 148, 3737–3741. https://doi.org/10.1099/00221287-148-11-3737
- Dewanjee, S., Gangopadhyay, M., Bhattacharya, N., Khanra, R., Dua, T.K., 2015. Bioautography and its scope in the field of natural product chemistry. J Pharm Anal 5, 75–84. https://doi.org/10.1016/j.jpha.2014.06.002
- El Sayed, K.A., 2000. Natural Products as Antiviral Agents. Studies in Natural Products Chemistry 24, 473–572. https://doi.org/10.1016/S1572-5995(00)80051-4
- Engstrom-Melnyk, J., Rodriguez, P.L., Peraud, O., Hein, R.C., 2015. Clinical Applications of Quantitative Real-Time PCR in Virology, in: Methods in Microbiology. pp. 161–197. https://doi.org/10.1016/bs.mim.2015.04.005
- Erel, O., 2004. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 37, 277–285. https://doi.org/10.1016/j.clinbiochem.2003.11.015
- Ezra, D., 2004. New endophytic isolates of Muscodor albus, a volatile-antibiotic-producing fungus. Microbiology (N Y) 150, 4023–4031. https://doi.org/10.1099/mic.0.27334-0
- Ezra, D., Castillo, U.F., Strobel, G.A., Hess, W.M., Porter, H., Jensen, J.B., Condron, M.A.M., Teplow, D.B., Sears, J., Maranta, M., Hunter, M., Weber, B., Yaver, D., 2004. Coronamycins, peptide antibiotics produced by a verticillate Streptomyces sp. (MSU-2110) endophytic on Monstera sp. Microbiology (N Y) 150, 785–793. https://doi.org/10.1099/mic.0.26645-0
- Flint, S.J., Enquist, W., Racaniello, V.R., Skalka, A.M., 2009. Virological Methods, in: Principles of Virology. ASM Press.
- Gulcin, İ., 2020. Antioxidants and antioxidant methods: an updated overview. Arch Toxicol 94, 651–715. https://doi.org/10.1007/s00204-020-02689-3
- Haney, E.F., Trimble, M.J., Hancock, R.E.W., 2021. Microtiter plate assays to assess antibiofilm activity against bacteria. Nat Protoc 16, 2615–2632. https://doi.org/10.1038/s41596-021-00515-3
- Herzog, E., Casey, A., Lyng, F., Chambers, G., Byrne, H., Davoren, M., 2007. A new approach to the toxicity testing of carbon-based nanomaterials—The clonogenic assay. Toxicol Lett 174, 49–60. https://doi.org/10.1016/j.toxlet.2007.08.009
- Hu, J.M., Hsiung, G.D., 1989. Evaluation of new antiviral agents: I. In vitro perspectives. Antiviral Res 11, 217–232. https://doi.org/10.1016/0166-3542(89)90032-6

- Idelevich, E.A., Groß, U., Becker, K., Bader, O., 2018. Comparative evaluation of different gradient diffusion tests for detection of azole resistance in Aspergillus fumigatus. Diagn Microbiol Infect Dis 91, 52–54. https://doi.org/10.1016/j.diagmicrobio.2018.01.003
- Jo HY, Kim Y, Park HW, Moon HE, Bae S, Kim J, Kim DG, Paek SH., 2015. The Unreliability of MTT Assay in the Cytotoxic Test of Primary Cultured Glioblastoma Cells. Exp Neurobiol. 24, 235–245. https://doi.org/10.5607/en.2015.24.3.235
- Joklik, W., 1988. Virology, 3rd ed. Appleton & Lange, Norwalk, Connecticut, San Mateo.
- Kim, Y.-S., Noh, Y.-K., Lee, G.-I., Kim, Y.-K., Lee, K.-S., Min, K.-R., 1995. Inhibitory Effects of Herbal Medicines on Hyaluronidase Activity. Korean Journal of Pharmacognosy 26, 265–272.
- Kırmusaoğlu, S., 2019. The Methods for Detection of Biofilm and Screening Antibiofilm Activity of Agents, in: Kırmusaoğlu (Ed.), Antimicrobials, Antibiotic Resistance, Antibiofilm Strategies and Activity Methods. IntechOpen, London. https://doi.org/10.5772/intechopen.84411
- Klöppel, A., Grasse, W., Brümmer, F., Morlock, G., 2008. HPTLC coupled with bioluminescence and mass spectrometry for bioactivity-based analysis of secondary metabolites in marine sponges. Journal of Planar Chromatography Modern TLC 21, 431–436. https://doi.org/10.1556/JPC.21.2008.6.7
- Kocherova, I., Kempisty, B., Hutchings, G., Moncrieff, L., Dompe, C., Janowicz, K., Petitte, J., Shibli, J.A., Mozdziak, P., 2020. Cell-based approaches in drug development-a concise review. Medical Journal of Cell Biology. https://doi.org/10.2478/acb-2020-0005
- Koudan, E. V., Zorina, A.I., Levin, A.A., Pereira, F.D.A.S., Petrov, S. V., Karshieva, S.Sh., Kasyanov, V.A., Manturova, N.E., Ustyugov, A.Yu., Potekaev, N.N., Parfenov, V.A., Karalkin, P.A., Khesuani, Y.D., Bulanova, E.A., Kopnin, P.B., Isaev, A.A., Mironov, V.A., Zorin, V.L., 2022. Correlation of the regenerative potential of dermal fibroblasts in 2D culture with the biological properties of fibroblast-derived tissue spheroids. Cell Tissue Res 390, 453–464. https://doi.org/10.1007/s00441-022-03690-1
- Kralik, P., Ricchi, M., 2017. A Basic Guide to Real Time PCR in Microbial Diagnostics: Definitions, Parameters, and Everything. Front Microbiol 8. https://doi.org/10.3389/fmicb.2017.00108
- Lee, K.J., Oh, Y.C., Cho, W.K., Ma, J.Y., 2015. Antioxidant and Anti-Inflammatory Activity Determination of One Hundred Kinds of Pure Chemical Compounds Using Offline and Online Screening HPLC Assay. Evidence-Based Complementary and Alternative Medicine 2015, 1–13. https://doi.org/10.1155/2015/165457
- Liarzi, O., Bar, E., Lewinsohn, E., Ezra, D., 2016. Use of the Endophytic Fungus Daldinia cf. concentrica and Its Volatiles as Bio-Control Agents. PLoS One 11, e0168242. https://doi.org/10.1371/journal.pone.0168242
- Lindhagen, E., Nygren, P., Larsson, R., 2008. The fluorometric microculture cytotoxicity assay. Nat Protoc 3, 1364–1369. https://doi.org/10.1038/nprot.2008.114
- Matuschek, E., Brown, D.F.J., Kahlmeter, G., 2014. Development of the EUCAST disk diffusion antimicrobial susceptibility testing method and its implementation in routine microbiology laboratories. Clinical Microbiology and Infection 20, 0255–0266. https://doi.org/10.1111/1469-0691.12373

- Mccauley, J., Zivanovic, A., Skropeta, D., 2013. Bioassays for Anticancer Activities, in: Methods in Molecular Biology. pp. 191–205. https://doi.org/10.1007/978-1-62703-577-4_14
- Mohan, M., Kozhithodi, S., Nayarisseri, A., Elyas, K.K., 2018. Screening, Purification and Characterization of Protease Inhibitor from Capsicum frutescens. Bioinformation 14, 285–293. https://doi.org/10.6026/97320630014285
- Molyneux P, 2004. The use of the stable free radical diphenylpicrylhydrazyl (DPPH) for estimating antioxidant activity. Songklanakarin Journal of Science and Technology (SJST) 26, 211–219.
- Momtaz, S., Mapunya, B.M., Houghton, P.J., Edgerly, C., Hussein, A., Naidoo, S., Lall, N., 2008. Tyrosinase inhibition by extracts and constituents of Sideroxylon inerme L. stem bark, used in South Africa for skin lightening. J Ethnopharmacol 119, 507–512. https://doi.org/10.1016/j.jep.2008.06.006
- Morokutti, A., Redlberger-Fritz, M., Nakowitsch, S., Krenn, B.M., Wressnigg, N., Jungbauer, A., Romanova, J., Muster, T., Popow-Kraupp, T., Ferko, B., 2013. Validation of the modified hemagglutination inhibition assay (mHAI), a robust and sensitive serological test for analysis of influenza virus-specific immune response. Journal of Clinical Virology 56, 323–330. https://doi.org/10.1016/j.jcv.2012.12.002
- Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65, 55–63. https://doi.org/10.1016/0022-1759(83)90303-4
- Munshi, A., Hobbs, M., Meyn, R.E., 2005. Clonogenic Cell Survival Assay, in: Methods in Molecular Medicine. pp. 21–28.
- Olivares, E., Badel-Berchoux, S., Provot, C., Jaulhac, B., Prévost, G., Bernardi, T., Jehl, F., 2016. The BioFilm Ring Test: a Rapid Method for Routine Analysis of Pseudomonas aeruginosa Biofilm Formation Kinetics. J Clin Microbiol 54, 657–661. https://doi.org/10.1128/JCM.02938-15
- O'Toole, G.A., 2011. Microtiter Dish Biofilm Formation Assay. Journal of Visualized Experiments. https://doi.org/10.3791/2437
- Ou, B., Hampsch-Woodill, M., Prior, R.L., 2001. Development and Validation of an Improved Oxygen Radical Absorbance Capacity Assay Using Fluorescein as the Fluorescent Probe. J Agric Food Chem 49, 4619–4626. https://doi.org/10.1021/jf0105860
- Özyürek, M., Güçlü, K., Tütem, E., Başkan, K.S., Erçağ, E., Esin Çelik, S., Baki, S., Yıldız, L., Karaman, Ş., Apak, R., 2011. A comprehensive review of CUPRAC methodology. Analytical Methods 3, 2439. https://doi.org/10.1039/c1ay05320e
- Parker, A.E., Walker, D.K., Goeres, D.M., Allan, N., Olson, M.E., Omar, A., 2014. Ruggedness and reproducibility of the MBEC biofilm disinfectant efficacy test. J Microbiol Methods 102, 55–64. https://doi.org/10.1016/j.mimet.2014.04.013
- Pastorino, G., Marchetti, C., Borghesi, B., Cornara, L., Ribulla, S., Burlando, B., 2017. Biological activities of the legume crops Melilotus officinalis and Lespedeza capitata for skin care and pharmaceutical applications. Ind Crops Prod 96, 158–164. https://doi.org/10.1016/j.indcrop.2016.11.047

- Patil, A.S., Paikrao, H.M., Kale, A.S., Manik, S.R., 2017. A TLC-Direct Bioautography Method for Detection of Antiurolithiatic Metabolites. J Chromatogr Sci 55, 578–585. https://doi.org/10.1093/chromsci/bmx002
- Phan, N.T., Joshi, N.K., Rajotte, E.G., López-Uribe, M.M., Zhu, F., Biddinger, D.J., 2020. A new ingestion bioassay protocol for assessing pesticide toxicity to the adult Japanese orchard bee (Osmia cornifrons). Sci Rep 10, 9517. https://doi.org/10.1038/s41598-020-66118-2

Pohanka, M., 2019. Biosensors and Bioassays Based on Lipases, Principles and Applications, a Review. Molecules 24, 616. https://doi.org/10.3390/molecules24030616

- Ponti, J., Ceriotti, L., Munaro, B., Farina, M., Munari, A., Whelan, M., Colpo, P., Sabbioni, E., Rossi, F., 2006. Comparison of Impedance-based Sensors for Cell Adhesion Monitoring and *In Vitro* Methods for Detecting Cytotoxicity Induced by Chemicals. Alternatives to Laboratory Animals 34, 515–525. https://doi.org/10.1177/026119290603400508
- Portilla, M., 2020. A Laboratory Diet-Overlay Bioassay to Monitor Resistance in Lygus lineolaris (Hemiptera: Miridae) to Insecticides Commonly Used in the Mississippi Delta. Journal of Insect Science 20. https://doi.org/10.1093/jisesa/ieaa067
- Ramata-Stunda A, Boroduskis M, Vorobjeva V, Ancans J, 2013. Cell and Tissue Culture-Based in Vitro Test Systems For Evaluation of Natural Skin Care Product Ingredients. Environmental and Experimental Biology 11, 159–177.
- Ratz-Lyko, A., Arct, J., Pytkowska, K., 2012. Methods for evaluation of cosmetic antioxidant capacity. Skin Research and Technology 18, 421–430. https://doi.org/10.1111/j.1600-0846.2011.00588.x
- Razinger, J., Lutz, M., Schroers, H.-J., Urek, G., Grunder, J., 2014. Evaluation of Insect Associated and Plant Growth Promoting Fungi in the Control of Cabbage Root Flies. J Econ Entomol 107, 1348–1354. https://doi.org/10.1603/EC14004
- Re, R., Pellegrini, N., Proteggente, A., Pannala, A., Yang, M., Rice-Evans, C., 1999. Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radic Biol Med 26, 1231–1237. https://doi.org/10.1016/S0891-5849(98)00315-3
- Riss, T., Niles, A., Moravec, R., Karassina, N., Vidugiriene, J., 2019. Cytotoxicity Assays: In Vitro Methods to Measure Dead Cells, in: Markossian S, Grossman A, Brimacombe K, et al. (Eds.), Cytotoxicity Assays: In Vitro Methods to Measure Dead Cells. Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda, MD.

Riss, T.L., Moravec, R.A., Niles, A.L., Duellman, S., Benink, H.A., Worzella, T.J., Minor, L., 2004. Cell Viability Assays.

Rivoal, J., Smith, C.R., Moraes, T.F., Turpin, D.H., Plaxton, W.C., 2002. A Method for Activity Staining after Native Polyacrylamide Gel Electrophoresis Using a Coupled Enzyme Assay and Fluorescence Detection: Application to the Analysis of Several Glycolytic Enzymes. Anal Biochem 300, 94–99. https://doi.org/10.1006/abio.2001.5445

- Rodriguez-Tudela, J.L., Arendrup, M.C., Barchiesi, F., Bille, J., Chryssanthou, E., Cuenca-Estrella, M., Dannaoui, E., Denning, D.W., Donnelly, J.P., Dromer, F., Fegeler, W., Lass-Flörl, C., Moore, C., Richardson, M., Sandven, P., Velegraki, A., Verweij, P., 2008. EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clinical Microbiology and Infection 14, 398–405. https://doi.org/10.1111/j.1469-0691.2007.01935.x
- Romar, G.A., Kupper, T.S., Divito, S.J., 2016. Research Techniques Made Simple: Techniques to Assess Cell Proliferation. Journal of Investigative Dermatology 136, e1–e7. https://doi.org/10.1016/J.JID.2015.11.020
- Sabotič, J., Popovič, T., Brzin, J., 2009. Aspartic proteases from basidiomycete Clitocybe nebularis. Croatica Chemica Acta 82.
- Sabotič, J., Trček, T., Popovič, T., Brzin, J., 2007. Basidiomycetes harbour a hidden treasure of proteolytic diversity. J Biotechnol 128, 297–307. https://doi.org/10.1016/j.jbiotec.2006.10.006
- Sanané, I., Legrand, J., Dillmann, C., Marion-Poll, F., 2021. High-Throughput Feeding Bioassay for Lepidoptera Larvae. J Chem Ecol 47, 642–652. https://doi.org/10.1007/s10886-021-01290-x
- Sepčić, K., Sabotič, J., A. Ohm, R., Drobne, D., Jemec Kokalj, A., 2019. First evidence of cholinesterase-like activity in Basidiomycota. PLoS One 14, e0216077. https://doi.org/10.1371/journal.pone.0216077
- Sims, M., 1965. Methods for Detection of Enzymatic Activity after Electrophoresis on Polyacrylamide Gel in Drosophila Species. Nature 207, 757–758. https://doi.org/10.1038/207757b0
- Singleton, V.L., Orthofer, R., Lamuela-Raventós, R.M., 1999. Analysis of total phenols and other oxidation substrates and antioxidants by means of folin-ciocalteu reagent, in: Methods in Enzymology. Elsevier, pp. 152–178. https://doi.org/10.1016/S0076-6879(99)99017-1
- Šmid, I., Rotter, A., Gruden, K., Brzin, J., Buh Gašparič, M., Kos, J., Žel, J., Sabotič, J., 2015. Clitocypin, a fungal cysteine protease inhibitor, exerts its insecticidal effect on Colorado potato beetle larvae by inhibiting their digestive cysteine proteases. Pestic Biochem Physiol 122, 59–66. https://doi.org/10.1016/j.pestbp.2014.12.022
- Sternberg, E.D., Waite, J.L., Thomas, M.B., 2014. Evaluating the efficacy of biological and conventional insecticides with the new 'MCD bottle' bioassay. Malar J 13, 499. https://doi.org/10.1186/1475-2875-13-499
- Sterniša, M., Sabotič, J., Janež, N., Curk, T., Klančnik, A., 2023. SIMBA method simultaneous detection of antimicrobial and anti-biofilm activity of new compounds using Salmonella Infantis. Bio Protoc.
- Sterniša, M., Sabotič, J., Klančnik, A., 2022. A novel approach using growth curve analysis to distinguish between antimicrobial and anti-biofilm activities against Salmonella. Int J Food Microbiol 364, 109520. https://doi.org/10.1016/j.ijfoodmicro.2021.109520

Strömstedt, A.A., Felth, J., Bohlin, L., 2014. Bioassays in natural product research - Strategies and methods in the search for anti-inflammatory and antimicrobial activity. Phytochemical Analysis 25, 13–28. https://doi.org/10.1002/PCA.2468

Suchman, E., Blair, C., 2007. Cytopathic Effects of Viruses Protocols. ASM Protocols.

- Thring, T.S., Hili, P., Naughton, D.P., 2009. Anti-collagenase, anti-elastase and anti-oxidant activities of extracts from 21 plants. BMC Complement Altern Med 9, 27. https://doi.org/10.1186/1472-6882-9-27
- Tomsheck, A.R., Strobel, G.A., Booth, E., Geary, B., Spakowicz, D., Knighton, B., Floerchinger, C., Sears, J., Liarzi, O., Ezra, D., 2010. Hypoxylon sp., an Endophyte of Persea indica, Producing 1,8-Cineole and Other Bioactive Volatiles with Fuel Potential. Microb Ecol 60, 903–914. https://doi.org/10.1007/s00248-010-9759-6
- Van Wart, H.E., Steinbrink, D.R., 1981. A continuous spectrophotometric assay for Clostridium histolyticum collagenase. Anal Biochem 113, 356–365. https://doi.org/10.1016/0003-2697(81)90089-0

Vichai, V., Kirtikara, K., 2006. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1, 1112–1116. https://doi.org/10.1038/nprot.2006.179

Zamora, J.L.R., Aguilar, H.C., 2018. Flow virometry as a tool to study viruses. Methods 134–135, 87–97. https://doi.org/10.1016/j.ymeth.2017.12.011

Žun, G., Kos, J., Sabotič, J., 2017. Higher fungi are a rich source of l-amino acid oxidases. 3 Biotech 7, 230. https://doi.org/10.1007/s13205-017-0813-7

Author declaration

[Instructions: Please check all applicable boxes and provide additional information as requested.]

1. Conflict of Interest

Potential conflict of interest exists:

We wish to draw the attention of the Editor to the following facts, which may be considered as potential conflicts of interest, and to significant financial contributions to this work:

The nature of potential conflict of interest is described below:

 \square No conflict of interest exists.

We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

2. Funding

Funding was received for this work.

All of the sources of funding for the work described in this publication are acknowledged below:

[List funding sources and their role in study design, data analysis, and result interpretation]

Funding sources had no role in study design, data analysis or result interpretation.

This publication is based upon work from COST Action CA18238 (Ocean4Biotech), supported by COST (European Cooperation in Science and Technology) program.

Research of Jerica Sabotič and Nika Janež was supported by Slovenian Research agency (J4-2543, J4-4555, P4-0127, P4-0432).

Research of Evita Strode was supported by ERDF post-doctoral research grant 1.1.1.2/16/I/001 (application No 1.1.1.2/VIAA/3/19/465).

Susana Gaudêncio: This work is financed by national funds from FCT - Fundação para a

<u>Ciência e a Tecnologia, I.P., in the scope of the project UIDP/04378/2020 and</u> <u>UIDB/04378/2020 of the Research Unit on Applied Molecular Biosciences - UCIBIO</u> and the project LA/P/0140/2020 of the Associate Laboratory Institute for Health and <u>Bioeconomy - i4HB.</u>

Research of Anna Luganini and Giovanna Cristina Varese was financed by the University of Torino (Ricerca Locale) and the European Commission – NextGenerationEU, Project "Strengthening the MIRRI Italian Research Infrastructure for Sustainable Bioscience and Bioeconomy", code n. IR0000005.

Research of David Ezra was supported by The Chief Scientist of the Israeli Ministry of Agriculture and Rural Development (MOARD), grant number 20-02-0122, and Copia Agro Israel

Research of Dina Simes was funded by the Portuguese National Funds from FCT— Foundation for Science and Technology, through projects UIDB/04326/2020, UIDP/04326/2020 and LA/P/0101/2020 and AAC n° 41/ALG/2020 - Project n° 072583 – NUTRISAFE.

No funding was received for this work.

3. Intellectual Property

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

4. Research Ethics

We further confirm that any aspect of the work covered in this manuscript that has involved human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

IRB approval was obtained (required for studies and series of 3 or more cases)

Written consent to publish potentially identifying information, such as details or the case and photographs, was obtained from the patient(s) or their legal guardian(s).

5. Authorship

The International Committee of Medical Journal Editors (ICMJE) recommends that authorship be based on the following four criteria:

- 1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
- 2. Drafting the work or revising it critically for important intellectual content; AND
- 3. Final approval of the version to be published; AND
- 4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. For more information on authorship, please see <u>http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html#two</u>.

 \square All listed authors meet the ICMJE criteria. \square We attest that all authors contributed significantly to the creation of this manuscript, each having fulfilled criteria as established by the ICMJE.

One or more listed authors do(es) not meet the ICMJE criteria.

We believe these individuals should be listed as authors because:

[Please elaborate below] [SEP]

 \boxtimes We confirm that the manuscript has been read and approved by all named authors.

 \boxtimes We confirm that the order of authors listed in the manuscript has been approved by all named authors.

6. Contact with the Editorial Office

The Corresponding Author declared on the title page of the manuscript is:

[Insert name below]

This author submitted this manuscript using his/her account in EVISE.

We understand that this Corresponding Author is the sole contact for the Editorial process (including EVISE and direct communications with the office). He/she is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs.

We confirm that the email address shown below is accessible by the Corresponding Author, is the address to which Corresponding Author's EVISE account is linked, and has been configured to accept email from the editorial office of American Journal of Ophthalmology Case Reports:

[Insert email address you wish to use for communication with the journal here]

Someone other than the Corresponding Author declared above submitted this manuscript from his/her account in EVISE:

[Insert name below]

We understand that this author is the sole contact for the Editorial process (including EVISE and direct communications with the office). He/she is responsible for communicating with the other authors, including the Corresponding Author, about progress, submissions of revisions and final approval of proofs.

We the undersigned agree with all of the above.

Author's name (Fist, Last)

Signature

Date

Digitally signed by JERICA SABOTIČ Date: 2023.07.08 22:47:22 +02'00'

8 July 2023_____

1. Jerica Sabotič

4